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One of the biggest challenges for biochemical researchers in the postgenomic era remains 
the elucidation of structure-activity relationships in proteins. While many proteins can be 
routinely produced by recombinant protein expression and studied in a controlled 
environment, post-translational modifications (PTMs), such as acylation, methylation, 
phosphorylation, lipidation, prenylation, ubiquitination, or glycosylation are additionally 
required to reproduce the diversity found in nature.[1,2] Traditionally, these modifications 
have been carried out by targeting nucleophilic amino acid (AA) side chains, often by 
enzymatic means. This process frequently results in a heterogeneous product distribution. 
Furthermore, this approach is inherently limited to the chemistry encoded in the 20 common 
proteinogenic amino acids and while efforts have been made to incorporate unnatural AAs 
by expansion of the genetic code, this process is often labor-intensive.[3–5] Of special 
interest is the introduction of non-natural modifications, such as fluorescent labels, to 
proteins of interest. Fluorescence assays in their simplest form allow the visualization of 
the protein in its environment, whereas more advanced methods can reveal details about 
protein-protein interactions or conformational changes.[6] While the discovery of the 
genetically encoded green fluorescent protein (GFP) and its application as a protein tag 
first bypassed the need for site-selective targeting and has thus led to an increase in the 
understanding of protein interactions, disadvantages still remain. Usage of GFP is limited 
to biomolecules accessible by protein expression and its large size presents an additional 
drawback, since this may directly influence the structure of the studied molecule.[7,8] These 
restrictions can be circumvented by applying a two-step tag-and-modify approach. First, a 
chemical tag with unique reactivity is installed genetically or via the cell’s biosynthetic 
pathway and subsequently targeted by a reporter group with complementary functionality. 
Ideally, the reaction proceeds fast and selectively in a minimally invasive manner.[9] 
The scope of these methods can be transferred to the field of peptide therapeutics, where 
control over drug loading - and therefore product homogeneity - is an important objective. 
Similarly, this approach can be used for the creation of uniform biomaterials, where site-
selective modifications allow control over material structure and function.[10,11] The 
discovery of additional methods for the chemoselective modification of proteins, as well as 
the scope expansion of currently existing methodology is therefore worth investigating.  
 
Within the scope of this thesis, fundamental research on the application and effect of 
templates for protein labeling is conducted. A long-term research goal in our workgroup is 






maintaining site selectivity. Our approach in reaching this goal is based on the use of 
peptide templates to facilitate the labeling reaction at low concentrations by increasing the 
effective molarity of the reactants. The sequence specificity of the template is furthermore 
responsible for ensuring site-selectivity. Introduction of photocleavable linkers (PCL) 
between the template strands and tags aid in the (partial) removal of the reaction scaffold 
after transfer of the label to the target protein. Based on previous work in our group by 
Middel et al.,[12]  photocleavable peptide nucleic acid (PNA) templates are investigated with 
respect to their orthogonality. To extend the scope of this method, the template’s ability to 
enhance a cross-coupling reaction is explored. Finally, coiled-coil peptides are investigated 
as templates because of the additional layer of orthogonality they provide in terms of 
recognition and site-selectivity and their standalone ability to serve as a platform for 
stoichiometric bioconjugations at low concentrations.  
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2 State of the art 
2.1 Classic methods for chemical protein modification 
 
Classic methods for protein bioconjugation make use of the chemical diversity embedded 
in the side chains of the canonical amino acids. Of these, nucleophilic amino acids, such 
as cysteine and lysine are most often targeted. The thiol group of cysteine can undergo 
disulfide exchange to form mixed disulfides,[13] alkylation with α-halocarbonyls[13] or Michael 
addition with α,β-unsaturated carbonyls (e.g. maleimides[13,14] or vinyl sulfones[15]). The ε-
amino group of lysine can be favored over the N-terminus by pH control. It primarily 
undergoes reactions with electrophiles, such as activated acids to form amides,[16] 
iso(thio)cyanates to form urea and thiourea compounds,[17] as well as reductive amination 
with aldehydes.[18] An overview of these methods is presented in Figure 1. 
 
 
Figure 1: Classic methods of protein modification on cysteine (left) and lysine (right) through (a) disulfide 
exchange, (b) alkylation, (c) Michael addition, (d) amide formation, (e) urea or thiourea formation and (f) 
reductive amination. 
 
A major drawback of these reactions is the selectivity. While other nucleophiles can lead 
to side reactions, the simple presence of more than one target amino acid in the protein 
sequence will lead to a statistical product distribution. This can be partly circumvented by 
different accessibility of the target residue (i.e. surface-exposed versus hydrophobically 
shielded) and substoichiometric addition of the reagent.[16] However, none of these 
methods have prevailed for single site-selective labeling. 
A major exception is the ligation of thioesters with an N-terminal cysteine to give a native 
peptide bond. The reaction, termed native chemical ligation (NCL), was first reported by 
Kent and co-workers.[19] It allows the condensation of unprotected peptide fragments under 
physiological conditions by transthioesterification of an N-terminal cysteine with a  





C-terminal thioester, followed by an irreversible intramolecular S,N-acyl shift that proceeds 
through a 5-membered transition state, to yield an amide bond between the two fragments 
(see Figure 2). While non-terminal cysteines can also react with the thioester, the  
S,N-acyl shift cannot occur, thus leading to a reversion to the starting materials. Due to its 
high chemoselectivity, NCL has become a staple in protein (semi)synthesis and 
modification. With the help of NCL, proteins larger than the limitation of conventional solid 
phase peptide synthesis (SPPS) have been accessed and studied, most impressively 
demonstrated in the synthesis of a 203-residue HIV-1 protease dimer.[20,21] While the 
requirement of a cysteine residue in the peptide sequence poses some limitations due to 
its low abundance,[22] introduction of desulfurization protocols, coupled with the use of other 
cysteine surrogates has expanded the scope of the reaction,[23–25] which also includes the 
use of fluorescent thioesters as chemical probes.[26] 
 
 
Figure 2: Mechanism of the native chemical ligation (NCL). An N-terminal cysteine and a C-terminal thioester 
undergo reversible transthioesterification, followed by an intramolecular, irreversible S-to-N acyl shift. 
 
2.2 Bioorthogonal reactions 
 
To overcome the limitations in control over extent and location of the modification 
associated with classic methodology, new functional groups with unique reactivity are 
introduced to the target protein. This can either be achieved by metabolic labeling of natural 
biomolecules with modified metabolic precursors[27] or by synthetic incorporation of an 
unnatural moiety.[28] After incorporation, this tag can be subsequently targeted by a probe 
molecule equipped with a complimentary functionality. The participating functional groups 
should be inert to biological moieties, stable under physiological conditions, not interact 
with a biological system and ideally be small in size as to not perturb the protein. The 
conjugation reaction should proceed fast and selectively at low concentrations and under 
biocompatible conditions without the production of toxic side products (for in vivo 
applications). This concept of “bioorthogonal” reactions was introduced by Bertozzi and  
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co-workers.[29,30] As of today, a conjugation reaction fulfilling every criterion remains an 
ideal, however some of the reactions discussed in this chapter have come close. 
 
2.2.1 Oxime and hydrazone ligation 
 
The keto group, while omnipresent in organic chemistry, is absent from the side chains of 
the canonical amino acids. Due to its unique reactivity, it presents a target for the selective 
modification with hydroxylamine or hydrazine derivatives (see Figure 3). While keto groups 
can be present in cofactors and metabolites, oxime and hydrazine forming ligations are 
compatible in a variety of biological systems lacking these functionalities.[31] The oxime 
bond is stable under physiological conditions, whereas hydrazones are often reduced to 
form a more stable linkage. Oxime ligations tend to have moderate reaction rates at acidic 





Figure 3: Condensation of an aldehyde/ketone with (a) a hydroxylamine or (b) a hydrazine derivative to form 
oxime or hydrazone linkages.  
 
Schultz and co-workers reported the site-selective, genetic incorporation of  
p-acetylphenylalanine into anti-Her2 antibody Fab fragments, as well as full-length IgG in 
E. coli and mammalian cells, respectively. The amino acid was targeted with a 
hydroxylamine modified variant of the antineoplastic agent auristatin F to create a 
homogenous antibody-drug conjugate (ADC) with precise control over stoichiometry. While 
the ADC showed excellent pharmacokinetics and a high cytotoxic activity against Her2+ 
cancer cells, both in vitro and in mouse xenograft treatment models, the rate constant of 
the oxime ligation was far from optimal. Despite being performed at pH 4.5, reaction times 






of one to four days and a twenty to thirty-fold reagent excess of the drug were required 
(see Figure 4a).[33] 
To overcome this problem, Dawson and co-workers disclosed the role of aniline as a 
nucleophilic catalyst that undergoes a transamination with the carbonyl compound, thereby 
increasing the reaction rate by a factor of 400 at pH 4.5 and a factor of 40 at pH 7.0.[32] This 
principle was utilized in the rapid labeling of model peptide substrates and human serum 
albumin via oxime or hydrazone ligation, demonstrating rate constants of 101-103 M-1 s-1at 
low micromolar concentrations and neutral pH.[34] The broad applicability was further 
demonstrated by Zeng et al. in the labeling of cell-surface sialylated glycoproteins by 




Figure 4: (a) Synthesis of an ADC via oxime ligation and (b) labeling of cell-surface sialylated glycoproteins by 
aniline-catalyzed oxime ligation. Figure based on [33,35]. 
 
Further studies by Proulx and co-workers showed that incorporation of electron rich N-aryl 
groups to peptides leads to coupling with alkoxyamines to yield ketoximes, with O2 being 
the only additive. Mechanistically, the ligation involves the in situ generation of a protonated 
aniline Schiff base that reacts with the alkoxyamine while expelling aniline.[36,37] In addition, 
Xu et al. reported the use of easy to modify electron deficient chloro-benzaldehyde 
reagents to increase the reactivity of the keto compound in the imine formation to provide 
a fast, catalyst free hydrazone ligation. The diversity of the scope was demonstrated by 
modifying ubiquitin with fluorescent labels, a drug, or polyethylene glycol (PEG), the latter 
showing 96% conversion at micromolar concentrations at pH 7 after 30 min.[38,39]  
 
(b) 
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2.2.2 Ketoacid-hydroxylamine (KAHA) and potassium acyltrifluoroborate 
(KAT) ligations 
 
Another reaction between a keto compound and a nucleophile enhanced by the α-effect 
was disclosed by Bode and co-workers with the KAHA ligation. It describes the 
decarboxylative condensation of α-ketoacids with N-alkylhydroxylamines to form a native 
amide bond (see Figure 5). The reaction proceeds without additives or formation of 
byproducts, despite using unprotected functional groups and can be carried out in polar 
protic and aprotic solvents.[40] Further mechanistic studies revealed that the reaction with 
O-unsubstituted hydroxylamines proceeds via formation of nitrone and oxaziridine 
intermediates, whereas the reaction with unsubstituted oxaproline forms an ester under 




Figure 5: Amide bond forming ligation between unprotected ketoacid peptide fragment 1 and hydroxylamine 
(oxaproline) peptide fragment 2. 
 
The ligation strategy was further optimized by the synthesis of SPPS-compatible resins that 
form enantiopure α-ketoacids upon cleavage,[43–45] the synthesis of oxaproline and 
oxazetidine derivatives that lead to different amino acid side chains at the ligation  
site[44,46–48] and the introduction of (photocleavable) protecting groups for the hydroxylamine 
and ketoacid functionalities.[49,50] Despite being limited to a lower pH and possessing a 
slower reaction rate than NCL, the KAHA ligation is broadly applicable in the synthesis of 
proteins by utilizing aqueous acidic NMP or DMSO, allowing various ligation sites that are 
more common than cysteine (the ligation site of NCL), utilizing easily protected functional 
groups, while being tolerant to all canonical amino acids. These advancements have 
culminated in the total chemical synthesis of the 20 kDa heme protein nitrophorin 4 by 
sequential ligation.[51] The requirement of strong acidic conditions can also be turned into 
an advantage by allowing the synthesis of difficult peptides with highly hydrophobic 
sequences (the low pH prevents aggregation). This was demonstrated in the synthesis of 
a cyclic, antibacterial peptide with a large hydrophobic segment. HFIP was used as a co-
solvent in the ligation of two sub-fragments, whereas the following cyclization occurred 
spontaneously in a mixture of water and DMSO. Of note, both ligation and cyclization were 





carried out as KAHA ligations, with photocleavable protecting groups (PPGs) allowing site-
selectivity.[50] 
In an effort to find a chemoselective reaction that proceeds with a faster reaction rate under 
dilute concentrations, Bode and co-workers further identified potassium acyltrifluoroborates 
(KATs) as ligation partners for hydroxylamines. The reaction proceeds fast and selectively 
on unprotected peptides under acidic conditions in aqueous media at room temperature to 
yield an amide bond (see Figure 6).[52,53] 
 
 
Figure 6: Amide bond forming ligation between an unprotected hydroxylamine and a potassium 
acytrifluoroborate. 
 
Biotinylation, PEGylation, palmitoylation, and introduction of a dye molecule were 
successfully demonstrated on a 31mer GLP1-analogue. The reaction proceeded within 
minutes at a 1 mM concentration.[53] In a study comparing reaction rates of chemoselective 
ligations, an influence of the pH value on the rate constant was revealed. A second-order 
rate constant of 0.39 M-1s-1 was determined for the reaction between a hydroxylamine 
containing model peptide and a KAT dye in ammonium acetate buffer (pH 5.1, 200 μM 
reagent concentration). The same reaction was carried out in presence of oxalic acid in 
H2O/tBuOH to reveal a rate constant of 22.4 M-1s-1 (25 μM substrate concentration).[54] The 
ligation was furthermore demonstrated to be orthogonal to the Cu(I)-catalyzed azide-alkyne 
cycloaddition (CuAAC), thiol-Michael addition and strain-promoted azide-alkyne 
cycloaddition (SPAAC).[55,56] This versatility was impressively demonstrated by Mazunin et 
al. with the stepwise immobilization of multiple bovine serum albumin (BSA) derivatives on 
a PEG hydrogel scaffold. The hydrogel was synthesized by a Michael-type reaction of a 
thiol and a vinyl sulfone. The resulting gel was doped with an azide for targeting via SPAAC 
and either a hydroxylamine or potassium acyltrifluoroborate for targeting via KAT ligation. 
Staining occurred by exposure to fluorescent BSA derivatives bearing a complementary 
moiety (cyclooctyne for SPAAC and a potassium acyltrifluoroborate or a hydroxylamine for 
KAT ligation). The order in which the staining was carried out proved to be inconsequential, 
resulting in dual immobilization of the proteins (see Figure 7).[56] 
 




Figure 7: Dual independent immobilization of BSA derivatives onto hydrogels. Depicted is the 1st staining via 
SPAAC ligation of a fluorescein containing, cyclooctyne modified BSA and 2nd staining via KAT ligation of a 
hydroxylamine modified, rhodamine containing BSA variant. Figure based on [56]. 
 
2.2.3 Staudinger ligation 
 
The Staudinger ligation was developed by the Bertozzi group as a modification to the 
Staudinger reduction. Herein, azides are treated with triphenylphosphine to give aza-ylides 
that are subsequently hydrolyzed to yield primary amines.[57] The mild conditions, tolerance 
of water and abiotic nature of both participating functional groups would make this reaction 
a prime candidate for biological applications. Alas, the initially formed covalent bond 
between the substrates is later hydrolyzed. To address this issue, an ester group was 
introduced in ortho position to the phosphorus atom at one of the aryl rings to act as an 
electrophilic trap. Formation of the aza-ylide intermediate occurs according to the known 
mechanism, however a nucleophilic attack of the nitrogen atom on the electrophilic trap 
yields a cyclic intermediate that forms a stable amide-linked product upon hydrolysis (see 
Figure 8a).[58] 
 






Figure 8: Schematic representation of (a) the Staudinger ligation, (b) traceless variants and (c) the Staudinger-
phosphite reaction. 
 
This method was successfully employed in the labeling of live cells. Azides were 
incorporated within the cell surface by metabolization of a synthetic azidosugar (metabolic 
labeling). Subsequently, these moieties were addressed by a number of phosphine probes 
to form covalent linkages (tagging).[58] Biotinylation,[58] dual incorporation of fluorophores 
with an orthogonal hydrazone ligation,[59] FRET-based turn-on fluorescence,[60] and real-
time bioluminescence imaging[61] have been demonstrated. The general concept of this so-
called metabolic labeling approach is illustrated in Figure 9. 
 
 
Figure 9: Depiction of the metabolic labeling approach. Azides are delivered to the cell surface by unnatural 
sialic acid biosynthesis and addressed by a variety of phosphine probes in a Staudinger ligation. Figure based 
on [59]. 
 
In addition, “traceless” approaches have been reported independently by the groups of 
Raines and Bertozzi (see Figure 8b). Here, the phosphine starting material was modified 
to expel the phosphine oxide in a manner similar to NCL to yield an unaltered amide bond 
between the ligation partners.[62,63] This technique has been successfully employed on the 
solid phase in tandem with NCL to synthesize the functional protein ribonuclease A.[64] 
The Staudinger ligation proceeds with high selectivity, however, slow kinetics are an 
obstacle for in vivo applications.[30] Attempts to increase the electron density of the 
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phosphine substituents, and therefore the reaction rate, were partly successful since 
phosphine oxidation by air was observed as a side reaction.[65] To address the latter issue, 
Hackenberger and co-workers applied air-stable phosphites as ligation partners to yield 
phosphoramidate linkages after hydrolysis (see Figure 8c).[66] With this approach, up to two 
functional groups can be introduced to the target molecule, including biotin[67] and PEG.[68] 
Addition of a PPG to the phosphite allows the generation of charged phosphoramidates 
that are of interest as biologically relevant phosphate ester mimics.[66] 
 
2.2.4 Copper(I)-catalyzed azide alkyne cycloaddition (CuAAC) 
 
The proposal of azide and alkyne reacting in a concerted [3+2] cycloaddition was first made 
by Huisgen. However, the studied 1,3-dipolar additions exhibited slow reaction kinetics, 
making elevated temperatures or pressures necessary.[69] The groups of 
Fokin/Sharpless[70] and Meldal[71] independently reported the catalytic effect of Cu(I) on the 
1,3-dipolar cycloaddition of azides and terminal alkynes to produce 1,4-disubstituted  
1,2,3-triazoles. The formation of copper acetylides activates the terminal alkyne towards 
reactions with azides. The reaction proceeds fast and selectively in high yields at room 
temperature in aqueous systems, needing only the addition of a reducing agent for the use 
of more cost-efficient Cu(II) salts. This reaction therefore signifies the first click reaction[a][72] 
with the additional potential to be bioorthogonal.[70] The reaction rate can be further 
increased by using ligands that stabilize the Cu(I) oxidation state in water.[73,74] 
 
 
Figure 10: (a) Schematic representation of the CuAAC and (b) biocompatible version applied to the labeling of 
cell-surface sialic acids. Figure based on [75]. 
 
[a] Click reactions comprise a family of reactions that are defined by their high thermodynamic driving force, 
thereby enabling rapid and selective heteroatom linkage. Reactions of this type are modular, wide in scope, 
have a high yield and proceed under simple reaction conditions from readily available starting materials without 
the need for chromatographic purification of the products.[72]  
(a) 
(b) 





Wang et al. applied the ligation method to a more complex biological system. Cowpea 
mosaic virus (CPMV) was decorated with azide or alkyne handles at surface exposed lysine 
residues or with an alkyne functionality at exposed cysteine residues. The virus was 
visualized with fluorescein dyes bearing compatible functional groups.  
Tris((1-benzyl-4-triazolyl)methyl)amine (TBTA) was used as a ligand to stabilize Cu(I) and 
to protect the protein from potentially harmful soluble copper species. Labeling was 
performed with a large dye excess in slightly basic phosphate buffer (pH 8.0) containing 
5% tBuOH and a metal to ligand ratio of 1:2 at 4 °C for 16 h (see Figure 10a).[76] Chang et 
al. reported a similar approach for the labeling of alkynylated sialic acids in the organs of 
mice. After metabolic incorporation of the sialic acid analogue in live mice, the organs were 
harvested and the metabolized sugars visualized by biotin azide. A large excess of CuSO4 
and sodium ascorbate (NaAsc) was used in addition to TBTA to drive the labeling reaction 
to completion at room temperature within 1 h.[77] One of the biggest challenges to apply 
CuAAC ligation in living systems is the toxicity associated with the CuSO4/CuBr, NaAsc 
and TBTA catalytic system. Due to the low water solubility of the TBTA ligand, high copper 
loading becomes necessary, thereby increasing the risk of free Cu(I) ions that escape the 
coordination sphere of the ligand and form reactive oxygen species that are detrimental to 
the cell metabolism. E. coli cells were observed to survive treatment with 100 μM CuBr for 
up to 16 h, however, they were unable to divide. Most mammalian cells underwent 
apoptosis and cell lysis within 20 minutes upon treatment with 1 mM Cu(I); similar effects 
were observed for zebrafish embryos. Soriano del Amo et al. therefore screened a library 
of TBTA analogues. A bis(tert-butyltriazolyl) ligand (BTTES) was identified as a 
compromise between reaction rate and water solubility. A metal to ligand ratio of 1:6 was 
observed to completely suppress apoptosis. Live cell labeling was performed on 
functionalized cell-surface glycoconjugates within 14 min, utilizing 75 μM Cu(I) (see Figure 
10b). No long-term effect on cell growth was observed. The authors therefore applied the 
ligand to the labeling of fucosylated glycans in zebrafish embryos, only observing minor 
defects.[75] An alternative approach was disclosed by Uttamapinant et al., utilizing picolyl 
azides as internal chelators for Cu(I). Due to the increase of the effective concentration at 
the ligation site, the copper concentration could be lowered to a level of minimal toxicity. 
The resulting increase in reaction rate was also observed to offset the lowering of the 
copper concentration and showed a rate increase similar to a conventional system with the 
water-soluble THPTA ligand. The viability of this approach was demonstrated by in cellulo 
labeling of lipoic acid ligase bearing a picolyl azide moiety, as well as in rat neuron 
cultures.[78] 
In another display of the versatility of CuAAC, Kofoed et al. reported the synthesis of an 
active enzyme by Cu(I)-catalyzed ligation. Two inactive halves of the tobacco etch virus 
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(TEV) protease bearing an azide and alkyne moiety respectively, were ligated. The created 
triazole bridge was observed to mimic the natural protein loop and the semi-synthetic 
protein exhibited the same activity as the wild type (WT). These findings demonstrate the 
isosteric nature of the triazole bond and provide a tool for the semisynthesis of difficult to 
express proteins.[79] 
 
2.2.5 Strain-promoted azide alkyne cycloaddition (SPAAC) 
 
In an effort to completely circumvent the need for a catalyst, Bertozzi and co-workers 
reported the reaction of an azide with a strained alkyne, cyclooctyne (see Figure 11). 
Driving force of the reaction is the bond angle deformation (163°) of cyclooctyne, resulting 
in close to 18 kcal/mol of ring strain. The energetic difference of the strained ground state 
to the transition state accelerates the reaction in comparison to the reaction with unstrained 
alkynes. The strain-promoted [3+2] cycloaddition is well tolerant of physiological conditions 
and was therefore applied by the authors in in cellulo labeling experiments. Metabolic 
labeling of cell surface glycans in Jurkat cells with azidosialic acid, followed by labeling with 
biotinylated cyclooctyne for 1.5 h showed robust labeling without evident cell toxicity.[80] 
The rate constant of the reaction was later reported to be 2.4∙10-3 M-1s-1, which is 
comparable to the Staudinger ligation, but slower than most CuAAC reactions.[65] 
 
 
Figure 11: General representation of the SPAAC between an azide and a cyclooctyne derivative. 
 
To further enhance the reaction rate, different cyclooctyne derivatives were investigated. 
Baskin et al. reported the introduction of an electron withdrawing difluoromethylene moiety 
(DIFO), resulting in a second-order rate constant of 0.076 M-1s-1 in acetonitrile.[81] Ning et 
al. fused two aryl rings to the cyclooctyne core (DIBO), imposing additional ring strain and 
a conjugated system with the alkyne, resulting in a second-order rate constant of 0.17 
M-1s-1 in methanol.[82] Introduction of an additional sp2-like center within the cyclooctyne ring 
in the form of an amide bond and retaining the two aryl substituents (BARAC) resulted in a 
second-order rate constant of 0.96 M-1s-1 in acetonitrile.[83] In addition, each cyclooctyne 
derivative was successfully used in the live cell labeling of azide surface glycans. 





Showing promising results in live cells, SPAAC was applied to small model organisms. 
Laughlin et al. used DIFO-fluorophore conjugates for the imaging of azide-modified cell-
surface glycans in developing zebrafish. Within a minute of exposure to DIFO-647, 
fluorescence was observed without background noise, increasing in a time-dependant 
manner. In order to achieve distinction between temporally different glycan populations, a 
two-color imaging strategy was developed. Cell-surface glycans were visualized with DIFO-
647 (red) at 60 h post fertilization (hpf). Newly secreted glycans were visualized in a second 
step by treatment with DIFO-488 (green). This method gave insight into the cell-surface 
expression, intracellular trafficking and tissue distribution of glycans during embryonic 
development of zebrafish.[84] The strategy was refined in the dual-color imaging of 
developing C. elegans. Here, an azide-modified glycan population was first visualized with 
DIFO-488, followed by additional incubation with the azido-sugar (metabolic precursor). 
The resulting nascent glycans were visualized with DIFO-566 (red).[85] For visualization in 
the early stages of embryogenesis in zebrafish, a different approach was chosen. 
Azidosugars were directly administered via microinjection at the one-cell stage and labeled 
with DIFO-488 to visualize mucin-type O-glycans within 9 hpf, followed by a second 
labeling step with DIFO-555 (red) 2 h or 12 h later, revealing differences in the distribution 
of both glycan populations. In addition, sialylated glycans were imaged utilizing a 
nonmetabolic approach. Selective oxidation was performed with NaIO4, followed by 
targeting of the aldehyde with an Alexa Fluor 488 reagent bearing an aminooxy moiety 
(AO-488). Labeling was observed starting at 7 hpf. Since both oxime ligation and SPAAC 
are orthogonal, dual labeling was carried out simultaneously in the same embryo. They 
were microinjected with the azidosugar, followed by incubation with NaIO4 to produce an 
azide and aldehyde moiety at the cell surface, respectively. The functionalities were 
targeted with DIFO-555 in a SPAAC and AO-488 in an oxime ligation. Time-lapse imaging 
visualized differences between O-glycans and sialylated glycans in the enveloping layer 
during different stages of embryogenesis, as well as a rapid reorganization of cell surface 
glycans during mitosis.[86] 
Following these results, labeling was studied in live animals. Metabolic precursors of sialic 
acid were administered to mice to produce cell-surface glycans bearing an azide 
functionality. Different cyclooctyne-FLAG conjugates, as well as Phos-FLAG, bearing a 
triarylphosphine handle for Staudinger ligation, were examined. DIMAC, a water-soluble 
dimethoxy azacyclooctyne, and DIFO showed the most promise in preliminary tests. 
Administration of Phos-FLAG, DIMAC-FLAG and DIFO-FLAG showed labeling in all 
harvested organs (most dominantly intestine, heart and liver). However, despite the 
comparable kinetics between Phos-FLAG and DIMAC-FLAG and the 10-fold faster kinetics 
of DIFO-FLAG ex vivo, the triarylphosphine probe produced more reaction products on the 
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same timeframe and administered concentration. Further studies revealed that the 
hydrophobic DIFO-FLAG and to an extent DIMAC-FLAG bind to mouse serum albumin, 
resulting in imperfect agents for in vivo applications.[87] 
 
2.2.6 Inverse electron demand Diels-Alder reactions (IEDDA) 
 
Sauer and co-workers first reported on the kinetics of the reaction between electron-
deficient 1,2,4,5-tetrazines (Tz) and olefins, observing that strained dienophiles react 
extraordinarily fast. trans-Cyclooctene (TCO) was reported to be the most reactive 
substrate.[88] The groups of Fox[89] and Hildebrand[90] independently reported the application 
of IEDDA reactions for bioconjugation. Since the conditions reported by Sauer were not 
biocompatible, as the tetrazines were observed to react with water,[91] different substrates 
had to be identified. Fox and co-workers therefore reported the reaction of 3,6-di(2-pyridyl)-
s-tetrazine with TCO. The reaction displayed very fast kinetics (k2 = 2000 M-1s-1) and 
tolerance to more complex solvent systems, such as cell medium and cell lysate, with 
dinitrogen being the only byproduct. The reaction was applied to the labeling of the 
11.7 kDa protein thioredoxin (Trx), modified with a TCO derivative. In acetate buffer (pH 
6.0), the reaction between 15 μM Trx-TCO and 30 μM of the aforementioned Tz was 
complete within 5 min, thereby demonstrating the ability to label biomolecules rapidly at 
low concentrations and near equistoichiometric substrate ratios (see Figure 12a).[89]  
 






Figure 12: Schematic representation of IEDDA reactions with substituted s-tetrazines, targeting (a) trans-
cyclooctene, (b) methylcyclopropene and (c) cyclooctyne. 
In contrast, Hildebrand and co-workers utilized a norbornene derivative as a reaction 
partner for 3-(4-benzylamino)-s-tetrazine. The reaction displayed kinetics of 1.9 M-1s-1 in 
aqueous buffer and 1.6 M-1s-1 in fetal bovine serum (FBS). Labeling in a biological context 
was carried out in live SKBR3 human breast cancer cells after treatment with trastuzumab 
antibodies conjugated with norbornene and tetramethylrhodamine (for visualization). 
IEDDA conjugation was carried out using 200 nM of antibody and 50 μM of a near-infrared 
(NIR) fluorophore tetrazine conjugate (Tz-VT680) in 10% FBS/HBSS solution at 37 °C for 
30 min, thereby providing dual-channel labeling.[90] 
Rossin et al. applied the IEDDA ligation for pretargeted tumor imaging in live mice. Animals 
bearing colon carcinoma xenografts were targeted with TCO-modified antibodies, followed 
by reaction with a 3,6-diaryl-s-Tz radiolabeling probe (111In-DOTA). A rate constant of 
13090 M-1s-1 was observed at a concentration of 1.67 μM in PBS at 37 °C, resulting in 
complete conversion after 3 min. Labeling in living animals was performed with 3.4 eq. of 
the [111In]-Tz derivative for 1 h, after which single photon emission computed tomography 
(SPECT) was performed. Despite the observation of a high amount of free mAb-TCO 
circulating in blood, a 52% reaction yield in tumor was observed. This report demonstrates 
the high selectivity and reaction rate of IEDDA in complex reaction environments, making 
it a prime target for applications limited by degradation of one of the starting materials, in 
this work the circulation half-life of the [111In]-Tz conjugate, which is 9.8 min (see Figure 
13).[92] 




Figure 13: Schematic representation of tumor targeting using the IEDDA reaction. Mice bearing colon cancer 
xenografts were injected with a TCO-mAb conjugate, followed by [111In]-Tz. Figure based on [92]. 
 
In an effort to create a minimally invasive tag, Yang and co-workers studied the reaction of 
substituted methylcyclopropenes with tetrazines (see Figure 12b). A rate constant of  
13 M-1s-1 was observed for the reaction of a methylcyclopropene equipped with a 
carbamate handle and benzylalcohol tetrazine in 12% DMSO/H2O at 37 °C. Application in 
a biological context was demonstrated by incubating SKBR3 breast cancer cells with 
cyclopropane phospholipids and subsequent imaging with a Tz-BODIPY fluorophore within 
an hour.[93] Patterson et al. used methylcyclopropane and azido sialic acid conjugates for 
metabolic incorporation into cell surface glycans. Simultaneous labeling was performed for 
1 h in Jurkat cells with a Tz-biotin and a DBCO-rhodamine derivative (100 μM each), 
respectively, thereby illustrating the orthogonality of IEDDA and SPAAC ligations.[94] In 
addition to the aforementioned orthogonality, Nikić and co-workers reported a pair of 
IEDDA reactions selective among themselves. The strategy is based on the fact that 
tetrazines can react with strained alkenes, as well as strained alkynes. A cyclooctynyl 
(SCO)-lysine derivative was shown to react with H-Tz with a rate two times higher than the 
corresponding SPAAC with an azide (see Figure 12c). It did however not show significant 
reactivity towards Me-Tz under the reported conditions. Therefore, an isomerism stable 
variant of TCO, termed TCO* was used to target said moiety. Since TCO* exhibits reactivity 
towards both tetrazine derivatives, it had to be consumed first in labeling experiments. The 
authors therefore set up a scheme for dual-color labeling using super-resolution 
microscopy. Lysine-derived unnatural amino acids (UAAs) bearing SCO or TCO* moieties 
were genetically encoded into insulin receptors  and virus-like particles. Dual-color imaging 











2.2.7 Transition metal mediated ligations 
 
With the very notable exception of the CuAAC ligation, transition metals have not found 
widespread application in bioorthogonal reactions. Here, the restrictions imposed by 
biological systems weigh heaviest. Challenges include the solubility and activity of the 
catalyst in buffered systems and the possibility of protein-as-ligand interactions. The latter 
might lead to catalyst poisoning or sequestration and degradation of the protein. These 
problems can be partly circumvented by applying the labeling reagent and the catalyst in 
superstoichiometric amounts.[96] An overview of current transition metal mediated ligation 
methods is presented in Figure 14. 
In one of the earliest examples of transition metal mediated bond formation in proteins, 
Kodama et al. targeted a variant of the Ras protein that was genetically engineered to 
contain p-iodophenylalanine (pIPhe), with a Mizoroki-Heck reaction. Coupling was 
performed between the unnatural amino acid and a vinylated biotin in the presence of 
water-soluble Pd-TPPTS catalyst. Slightly basic conditions (pH 8.3) were applied, while a 
percentage of organic solvent and reaction times of 50 h were still needed to achieve a 
yield for the biotinylation of 2%.[97] 
 
 
Figure 14: Schematic representation of transition metal mediated ligations: (a) Mizoroki-Heck,  
(b) Sonogashira, (c) Suzuki-Miyaura, and (d) olefin cross metathesis. 
 
Developments in this field gathered speed when Chalker et al. reported an inexpensive, 
water-soluble Pd-pyrimidine catalyst for Suzuki-Miyaura protein functionalization. 
Chemically installed p-iodobenzyl cysteine (PIC) was targeted in a mutant of subtilisin 
Bacillus lentus (SBL) with a variety of boronic acid derivatives and a glucose boronic ester. 
Reactions proceeded within 30 min for the acids and 60 min for the ester under mild 
conditions (37 °C, phosphate buffer pH 8.0). However, both the catalyst (50 eq.) and the 
(a) 
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reagent (500 eq.) were employed in superstoichiometric amounts.[98] The same catalyst 
was employed in the labeling of cell-surface channels at genetically encoded pIPhe in the 
OmpC protein with a fluorescein derived boronic acid (see Figure 15). Further 
investigations showed that the concentration of both Pd-catalyst and boronic acid can be 
lowered to a level, where they only exhibit low toxicity.[99] The same strategy and protein 
was used in the labeling with novel carbohydrate based boronic acids. The resulting cell 
surface glycans were visualized via the selective binding to fluorescein-lectin 
conjugates.[100] Bilyard et al. used the aforementioned carbohydrate based boronic acids 
for a mechanistical study of the glycosyltransferase enzyme glycogenin (GYG) that is 
responsible for the initiation of glycogenesis. The enzyme catalyzes its own 
autoglucosylation at the Tyr 195 residue. The authors mutated the residue to pIPhe which 
lacks the native glycosyl acceptor and therefore cannot undergo glucosylation. Pd-
mediated Suzuki-Miyaura cross-coupling with a variety of boronic acid sugar templates led 
to active species mimicking defined GYG glycoforms, representative of different 
intermediates of the enzyme’s catalytic cycle. Indeed, three distinct phases, prime, extend, 
and refine, were identified by this approach, thereby demonstrating how uniquely powerful 
transition metal based ligations can be if applied in the right context.[101] 
 
 
Figure 15: Suzuki-Miyaura labeling of the transmembrane protein OmpC (PDB ID: 2J1N) at a genetically 
encoded pIPhe residue, using the water-soluble (ADHP)2∙Pd(OAc)2 catalyst. Figure based on [99]. 
 
Water-soluble Pd-pyrimidine catalysts are not only limited to facilitating the Suzuki-Miyaura 
cross-coupling. Indeed, Li et al. reported the functionalization of a homopropargylglycine 
(HPG)-encoded ubiquitin (Ub) protein via Sonogashira cross-coupling. Modifications with 
a fluorophore, as well as PEGylation were achieved under mild conditions within 30 min in 
good to excellent yields. Similar to the previously reported Suzuki-Miyaura 
functionalizations, superstoichiometric amounts of catalyst and reagent (50 eq. each) were 
used. Utility of this method was furthermore demonstrated by fluorescence labeling of 
HPG-Ub in E. coli cells within 4 h.[102] 





Recent advances have further demonstrated that both reactions can be carried out in a 
ligand-free manner. Dumas et al. reported the PEGylation of proteins via Suzuki-Miyaura 
cross-coupling catalyzed by K2PdCl4,[103] whereas Li et al. used ligand-free Sonogashira 
coupling for in vivo protein labeling. Here, an alkyne analogue of pyrrolysine was encoded 
into a type III secretion toxin, OspF, and visualized in Shigella cells with a iodophenyl-
bearing fluorophore.[104] Furthermore, Ma et al. reported an N-heterocyclic carbene (NHC) 
stabilized palladium complex as an alternative catalyst for aqueous Suzuki-Miyaura cross-
coupling. Applicability was demonstrated by labeling of membrane proteins in HeLa cells 
with biotin. Comparable to the Pd-pyrimidine catalyst, labeling proceeded within 1 h at 
37 °C in PBS buffer (pH 8.0).[105] 
Recently, Bhushan et al. reported olefin cross-methasesis (CM) on a variety of proteins, as 
well as in human cells. S-Allylhomocysteine (Ahc) was introduced to the target protein as 
a priviledged substrate via Met codon reassignment. Allylic reaction partners were coupled 
using Hoveyda-Grubbs II catalyst in buffered systems containing significant amounts of 
organic solvent. Nonetheless, the Fc region of immunoglobulin G (IgG-Fc) was labelled 
with an olefin-biotin derivative in human cells, within 3 h. Recurrently, superstoichiometric 
amounts of catalyst (100 eq.) and olefin (5000 eq.) were required.[106] 
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2.2.8 Summary and conclusion 
 
 
Figure 16: Overview of the previously discussed prevalent bioorthogonal reactions in the context of protein 
modification and their respective rate constants. Rate constants were taken from [54,107]. The protein structure 
is part of FAAP20-UBZ (PDB ID: 3WWQ) and was used as a dummy protein for illustrative purposes. 
 
The reactions discussed in chapter 2.2 helped to provide detailed insight into protein 
structures, their dynamics and functions, both in vitro and in live organisms. Areas of 
application include the modification of protein functions, visualization of protein-protein 
interactions and protein trafficking up to super-resolution imaging, as well as the generation 
of protein-based pharmaceuticals. However, challenges still remain for the field of 
bioorthogonal chemistry. Figure 16 summarizes the previously discussed, prevalent 
methods of bioorthogonal labeling. Since rate constants greatly differ depending on 
environmental factors (pH value, temperature, solvent) and chemical surroundings, the 
specified second-order rate constants refer to a unifying study by Saito and co-workers. 
Here, chemoselective ligation reactions were evaluated for systems consisting of an 
unprotected peptide, equipped with a unique N-terminal functional group and an organic 
dye molecule bearing the complementary functionality. The reaction partners were supplied 





in equimolar ratio, using optimized conditions for aqueous systems.[54] For the IEDDA 
reaction, the rate constant was determined for the reaction between a tetrazine modified 
GFP derivative and sTCO under pseudo-first-order conditions and the second-order rate 
constant was derived from the measurements.[107] Taking into account that for 
stoichiometric reactions at a 100 μM reactant concentration, a rate constant of 1 M-1s-1 
would correspond to reaction times of over one day to achieve >90% conversion,[34] it 
becomes evident that most reactions to date do not yet meet this criterion for bioorthogonal 
ligations. Furthermore, the stability of hydroxylamines, phosphines and tetrazines poses 
problems for applications were longer incubation times are required. In addition, some of 
the presented reactions are not truly bioorthogonal: aldehydes and ketones are present in 
many metabolites in living systems, strained alkynes may react with free thiols and the 
Staudinger ligation, CuAAC and SPAAC target the same residue, while the presence of 
transition metals and the hydrophobicity of cyclooctyne and cyclooctene derivatives may 
still cause concerns for in vivo applications.[108] 
 
2.3 Templated ligations 
 
While the concept of bioorthogonal reactions can be seen as an expansion of conventional 
laboratory synthesis by offering uniquely selective functionalities with ideally high reaction 
rates, nature relies on a different approach to control reactivity. Here, a plethora of 
reactants are present in a system at concentrations too low (nM-μM) to enable 
spontaneous intermolecular reactions. Instead, selectivity and rate control are achieved by 
macromolecular templates. These molecules recognize reagents, bind them non-
covalently and bring their reactive centers into proximity, thereby increasing the effective 
molarity, while also providing catalytic functionality.[109] This concept is illustrated in Figure 
17 for the biosynthesis of isopenicillin N. 
  




Figure 17: Biosynthesis of isopenicillin N. The starting materials are selectively recognized and undergo 
enzyme-catalyzed peptide bond formation to give a tripeptide, which undergoes thiazolidine formation, 
catalyzed by IPN synthase (PDB ID: 1BK0).[110] Figure inspired by [109]. 
 
Exploitation of this strategy would offer interesting opportunities for protein labeling. Indeed, 
high selectivity has been achieved by utilizing proteins that undergo self-modification 
reactions, such as the SNAP,[111] CLIP,[112] Halo[113] or TMP[114] tag and fusing them to 
proteins of interest. However, the size of these tags (ca. 18-33 kDa) are of major concern. 
Another approach is to use enzymes that selectively promote reactivity between functional 
groups or short peptide recognition sequences and reactive probes, such as sortase A,[115] 
biotin ligase[116] or transglutaminase.[117] In these cases, high substrate concentrations or 
long incubation times may be required. The development of methods that focus solely on 
the concept of effective molarity, i.e. a reaction template is therefore of prime interest for 
biochemical researchers with the goal to create minimally invasive tags that facilitate 
specific labeling under dilute conditions. 
 
2.3.1 Nucleic acid templates 
 
Nucleic acids present an obvious choice as a template. Due to their natural occurrence 
they are already compatible with in vivo applications, while the Watson-Crick base pairing 
between two complementary nucleobases offers a high degree of selectivity and 
preorganization between the reaction partners. Liu and co-workers exploited these 
characteristics to develop the field of DNA-templated organic synthesis (DTS). Here, 
complementary DNA strands are utilized to enable reactions between organic molecules 
attached to opposing ends. This principle was successfully applied to the templated 
reaction of a thiol and a maleimide. The reaction proceeded at 25 °C and pH 7.5 with a 
reagent (strand) concentration of 60 nM and a rate constant of kapp = 105 M-1s-1. Under 
these heavily dilute reaction conditions, little to no product formation was observed for the 
nontemplated approach, as well as for mismatched template strands.[118] The same 
approach has been applied to a variety of organic reactions, such as reductive amination, 
Heck coupling, Wittig olefination, nitro-aldol and Huisgen cycloaddition.[119,120] Impressively, 





DTS was also applied to selectively form reaction products in a one-pot experiment of 
competing functional groups. Selectivity was installed by the choice of individual annealing 
sequences and template length, thus generating mismatches and suppressing the 
formation of undesired reaction products (see Figure 18).[121] 
 
 
Figure 18: Selective targeting of maleimide moieties with competing functional groups. Selectivity is achieved 
by incorporating templates with different annealing sequences and strand lengths. Figure based on [121]. 
 
Seitz and co-workers demonstrated that nucleic acid templates can also be used for the 
generation of native peptide bonds. Peptide nucleic acid (PNA) strands were chosen as 
reactive strands due to their compatibility with peptide chemistry. PNA is a non-ionic DNA 
analogue, based on an N-2-(aminoethyl)-glycine (aeg) backbone, to which the nucleobases 
are attached via carboxymethylene linkages. The molecule exhibits high affinity to 
complementary DNA or RNA templates and a low mismatch tolerance. Two short PNA 
fragments bearing either their native termini or a C-terminal glycine thioester on one strand 
and an N-terminal cysteine residue on the other were selected. The fragments were 
annealed to a complementary DNA strand in such a fashion that the reactive termini were 
facing each other. Formation of the peptide bond was achieved by addition of a 
carbodiimide reagent to the native termini or by native chemical ligation. Probe 
concentrations of 1 μM with respect to 500 nM template enabled successful ligation within 
120 min at 25 °C (see Figure 19).[122] Installation of an abasic site was found to further 
increase the initial reaction rate by 103 over the non-templated ligation and introduction of 
a single nucleobase mismatch led to a 103 fold increase in reaction rate.[123] 
 
 
Figure 19: DNA-templated formation of a native peptide bond. The DNA strand (grey) serves as a template for 
two complementary fragments of PNA, equipped with a C-terminal thioester (blue) or an N-terminal cysteine 
(red). The reaction proceeds via formation of a thioester which prompts an intramolecular nucleophilic attack 
by the α-amino group of the N-terminal cysteine to establish the amide bond. Figure based on [122]. 
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Research in our group has focused on one of the limitations of DNA templated ligation. 
While one of the templating scaffolds is removed upon product formation, previous designs 
had the second strand permanently attached to the distal site of the other reagent. Middel 
et al. introduced a photocleavable linker (PCL) between the guiding PNA strands and 
reactive peptide fragments that allowed traceless liberation of the ligated peptide upon 
irradiation (see Figure 20).[12] Recently, a similar approach has been reported by Hayashi 
et al. Introduction of photocleavable DNA templates to the side chains of peptide fragments 
allowed the simultaneous templated ligation of several peptide fragments.[124] 
 
 
Figure 20: Overview of the photocleavable, PNA mediated NCL. Base pairing of the PNA nucleobases brings 
the reactant peptides into proximity to enable NCL between a cysteine and a side chain bound thioester. After 
completion of the reaction, the ligation product is released by photolysis of an o-nitrobenzyl derived linker. 
Figure based on [12]. 
 
Furthermore, Gothelf and co-workers developed a strategy, which applies DNA templates 
in the labeling of proteins. This approach, referred to as DNA-templated protein conjugation 
(DTPC) relies on pretargeting of proteins with a guiding DNA strand, followed by annealing 
of a reactive strand to form a covalent bond with the target protein. In preliminary work, 
pretargeting of His6-tagged or WT-metal binding proteins (GFP-His6, serotransferrin) was 
carried out with a guiding strand, equipped with a metal binding moiety. A complimentary 
oligonucleotide (ON) strand modified with an NHS ester was added and underwent 
selective conjugation to the ε-amino group of a proximal lysine residue, located near the 
metal binding site on the protein. The conjugation was selective under dilute conditions 
(0.25 μM), displaying a conversion of 61% after 3 h. Product and guiding strand were 





separated by toe-hold-mediated strand displacement (see Figure 21).[125] The scope of this 
technique was broadened by utilizing reductive amination as the DTPC reaction on  
GFP-His6. Additionally, installation of an oxidation labile linker between the aldehyde 
moiety and the reaction template gave access to a second reaction handle. A 1,2-diol linker 
was used to install an aldehyde moiety upon oxidative cleavage that was subsequently 
targeted by alkoxyamine-PEG 5000.[126] DTPC was furthermore used in the synthesis of an 
ADC. A guiding strand equipped with a Ni2+ chelating ligand was used to target a cluster of 
three histidine residues in the Fc domain of the antibody cetuximab. Annealing of the 
complementary reactive strand bearing an aldehyde moiety, followed by reductive 
amination targeting a proximal lysine residue yielded a covalent linkage between DNA 
duplex and mAb. As cargo, the hydrophobic anticancer drug doxorubicin was selected. The 
drug intercalates non-covalently into ds-DNA. While normally suffering from poor selectivity 
due to lack of active targeting capability, using the antibody as a delivering system negated 
this effect. Additionally, the selectivity of DTPC yielded homogeneous ADCs and therefore 
control of loading capacity. The construct was shown to exhibit highly selective cell toxicity 
against EGFR+ cancer cells, allowing the release of the non-covalently bound drug after 
internalization of the ADC.[127] Other methods of pretargeting have been explored in the 
form of protein-binding cyclic peptides.[128] 
 
 
Figure 21: Illustration of DNA-templated protein conjugation on GFP-His6 (PDB ID for GFP: 1GFL). The 
histidine-tag (green semicircles) of the protein is pretargeted by the guiding DNA strand (blue) bearing a Ni2+ 
(lime green) chelating ligand (blue semicircles). The reactive DNA strand bearing an NHS ester (red) is 
annealed, followed by covalent linkage to an ε-amino residue proximal to the His-tag. The guiding DNA strand 
is removed by strand displacement. Figure based on [125]. 
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2.3.2 Peptide templates 
 
While nucleobases offer a defined scaffold to form complementary interactions, transfer of 
this information in peptides is more intricate. Since a uniquely defined and predictable 
protein tertiary structure is required to perform this task, it necessitates intimate knowledge 
of the relationship between peptide sequence and protein structure. Lee et al. disclosed 
that a 32-residue α-helical peptide based on the leucine zipper homodimerization domain 
of yeast transcription factor GCN4 was able to template its own self-replication. Recognition 
in the leucine zipper is based on the structural motif of an α-helical coiled-coil peptide. It is 
defined by an amphiphilic primary sequence consisting of a series of heptad repeats 
(abcdefg)n, where the amino acids at positions a and d define a hydrophobic core that 
serves as a continuous recognition surface throughout the protein. Native chemical ligation 
on the solvent-exposed surface was performed between a 17-residue thioester fragment 
and a 15-residue fragment bearing an N-terminal cysteine, each identical in sequence to 
their complementary part on the template chain. An autocatalytic efficiency of 
approximately 500 was achieved for the ternary reaction.[129] Introduction of charged 
residues flanking the hydrophobic core led to a higher degree of selectivity through salt-
bridge formation for matching pairs and electrostatic repulsion for mismatched pairs. To 
achieve this effect, Kennan et al. introduced charged residues (lysine or glutamic acid) i at 
heptad positions e and g that would form salt-bridges with amino acids of opposite charges 
at position i’+5 or i’-5, respectively, on the complementary strand. The resulting entropic 
gain from binding the substrate led to a 4100-fold increase in initial reaction rate of the 
autocatalytic reaction over the non-templated ligation.[130] 
Tamamura and co-workers used an antiparallel coiled-coil trimer of a GCN4 mutant to 
develop a tool for the fluorescent imaging of proteins. A dimeric coil-loop-coil motif was 
established as a tag motif, wherein the loop contained a cysteine residue for crosslinking 
and two leucine residues had been substituted for alanine to provide a hydrophobic pocket 
for an environmentally sensitive dye. The dye was introduced to the side chain of the 
complementary third α-helical peptide, which was further modified N-terminally with 
chloroacetic acid. Upon addition of the probe peptide to the tag, a covalent link between 
the two fragments was established and the fluorescence of the dye increased due to the 
hydrophobic environment. Proximity induced crosslinking was performed in a one-to-one 
ratio of substrates at a concentration of 1 μM for 20-30 min (see Figure 22).[131] 
  






Figure 22: Fluorophore labeling by proximity induced crosslinking. An antiparallel coiled-coil dimer serves as 
a reaction scaffold for a probe strand bearing an environmentally sensitive dye. Upon recognition, the trimer is 
established by formation of a covalent bond between linker region of the dimer and N-terminus of the probe. 
Binding of the dye inside the hydrophobic cavity greatly increases fluorescence. Figure based on [131]. 
 
Further studies on the coiled-coil motif have revealed a basic set of characteristics that 
define the sequence-to-structure relationship. The term defines two or more α-helical 
peptides with a 3.5-residue repeat that wrap around each other, forming a left-handed 
supercoiled quaternary structure. Following the aforementioned general heptad repeat 
pattern of (abcdefg)n, where a and d are hydrophobic amino acids, interactions between 
helices are mainly controlled by these two positions. The side chains of amino acids a and 
d (knobs) thereby insert into diamond-shaped regions, formed by the side chains of the 
recipient helix (holes). These interactions lead to the formation of a hydrophobic core along 
the continuous heptad pattern. The steric demand of the amino acid side chains placed at 
positions a and d (Ile or Leu) furthermore controls the oligomer state of the coiled coils, 
owing to the fit into the resulting holes. A rationally designed toolkit for de novo design 
additionally requires glutamic acid and lysine at positions g and e to establish 
intermolecular salt bridges, while alanine at positions b and c promotes helicity. Introduction 




Figure 23: Helical-wheel representation of a coiled-coil heptad unit. Small letters represent the heptad position, 
whereas the capitalized letters represent the corresponding amino acid. The hydrophobic core is highlighted 
by amino acids on grey background, salt bridges are established between glutamic acid and lysine at positions 
e and g. Figure based on [133]. 
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Litowski et al. used these general design principles to design a heterodimeric parallel 
coiled-coil, termed E3/K3, in which dimer formation is specified by having all glutamic acid 
residues at positions e and g of one strand (E3), and lysines on the opposing strand (K3). 
Charged residues at position f were opposite to those at positions e and g to decrease the 
net charge. The dimer, comprised of three heptad repeats per coil, showed a dissociation 
constant of 70 nM (see Figure 23).[133] In a series of publications, the groups of Seitz and 
Beck-Sickinger applied this system for the covalent labeling of membrane proteins. In their 
seminal work, the E3/K3 coiled-coil served as a tag/probe pair to transfer a fluorescent 
label from the K3-donor strand to the target protein-fused E3-acceptor strand via templated 
NCL. Therefor, the E3-peptide bearing an N-terminal cysteine was fused to the WW2 
protein domain (5.8 kDa total). The K3 peptide, bearing a thioester-linked fluorophore 
(TAMRA) was added and transfer of the probe (1.0 μM) to the WW2 domain (0.5 μM) 
occurred in 58% yield after 10 min in neutral buffer. General applicability of the method in 
a complex environment was demonstrated for the labeling of the Cys-E3-tagged human 
neuropeptide Y2 receptor (hY2R(1-46)), C-terminally fused to the autofluorescent eYFP 
(37.5 kDa total). Addition of the TAMRA-K3 tag provided labeling within two minutes at a 
probe concentration of 20 μM or 100 nM for the labeling of cells expressing Cys-E3-hY2R-
eYFP. These finding demonstrated a minimally invasive tag/probe system, applicable for 
rapid in cellulo fluorescent imaging at low concentrations of the labeling agent (see Figure 
24).[134] The scope of this method was further broadened by introducing a variety of 
fluorescent dyes (TAMRA, AF350 or ATTO488) and labeling of different membrane 
proteins of the family of G protein-coupled receptors (GPCR), such as hY1R, hY2R, hY4R, 
hY5R, human neuropeptide FF receptors 1 (hNPFF1R) and 2 (hNPFF2R) and the human 
dopamine receptor 1 (hD1R). The authors further observed different yields for the transfer 
of the fluorescent label. While AF350-equipped K3 showed 58% yield after 2 min, 
ATTO488 transfer reached 50% after 10 min and transfer of TAMRA plateaued at 41% 
after 5 min. The latter effect was attributed to competing hydrolysis of the TAMRA-thioester, 
while the general discrepancy in reaction rate was attributed to the difference in fluorophore 
structure. It was furthermore observed that the K3-donor peptide does not penetrate the 
cell membrane, which limits the application of this method to the labeling of extracellular 
proteins.[135] In addition, the templated acyl transfer was used to investigate the 
internalization of GPCRs. A two-color pulse-chase experiment was designed to visualize 
the internalization pathway of two separately labeled and stimulated populations of hY2R. 
For this, unstimulated, Cys-E3-tagged GPCRs were labeled with TAMRA-K3. Stimulation 
(i.e. internalization) of the receptor was induced by addition of the exogeneous ligand 
porcine neuropeptide Y (pNPY). After 30 min, ATTO488-K3 was used to label the 
remaining hY2R at the cell surface. Again, the receptors were internalized and the two 





populations were tracked by fluorescence microscopy. The experiment revealed the fusion 
of both subsets within the early endosome 10 min after the second stimulation.[136] 
 
 
Figure 24: Schematic representation of coiled-coil mediated membrane protein labeling by acyl transfer. The 
acceptor strand (red) is fused to the protein of interest. Upon addition of the donor strand (blue) and coiled-coil 
recognition, NCL transfers the thioester-linked fluorophore from the donor to the acceptor strand. Figure based 
on [136]. 
 
Wang et al. used a similar system for protein labeling by covalently linking two coiled-coil 
strands. The utilized CCE3/CCK3 pair is similar to the previously described E3/K3 motif, 
but isoleucine residues in the hydrophobic core were replaced by valine. Furthermore, a 
pair of opposite amino acids in the hydrophobic core (a-a’ or d-d’) were replaced by cysteine 
and an α-chloroacetyl functionalized amino acid. Formation of the heterodimer was 
followed by an SN2 reaction to establish a thioether bond with the same length as the 
natural distance between the two strands. The authors found a preference for substitution 
of terminal amino acids, observing 50% conversion after 13.8 min when replacing the first 
a position in both strands. This effect was explained by a lower disturbance of the overall 
peptide structure and its stability, a higher flexibility of the functional groups at the strands 
termini and a better hydration of the leaving group (chloride ion). It was also shown that the 
use of coiled-coil tectons, i.e. peptides with maximum specificity to their binding partner, 
provided orthogonality for the covalent ligation of three coiled-coil pairs. Application of the 
covalent dimer formation for labeling purposes was shown by labeling a modified epidermal 
growth factor receptor (EGFR) on the surface of mammalian cells. Prior experiments had 
shown that labeling was more efficient when employing the CCK3 strand as a dimer, which 
resulted in labeling of the receptor within 20 min at a probe concentration of 0.2 μM or 
1.0 μM.[137] 
Similarly, Yano et al. used an in cell-crosslinking approach based on a sulfosuccinimide 
ester to covalently label membrane proteins. A heterodimeric parallel coiled-coil pair was 
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selected, and lysine residues were substituted for arginine to avoid side reactions. The 
fluorescent dye was attached to the N-terminus of the probe, (RIAALRE)3GC, while the  
C-terminal amide was labelled with a sulfosuccinimide ester. The probe sequence, 
(EIAALER)3, was fused to the target protein via a lysine containing linker peptide. The 
method was used to label the β2-adrenergic receptor in CHO-K1 cells, as well as to analyze 
the oligomer states of glycoprotein A by FRET measurements. In both cases, labeling was 
carried out with a probe concentration of 150 nM for 20 min.[138] 
Ball and co-workers demonstrated additional applications of a coiled-coil template by using 
a dirhodium metallopeptide catalyst for the covalent modification of a variety of amino acid 
side chains. The system used a heterodimeric coiled-coil based on Hodges’ E/K peptides. 
The metallopeptide catalyst was generated by attaching Rh2(OAc)4 through glutamate side 
chains at heptad positions a and e of the K3 strand. On the acceptor strand (E3), tryptophan 
was introduced at the heptad position g opposite the catalytically active site. The catalyst 
was utilized for the covalent modification of Trp with a styryl-diazo reagent. 74% conversion 
was achieved within 2 h, a catalyst loading of 2 mol%, a substrate concentration of 50 μM 
and 70 eq. of the diazo compound at pH 6.2. It was further demonstrated that the 
modification of Tyr and Phe was likewise possible, albeit at a lower reaction rate, reaching 
50% conversion after 5 h with a catalyst loading of 20 mol%.[139] The scope was further 
expanded to include amino acids Cys, Gln, Asn, Glu, Asp, Arg, Ser, His and Lys as possible 
targets for the diazo reagent. In addition, modification was carried out utilizing a naturally 
occurring coiled-coil pair. A glutamine residue in the leucine zipper (bZip domain) of the 
oncogene c-Fos was selected and targeted by an affinity-optimized variant of its natural 
binding partner c-Jun, with glutamate residues at heptad positions a and g binding 
Rh2(OAc)4. Modification of c-Fos (100 μM) was carried out using two equivalents of the 
peptide catalyst and an excess (10 mM) of the diazo reagent. Higher yields were observed 
at lower temperatures (17% at room temperature compared to 52% at -15 °C after 24 h), 
which was justified by a higher stability of the coiled-coil at lower temperatures.[140] Chen et 
al. demonstrated the applicability of this method for the labeling of proteins under biological 
conditions. The proximity induced ligation proved to be efficient enough to overcome the 
preferred pH range of the catalyst of ≤ 6.2, as demonstrated by an 80% conversion after 
45 min in PBS buffer at pH 7.4. In addition, a biotin-diazo compound was synthesized and 
applied to the labeling of maltose binding protein (MBP). The tryptophan modified E3 
peptide was fused to the C-terminal end of the protein (1 μM) and reacted with diazo-biotin 
(100 μM) upon addition of the K3(Rh)2 catalyst (5 μM) in physiological buffer. 70% 
conversion was observed after a reaction time of 16 h at 4 °C (see Figure 25).[141] 
Interestingly, the repetitive nature of the heptad motif allows for the design of orthogonal 
acceptor/metallopeptide pairs. It was demonstrated that varying the position of the Trp 





residue on the acceptor strand (e or g) or within the sequence (2nd or 3rd heptad) created 
facial or axial mismatches that led to stark discrepancies in selectivity (~ 9:1) when 
competing with the corresponding matched pair. These findings were exploited for the 
simultaneous labeling of MBP and glutathione S-transferase (GST). The proteins were 
expressed as a fusion with tryptophan modified E3, bearing the residue at the g or e 
position of the second heptad, respectively. Employing two equivalents (2 μM) of the 
catalyst was sufficient to selectively label both proteins simultaneously with diazo-biotin 
(100 μM) at 4 °C within 16 h.[142] 
 
 
Figure 25: Proximity-induced protein labeling with a metallopeptide catalyst. Using a parallel heterodimeric 
coiled-coil, the dirhodium probe mediates the labeling of a tryptophan residue on the acceptor strand by 
catalyzing C-H activation. Figure based on [141], PDB ID for MBP: 1URD. 
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3 Project outline 
 
While an ideal bioorthogonal ligation would be suitable for any number of chemoselective 
protein modifications, in reality, disadvantages such as substrate stability and excess 
reagent use might restrict applications. Templated organic synthesis has been identified as 
a possible solution, taking inspiration from nature. There, such reactions are widely used 
in biological systems to accelerate or enable covalent bond formation by bringing reactants 
into proximity, thereby increasing their effective molarity. More widespread use of this 
approach has been limited by the fact that at least one part of the templating scaffold is 
retained on the target protein after the ligation. To address this limitation, Middel et al. 
disclosed a PNA templated NCL that allows the removal of the template strands from the 
ligation product via photolysis of a photocleavable linker. Here, the two N-terminally 
activated peptides, a thiol and a thioester, are attached via CuAAC between the azide 
moiety of a nitrobenzene linker and the directing PNA strands. PNA base pairing brings the 
reactive groups into proximity, thereby enabling ligation. Photocleavage of the PNA 
auxiliary groups leaves the ligation product, a side chain-to-side chain linked isopeptide.[12]  
To fully capitalize on the advantages of templated ligation, the long-term goal in our 
workgroup is to use this approach for the mediation of two simultaneous ligation events 
(see Figure 26). The orthogonality encoded within the sequence of the template (red or 
blue strands) would provide chemoselectivity for both reactions, even when employing 
functional groups with competing reactivity (moieties A and B). The purpose of this thesis 
is the development of methods necessary to achieve this goal. Therefore, orthogonal 
templates have to be identified and tested in a one-pot reaction that performs a parallel 
ligation. Orthogonality of the templates is achieved, if there is a significant energy gap 
between least favorable desirable and most favorable undesirable template interaction, i.e. 
between matched and mismatched pairs. This can be achieved in two ways. First, due to 
selectivity installed in the sequence of the template’s building blocks and second due to the 
use of two templates that utilize different modes of recognition. 
 






Figure 26: Schematic representation of the parallel functionalization of a protein employing two orthogonal 
templates (red and blue). Depicted are two reaction architectures leading to full (left) and partial (right) removal 
of the scaffold after successful ligation. 
 
Sequence-programmed control over product formation in a multicomponent ligation 
system  
 
The first project assesses the sequence selectivity and viability of PNA as an orthogonal 
template. Based on the findings by Middel et al.,[12] two independently complementary sets 
of parallel PNA strands (cPNA) are used as templates in a one-pot reaction between 
peptides with competing functionalities (see Figure 27). Annealing of the template strands 
is based on the self-recognition of complementary Watson-Crick base pairs.[143] PNA has 
been shown to exhibit a higher thermal stability and lower mismatch tolerance than its 
natural counterparts, DNA and RNA.[144] Therefore, two distinct duplexes are expected to 
show strong strand discrimination based on the energy penalty associated with a 
mismatched base pair. In addition, PNA oligomer synthesis is fully compatible with 
standard SPPS procedures, making it an ideal candidate for the identification of orthogonal 
template pairs. A series of oligomers with positional or size mismatches are synthesized, 
and their selectivity is determined by UV-Vis melting curve measurements. To facilitate this 
undertaking, a method for the automated solid phase synthesis of PNA oligomers is 
developed.  
 




Figure 27: Schematic representation of the PNA mediated one-pot reaction between peptide fragments with 
competing functionalities. Orthogonality is installed by selection of independently complementary oligomer 
sequences.  
 
Development of a PNA mediated Suzuki cross-coupling ligation 
 
The second project focuses on expanding the scope and optimization of the photocleavable 
template. Our goal is to promote a reaction between two latent halves of a fluorophore 
whose functionality is restored upon ligation. We chose the Suzuki coupling, since it has 
been well established for the work on peptides and proteins and is compatible to the 
required mild conditions.[96] Furthermore, access to halogenated tryptophan derivatives 
enables linear synthesis of the two ligation partners that would form a Trp-Phe 
fluorophore.[145,146] As a proof of concept, the ligation is demonstrated between two peptide 
strands and subsequently the influence of the template is investigated (see Figure 28). One 
of the drawbacks of Middel’s original system is the prolonged irradiation at low wavelengths 
necessary to cleave the guiding strands, thereby increasing the potential phototoxicity in 
biological systems. Coumarin derived photocages have been extensively studied[147] and 
display high quantum yields and ultrafast release.[148–151] A 7-diethylamino-4-
methylcoumarin (DEACM) derivative, based on the work of Seyfried et al.[152], is therefore 
pursued as a viable alternative to the 4,5-dimethoxy-2-nitrobenzyl (DMNB) linker. 
 






Figure 28: Schematic representation of the novel Suzuki coupling ligation strategy using photocleavable PNA 
strands as the directing scaffold. 
 
Evaluation of coiled-coil peptides as a platform for templated reactions 
 
Since most templated ligations rely on NCL or other ligations targeting canonical amino 
acids, we sought to find a platform that would support a variety of bioorthogonal ligation 
methods. Coiled coils were chosen as the templating motif, because of their facile 
synthesis, well understood association mechanism and previous application as a reaction 
scaffold.[132,153] They would furthermore provide an orthogonal template to PNA, since their 
association is mainly based on the interaction of hydrophobic residues, resulting in the 
formation of a hydrophobic core. Inspired by the work of Reinhardt et al.,[134] the aim of the 
third project is to attach different functional groups for bioorthogonal ligations to the  
N-termini of a parallel heterodimeric coiled-coil, thus achieving proximity induced covalent 
bond formation between the strands. Introduction of a photocleavable linker on the donor 
strand minimizes the tag size, ultimately resulting in a functional group transfer. The 
implementation of a variety of ligation reactions offers a modulable platform for an 
application-tailored approach (see Figure 29). 




Figure 29: Schematic representation of a novel coiled-coil templated tag-and-modify approach utilizing a 
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4 Results and discussion 
4.1 Sequence-programmed control over product formation in a 
multicomponent ligation system 
 
In this chapter, the ability of PNA templates to mediate multiple reactions simultaneously 
based on their sequence selectivity is evaluated. The system is based on complementary 
PNA/peptide hybrids that have been developed previously.[154] They consist of PNA 
decamers as recognition units and utilize Melnyk’s SEA native peptide ligation.[155] Hybrids 
are generated by conjugation with a photocleavable linker. This chapter introduces the 
general properties of PNA oligomers and their duplex formation (chapter 4.1.1), as well as 
the design of the system (chapter 4.1.2). Identification and selection of duplexes with 
sequence orthogonality is discussed based on UV-Vis melting curve measurements, while 
an emphasis is placed on the optimization of the PNA oligomer synthesis (chapter 4.1.3). 
The following subsections describe the buildup of the PNA/peptide hybrids consisting of 
the thioester surrogate for native peptide ligation (chapter 4.1.4), synthesis of the 
photocleavable linker and incorporation into peptides (chapter 4.1.5), as well as the 
conjugation to the PNA templates via CuAAC (chapter 4.1.6). The last section evaluates 
the selectivity of the templates in a competitive one-pot experiment (chapter 4.1.7). 
 
4.1.1 Properties of PNA oligomers and their duplex formation 
 
PNA is a fully synthetic DNA analogue in which the backbone consists of pseudopeptidic 
N-(2-aminoethyl)glycine (aeg) units that are structurally homomorphous to the deoxyribose 
phosphate backbone. The natural DNA nucleobases are retained and attached to the 
glycine nitrogen via a methylene carbonyl linker. Although originally designed as a DNA 
major groove binding ligand, PNA displays sequence-specific Watson-Crick binding to 
complementary nucleotides.[156] PNA hybridizes with both naturally occurring 
oligonucleotides, forming right-handed, antiparallel helices resembling B-DNA (PNA-DNA) 
or the A-form of RNA duplexes (PNA-RNA). The formed dimers exhibit thermal stabilities 
well above those of their corresponding natural counterparts, likely owing to the lack of 
repulsion between the backbones.[157–159] Two complementary PNA strands also form a 
duplex, with the antiparallel strand orientation being preferred. The antiparallel 
conformation of a 10-mer is approximately 20 °C more stable than the parallel version, 
which is comparable to complexes formed between DNA strands. The helices are wide and 
shallow with a large pitch (18 bp), with base pair stacking similar to the canonical A-form. 
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Because the monomers contain no asymmetric centers, helices are stacked alternating 
between right- and left-handed forms. Chiral information, and therefore control of the helix- 
handedness, can be introduced by addition of enantiomerically pure amino acids into the 
sequence or by binding to a chiral oligomer. Antiparallel PNA exhibits a low mismatch 
tolerance, with a single mismatch resulting in a drop of the melting temperature by 
approximately 20 °C.[143,160] 
 
4.1.2 System design and synthesis strategy 
 
The chimeric character of PNA between nucleic acids and peptides and the accompanying 
accessibility by SPPS,[157] as well as the stability in a cellular environment, i.e. towards 
nucleases and proteases, have made PNA the template of choice for the system described 
by Middel et al. Briefly, a parallel PNA duplex was used to align two reactive peptide 
fragments (thiol and thioester) to undergo NCL. Introduction of a photocleavable linker 
between the peptide and the PNA scaffold allowed traceless removal of the latter by 
irradiation.[12] After successful demonstration of this concept, a possible application lies in 
the dual functionalization of a protein with two imaging or bioactive moieties. This approach 
requires the identification of two orthogonal templates, in this case PNA duplexes. 
Selectivity is encoded within the nucleobase sequence. Even when employing competing 
functional groups in the ligation, strand displacement of the lower energy complex would 
leave only the groups attached to the matched strands with a sufficiently high effective 
molarity for a reaction to proceed. The feasibility of this strategy is evaluated in this chapter. 
The ligation approach has not been changed in comparison to the original approach and 
the most successful conditions have been selected. Its modular synthesis is presented in 
Figure 30. Synthesis of SPPS applicable building blocks of the DMNB-based PCL and the 
thioester precursor was required for the generation of the reactive peptide fragments. 
Conjugation to alkynylated PNA strands by on-resin CuAAC yielded the corresponding 
PNA/peptide hybrids, which after activation of the thioester and deprotection of the thiol 
fragment underwent templated NCL. Capping of the resulting free thiol and photocleavage 
of the templating strands yielded the side chain linked ligation product. Reaction 
procedures were duplicated from the PhD thesis of Stephen Middel or marginally improved 
upon, while emphasis was placed on the optimization of PNA coupling conditions and 
automatization.[154] 




Figure 30: Schematic representation of the photocleavable PNA-templated NCL approach. Figure inspired by 
[154]. 
 
4.1.3 Identification of complementary PNA duplexes with sequence 
orthogonality 
 
The influence of mismatched nucleobases on the thermal stability of oligomers containing 
at least one PNA strand has been best studied for antiparallel PNA-DNA duplexes. Kilså 
Jensen et al. conducted a study on the stability of antiparallel duplexes between 15-mer 
mixed sequence PNA and complementary DNA and RNA strands. Mismatches were 
introduced in one of the four center base positions and each possible mismatch (12 variants 
total) was investigated. Depending on the position and chemical nature of the mismatch, a 
drop in melting temperature of 8-19.5 °C was observed for the DNA-PNA complexes. 
Similar results were observed for the RNA-PNA complexes, where the destabilization 
ranged from 9.8-20.6 °C. The most stable mismatches occurred for the G∙T wobble base 
pairing, which still retains two hydrogen bonds.[161] A study by Igloi on the stability of single 
base mismatched 11-mer PNA-DNA 17-mer duplexes (5bp overhang on the 5'-end) 
affirmed the importance of mismatch position and chemical nature. Melting point 
differences of as low as 0.4 °C for a G∙T mismatch at the 3'-end were observed, contrasted 
by a drop in stability of 24.6 °C for a G∙G mismatch four base pairs from the 5'-end. The 
study revealed the G∙T and T∙T pairs to be most stable among the mismatches, while A∙A 
and G∙G contributed the most destabilization. Maximal destabilization occurred at positions 
four base pairs from either end.[162] Ratileinen et al. studied the effect of mismatches at the 
central position of 9-mer PNA-DNA and 12-mer PNA-DNA duplexes. While introduction of 
the mismatch on the DNA strand mirrored the aforementioned results, with drops in melting 
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temperature of 13-17 °C for the 9-mer and 15-21 °C for the 12-mer, introduction of the 
mismatched base pair on the PNA strand (only 9-mer series) resulted in a deviation from 
the trend. Stark drops in melting temperature were observed for C∙T and T∙T mismatches 
(32 °C and 29 °C), resulting in melting temperatures for the duplexes around 10 °C. On the 
contrary, the G∙T mismatch only displayed an 8 °C drop.[144] Studies on the destabilizing 
effect of purely PNA containing duplexes are scarce. Wittung et al. found that T∙T and C∙C 
mismatches in an antiparallel 10-mer decreased the melting temperature by 16 °C and 
20.5 °C, respectively. Introduction of two C∙C mismatches led to a destabilization of over 
25 °C.[143] Similarly, Sacui et al. determined drops in melting temperature of -20 °C and  
-27 °C when introducing a G∙T or T∙T mismatch on antiparallel, left handed γ-methyl PNA 
(γPNA). No hybridization was observed for the C∙T mismatch.[163] 
 
In order to conduct this study, it is important to have fast and reliable access to PNA 
oligomers of high quality. While PNA is fully compatible with solid phase synthesis, 
prolonged coupling times complicate the process. Coupling times of 45 min are required, 
which, in addition to deprotection (10 min) and capping (5 min), leads to a coupling cycle 
of 2 h per monomer since every step is performed in duplicate to guarantee maximum 
coupling efficiency. Furthermore, several washing steps are required that add to the total 
time. For a single 10-mer the coupling time therefore exceeds 20 h.[154] Taking inspiration 
from the current state of the art in SPPS, it seemed reasonable to assume that PNA 
synthesis could be carried out assisted by microwave irradiation and possibly also in an 
automated fashion on a peptide synthesizer. Based on previous work in our group by 
Geralin Höger on the synthesis of β-PNA,[164] a microwave assisted synthesis protocol was 
developed. Deprotection of the N-terminal Fmoc-protecting group was carried out with 20% 
piperidine in DMF at 40 °C for 1 min, followed by a second deprotection step at 50 °C for 
5 min. Coupling of the building blocks was performed after preactivation with HATU, HOAt, 
DIPEA and 2,6-lutidine at 50 °C for 2 x 20 min. The capping step remained unchanged, 
applying a mixture of 10% acetic anhydride and 5% 2,6-lutidine in DMF for 2 x 5 min at 
room temperature. These changes already resulted in a reduced coupling time by more 
than half compared to the manual room temperature approach. Next, a possible 
automatization of the coupling cycle was investigated. The development of the 
methodology described hereafter was carried out in collaboration with Denis Pahlke and 
Patrick Menzel. Since coupling protocols for automated microwave assisted SPPS differ 
from the manual approach and are dependent on the device manufacturer, we first tested 
a protocol developed by the CEM Corporation (Mathews, NC, United States)[165] on a 
Liberty Blue automated microwave peptide synthesizer. Here, coupling was performed on 
a PEG-PS resin (0.23 mmol/g) at a 50 μmol scale. Deprotection of the Fmoc-protecting 




group was carried out for 5 min at room temperature, followed by a second step for 10 min. 
Coupling was performed at 50 °C for monomers A, T and G and at 75 °C for 60 min for 
monomer C, using DIC and HOBt as activators. Surprisingly, when we translated this 
method to our 10-mer sequence (see Table 1, entry 1), only exchanging the resin for a 
NovaPEG Rink amide resin (0.17 mmol/g), we did not observe product formation. Instead, 
a peak corresponding to a truncation after the first coupling was identified in mass 
spectrometry. We decided to directly adapt our room temperature coupling method, since 
it includes additional washing steps, a capping step and less harsh coupling conditions. We 
also decided to test the standard activators DIC and Oxyma and to employ 2% piperazine 
(2 x 15 min) as the deprotection solution, since it is recommended by the manufacturer for 
small scale synthesis (here: 10 μmol).[166] In our hands, this strategy proved more 
successful, yielding the desired 10-mer in acceptable purity. Next, we tested the influence 
of microwave irradiation. We found that deprotection at 40 °C for 1 min, followed by 5 min 
at 40 °C and coupling times of 2 x 30 min at 50 °C proved ideal (see Figure 31). Oligomers 
synthesized in this way provided an optimal compromise between time saved and product 
purity. Decreasing the coupling time to 20 min led to an increased formation of deletion 
sequences, while the effect was more pronounced when increasing the coupling 
temperature. Manual microwave assisted synthesis seems to hold a slight edge over the 
automated version, since it employs more efficient coupling reagents and is better 
compatible with larger synthesis scales. Both methods are however viable and were 
employed in the identification of orthogonal PNA pairs. 
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Figure 31: HPLC chromatograms (215 nm) of (a) crude PNA 2, obtained by manual coupling at room 
temperature and (b) crude Fmoc-PNA 2, obtained by automated microwave supported coupling. The difference 
in retention times can be attributed to the absence or presence of an N-terminal Fmoc protecting group. 
 
To the best of our knowledge, studies on the destabilizing effect of mismatched base pairs 
in parallel PNA-PNA duplexes have not been published. While it seems reasonable to 
(b) 
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assume similar destabilizing effects in the range of 15-20 °C, experiments have to be 
carried out to verify this hypothesis. 
 
Table 1: PNA sequences employed in this thesis. Mismatch positions of entries 1-3 in regard to duplex 
formation with entry 4 are indicated in red. 
Entry Number Mismatch Sequence (N to C) Lys 
1 1 (PNA 1) none g tag atc act K2 
2 2 (PNA 1') C∙C, G∙G g tac atc agt K2 
3 3 (PNA 1'') A∙A, C∙C, G∙G g aac atc agt K2 
4 4 (PNA 2)  c atc tag tga K4 
5 5 (PNA 3)  acg tca caa cta K2 
6 6 (PNA 4)  tgc agt gtt gat K4 
 
Based on the original parallel duplex introduced by Wittung et al.[143] (see Table 1, entries 
1 and 4), two (C∙C and G∙G, entry 2) and three (A∙A, C∙C and G∙G, entry 3) mismatches 
were introduced. While a difference in melting temperature was observed for the 
mismatched complexes the differences were only subtle, with a decrease of 5 °C (PNA 1') 
and 4.6 °C (PNA 1'') when compared to the fully matched duplex (Tm = 46.3 °C). 
Furthermore, introduction of the third mismatch inexplicably led to no further destabilization 
(see Figure 32a). While these results starkly contrast the aforementioned trends,[143] an 
unintentional selection of a mismatch position with little contribution to the thermal 
stability[162] might offer an explanation. This seems however unlikely, since introduction of 
central mismatches supposedly result in the weakest binding interaction, possibly due to 
the remaining short specific regions on either side of the mismatch on the complementary 
strand. Another possible explanation is the coincidental design of unsurprisingly strong 
complexes, despite the introduced mismatches. A hybridization study of DNA to PNA 
oligomer arrays by Weiler et al. revealed few strong hybridization events with PNA 
oligomers containing up to three continuous mismatches in the center of the sequence.[167] 
No explanation of this phenomenon could be identified and therefore seems more like a 
chance encounter, unlikely to be replicated. Instead, it seems more probable that parallel 
PNA duplexes behave differently to their antiparallel counterparts. Therefore, a length 
mismatch was investigated. The 12-mer duplex of PNA 3∙PNA 4 (see Table 1, entries 5 
and 6) showed a melting temperature of 57.5 °C, which equals ΔT = 11.4 °C compared to 
the 10-mer (see Figure 32b). Although not an ideal value, this represented a good starting 
point. Mix-and-match experiments with the 10-mer strands however revealed a different 
picture (see Figure 32c). The mismatched 10-mer∙12-mer complexes were close in melting 
temperatures to the matched 10-mer duplex, with values ranging from 39.1 °C  




(PNA 2∙PNA 4) to 46.7 °C (PNA 1∙PNA 3). Nonetheless, it was decided to test a one-pot 
parallel ligation approach, hoping for sequence selectivity to prevail and applying the  
10-mer and 12-mer parallel duplexes as templates. 
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Figure 32: UV-Vis melting curve measurements of (a) parallel PNA 10-mers with base pair mismatches, (b) 
comparison of 10-mer and 12-mer duplexes and (c) size mismatch between 10-mer and 12-mer strands. 
Measurements were carried out with a strand concentration of 5 μM in TBS buffer (50 mM Tris-Cl, 150 mM 
NaCl) at pH 7.5. 
 
4.1.4 Synthesis of the thioester surrogate 
 
Central to the success of the presented ligation system was the incorporation of a thioester 
precursor that would tolerate the basic conditions necessary during the deprotection step 
of SPPS. The employed thioester was based on the bis(2-sulfanylethyl)amido (SEA) 
peptide ligation developed by Melnyk and co-workers (see Figure 33).[155,168] Activation of 
thioester surrogate I (SEAoff) takes place under reductive conditions, due to formation of 
dithiol II (SEAon) from a disulfide. In-situ formation of intermediate III via N,S-acyl shift yields 
a thioester applicable in NCL. The equilibrium of its formation however lies on the side of 
(a) 
(c) 
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the dithiol. It can be shifted, for example by removing the product via transthioesterification 
(e.g. with 3-mercaptopropionic acid (MPA)), to afford the final thioester (IV). 
 
 
Figure 33: Overview of the SEA native peptide ligation. Figure inspired by [154,155]. 
 
Unless otherwise stated, synthetic procedures in this part of the thesis were replicated from 
the PhD thesis of Stephen Middel[154] and are therefore presented in an abbreviated, 
summarizing form. For application in SPPS, the side chain of glutamic acid was modified 
with the SEAoff building block (see Figure 34). Therefore, bis([2-{triphenylmethyl} 
sulfanyl]ethyl)amine (8) was synthesized by reacting bis(2-chloroethyl)amine (7) with 
triphenylmethanethiol and DBU in an SN2 reaction in 48% yield. 8 was coupled to the side 
chain of N-Boc-protected glutamic acid, using PyBrOP as the coupling reagent. A moderate 
yield of 51% was achieved, followed by oxidative cleavage of the trityl protecting group (Trt) 
with iodine in 78% yield to afford 10. Boc deprotection and Fmoc protection of the amino 
group afforded the final SPPS building block (11) in 37% yield. 
 
 
Figure 34: Synthesis of Fmoc-Glu(SEAoff)-OH. 
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4.1.5 Synthesis of the photocleavable linker and incorporation into peptides 
 
Another key part of the designed system is the photocleavable linker (see PCL in Figure 
30), which allowed the removal of the templating strands upon ligation. The synthetic 
approach slightly deviates from the established procedure, since a Corey-Chaykovsky 
epoxidation was selected to synthesize 13, starting from commercially available  
6-nitroveratraldehyde (12). This stroke saves one synthetic step, since the original 
procedure was designed to transform the aldehyde into an alkene via a Wittig type reaction, 
followed by epoxidation with mCPBA. Since the Corey-Chaykovsky approach yielded a 
moderate 49% of the product, the overall yield of both strategies was similar. Nucleophilic 
ring opening of epoxide 13 with sodium azide provided intermediate 14 in 52% yield. 
Activation of the hydroxy group with N,N'-disuccinimidyl carbonate (DSC) yielded 82% of 
the PCL (15, see Figure 35), which was now directly applicable for peptide synthesis. 
 
 
Figure 35: Synthesis of the DMNB-derived photocleavable linker 15. 
 
Building block 11 was directly incorporated into the thioester peptide fragment following 
standard SPPS procedure, while PCL 15 was attached on resin employing the conditions 
outlined in Figure 36. 
 
 
Figure 36: On-resin coupling of the PCL to the corresponding peptide. 
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Coupling of the thiol fragment and conjugation of the PCL was achieved in a similar fashion, 
after introduction of a tert-butyl thiol protected cysteine to the side chain of the penultimate 
amino acid.  
 
4.1.6 Synthesis of PNA/peptide hybrids 
 
PNA strands 1-4 were synthesized using the newly developed protocols and prepared for 
on-resin CuAAC by introduction of an alkyne moiety. The coupling conditions are 
exemplary presented for PNA 2 in Figure 37.  
 
 
Figure 37: On-resin alkyne functionalization of PNA strands by coupling of propiolic acid. 
 
On-resin azide-alkyne cycloaddition between alkynylated PNA and PCL-peptide fragments 
was carried out using copper(I) iodide and sodium ascorbate. Subsequent cleavage from 
resin and purification by HPLC yielded the desired PNA/peptide hybrids (see Figure 38). 
 
 
Figure 38: Formation of PNA/peptide hybrids by on-resin CuAAC. 
 
In the case of the SEAoff peptide hybrids, transformation into the active species was 
achieved by dissolving the peptide in TCEP containing phosphate buffer at pH 3 and 
addition of MPA (see Figure 39). The individual PNA/peptide hybrids, as well as their 
respective chromatograms are presented in Figure 40. 
 






Figure 39: Transformation of the thioester precursor into the active species. 
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Figure 40: HPLC chromatograms (215 nm) of the purified PNA/peptide hybrids: (a) 10-mer thiol (21), (b) 10-
mer thioester (20), (c) 12-mer thiol (22) and (d) 12-mer thioester (23). 
 
4.1.7 Competitive PNA mediated NCL 
 
Following the successful synthesis of the two complementary PNA/peptide hybrid pairs, 
their reactivity was studied in a one-pot reaction (see Figure 41). Despite the high purity of 
starting materials, no product formation was observed upon addition of ligation buffer after 
24 h. Neither starting material, nor a (cross) reaction product was identified by UHPLC or 
LC-MS analysis. Instead, a reaction mixture without distinctly separated peaks was 
observed. This could be either the result of retention times of the reactants being too 
similar, or due to the fact that the nucleobase recognition was not selective enough, 
(c) 
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therefore forming mixed products, effectively lowering the concentrations under the 
detection limit. A combination of both factors seems likely, thereby disproving the 
applicability of parallel PNA duplexes for simultaneous ligation events. 
 




In this chapter it was evaluated whether orthogonal photocleavable PNA templates can 
mediate two ligation events with competing functional groups. To this end, a new method 
for the automated solid phase synthesis of PNA was developed. Strands of a variety of 
individual annealing sequences and lengths were synthesized to investigate their sequence 
selectivity via UV-Vis melting curve measurements. Surprisingly, individual base pair 
mismatches did not lead to a pronounced change in the melting temperature. Instead, a 
pair of length and sequence mismatched duplexes (PNA 1∙PNA 2 and PNA 3∙PNA 4) were 
suitable for an orthogonal ligation approach. They were therefore modified with a 
photocleavable linker and a thiol or thioester to undergo a competitive ligation experiment. 
Neither (cross) reaction products nor retained starting materials were identified. Instead, a 
mixture without distinct HPLC peaks was observed, presumably due to a lack of template 
selectivity. The approach was therefore not pursued further and instead focus was shifted 
to the ligation method and identification of a different template. 
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4.2 Development of a PNA mediated Suzuki cross-coupling 
ligation 
 
This chapter evaluates an additional ligation reaction for use with the PNA template. The 
method is based on the biocompatible Suzuki cross-coupling.[98] An introduction to this 
method is given and conditions for the stoichiometric conjugation of peptides are 
established (chapter 4.2.1). For the hybridization of peptides and PNA, a photocleavable 
linker with improved properties is designed. The synthesis and evaluation of its photolysis 
are discussed (chapter 4.2.2). The following subsection describes the synthesis of the 
PNA/peptide hybrids for Suzuki cross-coupling. Complications following the previously 
established strategy are discussed and an alternative approach, based on the synthesis of 
an unnatural borylated amino acid, is presented (chapter 4.2.3). The final chapter 
investigates the PNA templated Suzuki cross-coupling reaction and addresses possible 
interactions of the transition metal catalyst with the template nucleobases (chapter 4.2.4). 
 
4.2.1 Establishing conditions for Suzuki cross-coupling between peptide 
fragments 
 
We decided to investigate a different ligation method to broaden the scope of the templated 
ligation strategy. A conjugation method that would generate a fluorophore upon covalent 
linkage of the peptide fragments is highly desirable. It would offer the possibility to track the 
target protein via fluorescence microscopy, as well as give a live readout of the ligation 
progress. Previous research in our group by Swantje Nawratil already investigated the 
possibility to introduce a tetrazole-alkene “photoclick” or fluorescence-generating CuAAC 
reaction.[169] Since both attempts did not yield the desired templated peptide ligation with 
fluorophore generation, a third approach was explored. 
A possible cause for the reaction deficiency is the high steric demand of the modified 
peptide side chains. Therefore, a geometry agreeing with a natural, linear peptide structure 
was preferable. As previously discussed (see chapter 2.2.7), Suzuki coupling provides 
compatibility with biological systems and access to a fluorophore via cross-coupling of 
modified phenylalanine and tryptophan residues.[146,170] The required halogenated 
derivatives of tryptophan are accessible from the corresponding haloindole via tryptophan 
synthase catalyzed biotransformation.[145] The most prominent drawback of applying a 
transition metal mediated strategy, namely excess of catalyst and reaction partner, should 
be negated by application of the template. Since generation of an SPPS applicable 
halogenated tryptophan derivative is labor-intensive, it was decided to first optimize the 
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coupling conditions on a non-fluorescent system with easier accessible building blocks. 
Therefore, the viability of the coupling conditions had to be established. Chalker et al. had 
already demonstrated the applicability of the pyrimidine derived catalyst (ADHP)2∙Pd(OAc)2 
for the modification of Boc-pIPhe-OH with phenylboronic acid under biocompatible 
conditions.[98] Therefore, similar conditions were applied for the modification of test peptide 
26, bearing a iodophenylalanine residue. The reaction progress was monitored over 36 h 
by UHPLC measurements. Conversion of the reactants was observed forming the desired 
product, with 43% conversion after 12 h and 93% after 24 h. (see Figure 42).  
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 t = 24 h
 t = 12 h
 t = 0 h
 
Figure 42: (a) Suzuki coupling on a short peptide with phenylboronic acid and (b) reaction monitoring by 
UHPLC (215 nm). 
 
While the reaction proceeded sluggishly, especially in comparison with the lone 
halogenated amino acid, the method was further pursued for the coupling of two peptide 
fragments and eventually templated ligation. To obtain the borylated counterpart (28), a 
method for on-resin Miyaura borylation, developed by Afonso et al. was employed (see 
Figure 43).[171] 
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The reaction yielded the desired product under loss of the pinacol ester protecting group, 
which was presumably hydrolyzed during HPLC purification.[172] Nonetheless, 28 was used 
in a cross-coupling reaction with 26 employing the previously established conditions. Once 
again, product formation was observed, however, conversion proceeded even slower than 
for the coupling of 26 with phenylboronic acid. Product formation of 23% was observed 
after 36 h, while only 42% conversion was detected after 84 h. (see Figure 44). 
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 t = 84 h
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 t = 0 h
 
Figure 44: (a) Suzuki cross-coupling between two peptide fragments under biocompatible conditions and (b) 
reaction monitoring by UHPLC (215 nm). 
 
Judging from the decrease in reaction rates from the cross-coupling of amino acid and 
phenylboronic acid (fast) to peptide and phenylboronic acid (slow) to the coupling of two 
peptide fragments (very slow), a correlation to the steric hinderance in accessing the 
reaction partners seems apparent. These results explain the superstoichiometric use of 
reagents in Suzuki cross-coupling on proteins. A preorganization of the reaction partners 





4 RESULTS AND DISCUSSION 
54 
 
4.2.2 Development of a coumarin based photocleavable linker 
 
Before incorporation of the peptide fragments into PNA/peptide hybrids, the viability of a 
new photocleavable linker was assessed. One of the drawbacks of the previously utilized 
DMNB linker is its low quantum yield and excitation wavelength. This results in the use of 
high energy irradiation over a prolonged time. Furthermore, the release mechanism 
discussed below reveals the formation of a potentially toxic byproduct. Those factors 
suggested the necessity of a novel photocleavable linker with improved photophysical 
properties. Herein, nitroveratryl and coumarin based linkers are compared, starting with 
their photolysis mechanism and release in a test experiment. Some of the following 
experiments are part of the bachelor thesis of Ivana Gavrilova.[173]  
4,5-Dimethoxy-2-nitrobenzol (DMNB, or 6-nitroveratryl, NV) is a derivative of o-nitrobenzol 
and was first introduced as a photocleavable protecting group in 1970.[174] Introduction of 
the two methoxy groups increases the absorbance at higher wavelengths, enabling 
cleavage at 365 nm. Yet shorter wavelengths (λabs ≈ 345 nm) are more effective.[175] 
The photorelease mechanism of o-nitrobenzyl protected compounds (see Figure 45) 
comprises of three critical steps. First, the caged compound I undergoes a photoinduced 
H-atom transfer (HAT*), resulting in aci-nitro intermediate II. Ground state cyclization leads 
to the isoxazolidin-1-ol intermediate III, whose formation competes with the reverse HAT to 
reform the starting material. Under basic conditions, III is deprotonated giving intermediate 
IV, which cleaves irreversibly by release of the leaving group X and formation of  
o-nitrosobenzaldehyde derivative V.[176] O-nitrosobenzaldehydes are potentially toxic to 
surrounding bioprocesses.[147] Due to the low quantum yield and absorbance maxima of  
o-nitrobenzyl protecting groups, as well as the improved DMNB protecting group  
(Φ = 0.006, 365 nm, λabs = 345 nm), low wavelengths, combined with powerful irradiation 




Figure 45: Simplified mechanism of the photolysis of o-nitrobenzyl compounds. Figure based on [176]. 
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In contrast, coumarin derived photoremovable protecting groups (PPGs) have been 
extensively studied[147] and found application in caging a number of functionalities, including 
phosphates,[148,177,178] carboxylic acids,[179,180] amines,[181–183] alcohols[184] and thiols.[185] 
Deiters and co-workers furthermore demonstrated in vivo applications of protein 
activation.[186–188] Coumarin presents itself as a versatile platform, allowing for the caging of 
different functional groups via the alcohol moiety of a 4-hydroxycoumarin scaffold. 
Changing of the residues at positions six, seven or even two, alters the photochemical 
properties enabling a shift to higher wavelengths or two-photon uncaging.[175] 
7-Diethylamino-4-methylcoumarin (DEACM) was selected as a basis for the 
photocleavable linker due to the bathochromic shift introduced by the electron donating 
groups at the C-7 position, resulting in an absorption maximum around 390 nm. In addition, 
the molecule displays a high quantum yield (DEACM-puromycin, Φ = 0.47, 380 nm) and 
ultrafast release.[148–151] Once again, the uncaging mechanism offers insight about the 
advantages of this linker (see Figure 46). First, excitation of (coumarin-4-yl)methyl (CM) 
ester I by a photon takes place, followed by relaxation to the lowest singlet state II. This 
step competes with the deactivation by fluorescence and nonradiative processes. 
However, the rate constants of these processes are low, leading to a long lifetime of the 
excited state. Heterolytic ester cleavage leads to the formation of the singlet ion pair III, 
which can recombine to form the starting material. Again, due to the high stability of the 
coumarinylmethyl cation and the anionic product the ion formation successfully competes 
with the deactivation pathway. Following, the ion pair escapes from its solvent cage, leading 
to the solvent separated ions displayed in IV. A crucial part of the photolysis pathway is the 
reaction of the cation with water yielding the CM alcohol (V). Since the presence of water 
is not only tolerated, but necessary for the uncaging, this makes CM derivatives ideal 
candidates for biological applications. Decarboxylation of the carbamate yields the free 
amine and CM-OH (VI).[151,189,190] 




Figure 46: Photolytic cleavage pathway of a DEACM caged amine. Figure based on [151]. 
 
Following the design strategy presented by Seyfried et al.,[152] a DEACM-derived 
photolinker suitable for CuAAC derivatization was devised (see Figure 47). Briefly, 
aldehyde 31 was generated in a Riley oxidation in moderate yield, starting from 
commercially available 7-diethylamino-4-methylcoumarin (30). The alkyne functionality 
necessary for attachment of the PNA template was introduced in a zinc mediated Barbier 
reaction with propargyl bromide to give 32. Activation of the alcohol moiety with DSC 
yielded PCL 33 in acceptable yield, ready for direct peptide conjugation. 
 
 
Figure 47: Synthesis of the novel DEACM-derived photocleavable linker 33. 
 
In order to test the effectiveness of PCL photolysis, DEACM-derived 33 and DMNB-derived 
PCL 15 were attached to a test peptide and conjugated to a small organic molecule as 
cargo via CuAAC (see Figure 48). 
 




Figure 48: Test peptides bearing (a) DMNB and (b) DEACM derived PCLs, loaded with test cargo. 
 
Then, solutions of both derivatives were prepared for irradiation and the process followed 
by UHPLC. While the times necessary to reach full deprotection are somewhat 
comparable, the employed conditions for DMNB and DEACM differ significantly (see Figure 
49). 36 was irradiated at 347 nm (1000 W) for 10 min, while 38 was irradiated at 405 nm 
(100 mW) for 5 min. The photodeprotection assay proved 38 to be a successful PCL that 
fulfils the intended properties of a higher absorption maximum, combined with a faster 
release of the cargo. Since the geometries of the linker molecules differs in the steric bulk 
provided by the DEACM moiety, as well as by attachment of the cargo to the linker  
(1,4-regioisomerism), 15 was first evaluated as a linker for the templated Suzuki coupling 
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Figure 49: Photolysis of (a) 36 and (b) 38 and their respective UHPLC chromatograms (215 nm). A 50 μM 
solution of the respective compound was irradiated at 347 nm (1000 W) for 10 min (36) or at 405 nm (100 mW) 
for 5 min (38). 
 
4.2.3 Synthesis of PNA/peptide hybrids for templated Suzuki coupling 
 
Having established the ligation conditions and photophysical properties of the PCL, 
conjugation of PCL 15 to the iodinated peptide 39 followed the procedure described in the 
previous section (see Figure 50a). For the synthesis of the borylated peptide and 
attachment of the PCL, a slight adjustment was necessary. Since a glycine residue had to 
be introduced as a spacer between linker and ligation site, a different protecting group 
strategy had to be utilized. A protecting group on the N-terminus was found to be crucial 
for product formation during on-resin Miyaura borylation and since the Fmoc protecting 
group does not tolerate the combination of basic conditions and elevated temperatures of 
the Miyaura borylation, an alternative had to be identified. The Boc protecting group 
employed in the original method was unusable, since its deprotection conditions are the 
same as for the removal of the side chain protecting groups and cleavage of the peptide 
from the solid support. In order to selectively install the PCL, trityl (Trt) was therefore utilized 
(a) 
(b) 
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as the N-terminal protecting group. Selective removal of the highly acid labile group was 
achieved by treatment of the resin with 0.2% TFA in DCM, which did not affect the side 
chain protecting groups or the linkage to the resin. This strategy yielded the borylated 





Figure 50: Attachment of PCL to (a) the iodinated and (b) to the borylated peptide. 
 
With the PCL attached to the peptide fragments, hybridization to the alkynylated PNA 
sequences was performed by on-resin CuAAC (see Figure 51). However, contrary to the 
reactions described in chapter 4.1 (see Figure 38), no product formation could be observed 
by UHPLC or mass spectrometry. Instead, a complex reaction mixture was observed in the 
chromatograms that corresponded to neither starting material or product. Due to the only 
significant change in peptide sequence being the addition of iodinated and borylated amino 








Figure 51: Generation of the PNA/peptide hydrids necessary for templated Suzuki ligation. 
 
With the previously established pathway not being viable for the generation of PNA/peptide 
hybrids for templated Suzuki coupling, a new approach to acquire the ligation partners had 
to be identified. Since one of the drawbacks of the previous approach was the additional 
synthetic effort and purification step necessary in order to attach the PCL bearing peptide, 
a strategy for the linear build up of the hybrids was devised. An amino acid derived PCL 
was necessary for this undertaking and commercially available Fmoc-D-β-Phe(2-NO2)-OH 
was deemed suitable. While not ideal as a photolinker due to the disadvantages previously 
described for o-nitrobenzyl derived compounds, it could be employed in a proof of concept 
reaction. Therefore, iodinated PNA/peptide hybrids 47 and 49 were synthesized in one 
continuous SPPS cycle. On-resin Miyaura borylation of 47 proved unsuccessful, with only 
trace amounts of the product species identifiable by mass spectrometry (see Figure 52). 




Figure 52: Linear synthesis of iodinated PNA/peptide hybrids and on-resin Miyaura borylation of 47. 
 
An alternative pathway for the introduction of the boronic acid had to be found. Direct 
synthesis of SPPS building block Fmoc-Bpa-OH was the obvious approach (see Figure 
53). Following procedures by Malan[191] and Raines,[192] Boc-4-iodophenylalanine (50) 
underwent Miyaura borylation to give Boc-4-pinacolborane-phenylalanine (51) in good 
yield. N-terminal deprotection with HCl yielded the free amine (52) in quantitative yield, 
followed by Fmoc protection with Fmoc-OSu under basic conditions to yield the desired 
building block 53. Although product formation was observed, purification proved to be 
difficult, since the crude mixture began to oligomerize. A small sample was purified by 
HPLC, which probably led to the hydrolysis of the pinacol ester protecting group. 53 was 
directly applicable for SPPS and employed using standard coupling procedures at 50 °C. 
This resulted in the direct synthesis of 48. 
 
 
Figure 53: Synthesis of Fmoc-Bpa-OH (53). 
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4.2.4 PNA mediated Suzuki cross-coupling 
 
Having obtained both PNA/peptide hybrids necessary to perform template mediated Suzuki 
cross-coupling, the ligation was carried out in pH 8 phosphate buffer and its progress 
monitored by UHPLC. However, no conversion of the starting materials was observed after 
48 h, even after increasing the amount of catalyst to up to 10 eq. over time (see Figure 54). 
 
 
Figure 54: Templated Suzuki cross-coupling of PNA/peptide hybrids 48 and 49. 
 
Various explanations can be used to describe the absent reactivity of the hybrids. Improper 
horizontal positioning of the residues along the peptide sequence or incorrect vertical 
spacing may have led to a loss of reactivity. Furthermore, following the observations from 
the initial ligation test, more complex environments led to slower reaction rates. Should the 
templating effect be lacking to contribute, the reaction rate may have been to slow to 
observe. In addition, interference of the template with the catalyst is possible, either due to 
preorganization of the reactive moieties into an unsuitable geometry or by interaction of the 
palladium catalyst with the nucleobases. 
First, screening of different palladium complexes was performed to identify the most 
efficient catalyst. In a study on the Suzuki cross-coupling of halogenated phenylalanines 
and tryptophans, Willemse et al. had identified PdCl2(dppf) as a viable alternative to the 
Pd-pyrimidine catalyst (ADHP)2∙Pd(OAc)2. However, temperatures of 80 °C and 
50% iPrOH as a cosolvent were applied, both of which exceeds biocompatibility.[193] Davis 
and co-workers furthermore disclosed that water-soluble palladium complexes with 
guanidine ligands may surpass the catalytic efficiency of the respective pyrimidine system, 
depending on the substrates.[194] Furthermore, they described a ligandless system based 
on K2PdCl4.[103] In addition, a catalyst described by Ma et al.,[105] based on an N-heterocyclic 
carbene (NHC) ligand was tested because of its presumed higher complex stability. To 
replicate these conditions as best as possible under unifying aqueous conditions at 37 °C, 
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screening on Boc-pIPhe-OH as a model substrate in the cross-coupling reaction with 
phenylboronic acid was performed (see Table 2). 
 
Table 2: Screening of Boc-pIPhe-OH as a substrate in a cross-coupling reaction with phenylboronic acid. 
 
Entry Catalyst Solvent Additive Conversion[c] 
1 Pd(OAc)2 phosphate buffer pH 8 - 97% 
2 (ADHP)2∙Pd(OAc)2 phosphate buffer pH 8 - 97% 
3 Pd(dppf)Cl2 phosphate buffer pH 8 10% iPrOH 30% 
4 (TMG)2∙Pd(OAc)2 phosphate buffer pH 8 - 97% 
5 (NHC)2∙Pd(OAc)2 phosphate buffer pH 8 - 95% 
6 Pd(OAc)2 phosphate buffer pH 8 Ac-PNA 2[a] 0% 
7 (ADHP)2∙Pd(OAc)2 phosphate buffer pH 8 Ac-PNA 2[a] 0% 







3% - 96% 
(26.5 h) 
[a]: Ac-PNA 2 (6 mol%), [b]: K2CO3 (5.0 eq), Ac-PNA 2 (1 mol%), [c]: determined by UHPLC peak integration 
(215 nm, uncorrected). 
 
The ligandless catalyst Pd(OAc)2 (see Table 2, entry 1), as well as the water-soluble 
catalysts based on pyrimidine (entry 2), guanidine (entry 4) and NHC ligands (entry 5) 
performed exceptionally well with conversions of ≥ 95%. A more detailed look at the UHPLC 
reaction monitoring performed at 0.5, 1, 2, 3 and 4 hours however revealed that while the 
end results were similar, (ADHP)2∙Pd(OAc)2 had distinctly slower initial kinetics, only 
reaching 11% conversion after 0.5 h and 39% after 1 h. The ligandless system had already 
reached 94% conversion after 0.5 h, while the guanidine and NHC based systems had a 
more gradual rise (68% and 74% conversion after 0.5 h, respectively). Unsurprisingly, 
ferrocene-based catalyst Pd(dppf)Cl2 (entry 3) did not offer sufficient conversion, most 
likely due to the low amount of organic solvent and low temperature. To ascertain whether 
the presence of PNA would influence the reaction, 6 mol% of acetylated PNA 2 was added 
to the substrates. As the most efficient catalyst in the screening, Pd(OAc)2 was selected, 
in addition to (ADHP)2∙Pd(OAc)2 as the standard and (NHC)2∙Pd(OAc)2 due to its complex 
stability. In all cases (entries 6-8), no conversion was observed after 4 h and the same held 
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true after increasing the reaction time to 20 h. When the same experiment was performed 
with an excess of Pd-catalyst, slow conversion was observed (entry 9). After 4 h, 3% 
product formation was observed that rose to 19% after 8 h. 97% conversion was observed 
after 26.5 h, clearly indicating that the presence of PNA severely dampens the catalyst’s 
efficiency.  
To gain further insight into this issue, UV-Vis measurements were performed. Two modes 
of interaction of the catalyst with PNA seem feasible. First, direct binding of the metal to 
the nucleobases through the N-7 position of the purine bases or the N-3 position of the 
pyrimidine bases. This mechanism is believed to be the predominant target of metal-based 
anticancer complexes. While other modes of binding to the nucleobases have been 
observed, the N-7 position of guanine seems to be the most likely target.[195] Eichhorn et 
al. investigated the influence of metal ions Mg(II), Co (II), Ni(II), Mn(II), Zn(II), Cd(II) and 
Cu(II) on DNA structure and stability. They found that the melting temperature increased 
with higher concentration of Mg(II), Co(II) and Ni(II), owing to the sole (Mg(II)) or 
predominant binding to the phosphates. Whereas the increase in Cd(II) or Cu(II) 
concentration over 0.5 eq. resulted in a decrease in melting temperature, associated with 
binding to the nucleobases. The authors argued that the latter metals held the bases of 
unwound DNA in register and continued to do so upon cooling, thereby preventing 
rewinding of the duplex. Metal ions in the middle of the series showed the highest Tm at 
intermediate metal concentrations, where the stabilization of the charged backbone 
outweighed the destabilization due to binding to the nucleobases.[196] Since PNA possesses 
a neutral backbone, either no effect or a destabilizing effect would be expected.  
Second, intercalative binding of aromatic heterocycles through π-stacking is possible. 
While usually observed in fused aromatic systems, the employed pyrimidine based ligand 
ADHP partly fulfills the criteria. This mode of interaction usually results in hypochromism 
and a bathochromic shift in the observed band.[197] 
Two experiments were performed to differentiate between both scenarios. Melting curve 
measurements on the duplex PNA 1∙PNA 2 (for the sequences, see Table 1) were 
performed in the presence (0.05 or 2.5 eq.) or absence of (ADHP)2∙Pd(OAc)2 (see, Figure 
55a). While the melting curve corresponding to the addition of 0.05 eq Pd(II) was almost 
identical to the native one, a strong deviation was observed at the higher metal ion 
concentration. The corresponding melting curve showed a decreased hyperchromic effect 
and significantly lower melting temperature. Based on the previously discussed study by 
Eichhorn et al., [196] this seems to be indicative of metal ions binding to the nucleobases at 
higher concentrations. 
Furthermore, a titration experiment with increasing Pd(II) amounts was performed on the 
same double stranded PNA while monitoring the nucleobase absorbance (see Figure 55b). 




While a general trend could not be established, an interaction of catalyst and PNA seems 
to be evident, nonetheless.  
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Figure 55: (a) UV-Vis melting curve measurements of acetylated parallel PNA (PNA 1+2) upon addition of 
Pd(II). (b) Absorbance measurements under titration of various amounts Pd(II) (b). Measurements were carried 
out with a strand concentration of 5 μM in phosphate buffer (50 mM, pH 8.0). 
 
While not all of the previously discussed factors of the templated Suzuki cross-coupling 
can be dismissed, it seems likely that interaction of the PNA nucleobases with the palladium 
catalyst contribute most to the failed attempt. Based on the UV-Vis studies, binding of the 
catalyst to the nucleobases seems likely. Though the amount utilized in the ligation 
experiments proved insufficient to destabilize the duplex structure, binding of the palladium 
ions would still render the catalyst useless. Simply increasing the amount of catalyst could 
lead to a slow conversion, albeit at a loss of the templating effect due to unwinding of the 
helix. For a precise assertion of the positions and distances of the reactive sites, as well as 
the binding of the catalyst, X-ray crystallography could be performed, while NMR 
spectroscopy would provide an additional method to determine if palladium binds to the 




In this section, the ability of a PNA template to mediate a biocompatible Suzuki cross-
coupling reaction was assessed. The catalytic system was based on Davis’ water-soluble 
Pd-pyrimidine catalyst. Its efficiency was demonstrated in the modification of an iodinated 
small test peptide with phenylboronic acid or its borylated counterpart. Impressively, the 
reaction was performed without reagent excess and the catalyst was employed in a small 
percentage. However, an increase in the steric demand of the reactants was shown to slow 
the reaction considerably, possibly due to difficult accessibility of the functional groups by 
the palladium catalyst.  
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Installation of the PNA template proved to be challenging, since the functional groups of 
the peptides interfered with the CuAAC used for conjugation. This problem was overcome 
by utilizing an amino acid derived PCL and linear incorporation of iodo-phenylalanine and 
a newly synthesized borono-phenylalanine building block (53). The obtained PNA/peptide 
hybrids 48 and 49 were employed in a cross-coupling experiment. Presence of the template 
showed clear inhibition of the reaction. A catalyst screening in the presence of PNA, as 
well as UV-Vis titration and melting curve measurements with various amounts of Pd(II) 
suggest binding of the metal ions to the template’s nucleobases.  
Furthermore, a novel DEACM-based PCL (33) was synthesized and directly compared to 
the previously employed DMNB linker (15). Linkers were applied to a test setting and their 
photolysis was studied. The DEACM-based PCL proved to cleave marginally faster and 
under less harsh conditions. However, the attachment of both linkers via CuAAC and 
incompatibility with iodo- or borono-moieties prevented further studies with the PNA 
template. Its success does however provide a second-generation PCL as well as a starting 
point for the development of an amino acid-based linker with improved photophysical 
properties. 
Since PNA proved to be an unsuitable template for the mediation of a Suzuki cross-
coupling reaction, a different template architecture will be investigated in the next chapter. 
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4.3 Evaluation of coiled-coil peptides as a platform for templated 
reactions 
 
This chapter examines the use of coiled-coil peptides as reaction templates for 
biocompatible ligations. The strategy is based on a previously reported template mediated 
acyl transfer system.[134] A parallel heterodimeric coiled-coil dimer is used as a recognition 
unit to align N-terminal functional groups for covalent linkage. Herein, a variety of ligation 
methods are studied. The subchapters are categorized by reaction type. Chapter 4.3.1 
illustrates the design of the system and investigates the Suzuki cross-coupling reaction. 
Oxime ligation (chapter 4.3.2), cysteine alkylation (chapter 4.3.3) and SPAAC (chapter 
4.3.4) are discussed in the following sections. Finally, a photocleavable linker is used to 
perform a templated functional group transfer with partial scaffold release via oxime ligation 
(chapter 4.3.5). 
 
4.3.1 Coiled-coil templated Suzuki cross-coupling 
 
Because the experiments described in the previous chapter revealed a possible interaction 
of the palladium catalyst with the nucleobases of the PNA template and a reaction between 
the cross-coupling partners was not observed, a different reaction template had to be 
investigated. The coiled-coil motif was selected, since its rules for structure, oligomerization 
state and partner specificity are among the most well-understood for protein folding 
motifs.[132,198,199] In addition, the system provides easy access via SPPS at a lower time and 
monetary cost. Furthermore, despite offering limited modularity in its sequence, the design 
of orthogonal pairs based on hydrophobic and electrostatic mismatches is possible.[200–202] 
Thus, coiled coils offer the potential to mediate multiple simultaneous ligation events. The 
aim of this project is to design a platform to mediate functional group transfer from a donor 
to an acceptor strand, similar to the system proposed by Reinhardt et al.[134] In order to 
circumvent the restriction of using NCL to lead to cleavage of the donor strand, a 
photocleavable linker will be installed. This opens up the possibility of using faster, more 
selective ligation reactions in line with the previously established principles of 
bioorthogonality. Ideally, this system could be used to study the influence of the template 
on reaction kinetics, as well as to establish parameters for the distance between functional 
group and template at which preorganization is replaced by diffusion. Hodges’ parallel, 
heterodimeric IAAL E3/K3 coiled-coil[133] was selected as a starting template to re-evaluate 
the templated Suzuki cross-coupling. The original sequence was altered to include 
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tryptophan as a UV chromophore for concentration determination and reaction monitoring 
and the C-terminus was capped with glycine (see Table 3). 
 
Table 3: Sequence and heptad register of the coiled-coil strands based on Hodges’ E/K peptides. Peptides 
were synthesized as C-terminal amides. 
  Sequence and heptad register  
Entry Name gabcdef gabcdef gabcdef C-term. 
1 CC-E3 (56) EIAALEK EIAALEK EIAALEW G 
2 CC-K3 (57) KIAALKE KIAALKE KIAALKW G 
 
Phenylboronic acid and p-iodophenylalanine were introduced as ligation partners to the E3 
and K3 strand, respectively. Conditions for the aqueous Suzuki coupling of peptides, 
previously established in chapter 4.2, were applied (see Figure 56). However, no product 
formation was observed after 24 h. 
 
 
Figure 56: Suzuki coupling between modified coiled-coil strands. 
 
In order to exclude interference from the catalyst with the template formation, circular 
dichroism (CD) spectroscopy was performed. CD spectroscopy is an established technique 
for determining the structure of proteins in solution and has been commonly used to 
analyze coiled-coil interactions. Briefly, left-handed and right-handed circularly polarized 
light will be absorbed to different extents by asymmetric molecules, resulting in an elliptic 
polarization after passing through the sample. The ellipticity can be measured as the CD 
signal. A change in polarization will occur for a chromophore that is chiral, covalently bond 
to a chiral center or placed within an asymmetric environment of a three-dimensional 
structure. Different structural elements in proteins produce distinct CD spectra that can be 
used to characterize their secondary structure.[203,204] At pH 7 the IAAL E3/K3 coiled-coil 
exhibits the characteristics of an α-helix, with nearly equally intensive minima at 208 and 
222 nm and a maximum at 193 nm. However, under the same conditions, the individual 
strands show spectra of random coils with a minimum around 200 nm.[204–206] A shift in 
these parameters is indicative of a structural change. Apostolovic et al. discovered that the 




aforementioned E3/K3 coiled-coil becomes unstable at pH 5, resulting in its unfolding and 
the formation of E3 homotrimers that coexist with K3 unimers and a small amount of K3 
homodimers.[206] Similar observations were made by Yang et al. when investigating the 
antiparallel heterodimer formed by oppositely charged CCE and CCK peptides. When the 
pKa value of the charged side chain (Glu or Lys) was reached, the heterodimer unfolded 
and homodimers of one strand formed that coexisted with unimers of the other strand. 
Unfolding was already observed at a pH value as low as 9.[207] Thus, the stability of the 
employed E3/K3 coiled-coil was probed for acetylated species of 56 and 57 at pH 7 (see 
Figure 57a) and under catalytic conditions (see Figure 57b). However, both experiments 
were found to comply to coiled-coil parameters. Therefore, it can be concluded that the 
reaction did not falter due to unfolding of the template. 
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Figure 57: CD Spectra of acetylated peptides E3 (black), K3 (red), and their equimolar mixture (blue) in  
(a) pH 7 phosphate buffer and (b) pH 8 phosphate buffer upon addition of 1 μL 0.01 M (ADHP)2∙Pd(OAc)2 
solution. 
 
Instead, a focus was placed on increasing the distance between the functional groups and 
the template, thereby offering less steric constraint and easier access for the catalyst. 
Accordingly, peptides 56 and 57 were elongated with a glycine spacer and different variants 
of the K3 peptide were synthesized, containing an additional glycine (63),  
β-alanine (64) or γ-aminobutyric acid residue (65). The resulting four K3 peptides were 
modified with p-iodobenzoic acid and combined with phenylboronic acid modified peptide 
61 under cross-coupling conditions. No reaction was observed for any of the derivatives 
(see Figure 58). 




Figure 58: Coiled-coil templated Suzuki coupling utilizing different amino acid spacers on the K3 peptide. 
 
Next, changes in the template structure were investigated. Thomas et al. reported a version 
of the E3/K3 coiled-coil that includes asparagine at position a of the central heptad. While 
this change was found to overall destabilize the hydrophobic core, it also showed an 
improved specificity for dimer formation, presumably due to formation of a hydrogen bond 
between asparagine residues. Said change was also found to prevent slippage of the 
helices relative to each other because of a greater destabilization from unpaired asparagine 
residues. Therefore, the authors theorized that upon dimer formation, the peptides should 
be brought together in register. Furthermore, glutamine, lysine, and one of the 
chromophores tyrosine or tryptophan were introduced at the f positions and the sequences 
were capped by glycine residues. In addition, the authors found that elongating one or both 
helices by an additional half or full heptad further stabilized the helix.[208] Implication of these 
modifications were thought to be beneficial for templated ligation. First, introduction of 
arginine would ensure the alignment of the functional groups. Secondly, the higher KD value 
would result in a greater flexibility of the template, which might negate sterically constrained 
reaction geometries to some extent. These changes were applied to peptides 70 and 71. 
Furthermore, the crystal structure of IAAL E3/K3 (PDB ID: 1U0I) shows the  
N-termini of both peptides averted from one another. To prevent this from interfering in a 
successful reaction, peptide K3 was elongated by up to half a heptad to find a suitable 
geometry. The heptad register of the new sequences is shown in Table 4. Figure 59 shows 
the helical-wheel diagram of the coiled-coil heptad repeat and a one-heptad slice through 
the X-ray crystal structure of the asparagine containing heptad of GCN4 leucine zipper. 
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Table 4: Sequence and heptad register of the asparagine containing coiled coils and N-terminal elongation of 
the K-strand by one to three residues. Peptides were synthesized as C-terminal amides. 
  Sequence and heptad register  
Entry Name gabcdef gabcdef gabcdef gabcdef C-term.  
1 CC-E3N1 (70)  EIAALEK ENAALEW EIAALEQ GG 
2 CC-K3N1 (71)  KIAALKW KNAALKK KIAALKQ GG 
3 CC-K3N1+1 (72) Q KIAALKW KNAALKK KIAALKQ GG 
4 CC-K3N1+2 (73) KQ KIAALKW KNAALKK KIAALKQ GG 





Figure 59: (a) Helical-wheel diagram depicting asparagine (yellow) in the hydrophobic core of a heptad. (b) 
One-heptad slice through the X-ray crystal structure of the asparagine containing heptad of GCN4 leucine 
zipper (PDB ID: 2ZTA), showing the hydrogen bond between Asn residues (dotted line). Figure 59a was based 
on [208] and figure 59b was reprinted with permission from Thomas et al., J. Am. Chem. Soc. 2013, 135, 5161. 
Copyright 2013 American Chemical Society. 
 
Asparagine containing E3 (70) was modified with phenylboronic acid and combined under 
ligation conditions with asparagine containing K3 (71), elongated by zero to three heptad 
residues and modified with acetylated p-IPhe. No cross-coupling reaction between the 
peptides was observed after 24 h (see Figure 60). 
 
 
Figure 60: Coiled-coil templated Suzuki coupling utilizing Asn modified peptides and an N-terminal overhang 
of zero to three amino acid residues. 
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Following the observations laid out in this chapter and the previous one, the ensuing 
conclusion can be offered. Through a number of changes in the geometry of the functional 
groups, as well as in the reaction template, either by introduction of spacers, overhang or 
by virtue of an altogether different template, template mediated Suzuki coupling was not 
observed. Possible reasons include (i) steric constraint as a result of the reaction template, 
(ii) preorganization of the functional groups into unsuitable geometries by dimer formation 
of the template, (iii) interaction of the catalyst with the template and (iv) low nucleophilicity 
of the employed boronic acid. While interaction of the catalyst with the template seems to 
be more prevalent for the nucleobase template, steric constraint, preorganization, and low 
reactivity of the nucleophile all seem to be valid reasons, possibly pointing to a combination 
of all factors. 
 
4.3.2 Coiled-coil templated oxime ligation 
 
Due to the complications associated with the Suzuki cross-coupling approach, a different 
type of ligation reaction had to be identified. Staying within the principles of bioorthogonal 
reactions, oxime ligation was selected as a suitable candidate due to its simple reaction 
mechanism and low steric demand of the employed functional groups. While this reaction 
proceeds slowly under standard reaction conditions without the use of a nucleophilic 
catalyst,[32] increasing the effective concentration of the reagents by employing a reaction 
template might increase the reaction rate. 
In order to introduce a hydroxylamine functionality to one of the coiled-coil strands, Boc-
protected 4-(aminooxy)butanoic acid (86) was synthesized according to a procedure by 
Saito et al.[54] Briefly, N-Boc hydroxylamine (84) and ethyl 4-bromobutyrate (85) underwent 
Williamson ether synthesis, followed by basic hydrolysis of the ethyl ester protecting group. 
The product was obtained in moderate yield (see Figure 61). 
 
 
Figure 61: Synthesis of N-Boc-protected 4-(aminooxy)butanoic acid. 
 
Insertion of the building block to E3 peptide 70 under standard coupling conditions proved 
to be successful (see Figure 62). 
 




Figure 62: Introduction of a hydroxylamine moiety to the E3 peptide.  
 
For the introduction of an aldehyde moiety, oxidation of N-terminal serine with sodium 
periodate was chosen (see Figure 63 for the general approach). 
 
 
Figure 63: Schematic representation of the oxidation of an N-terminal serine with sodium periodate. Figure 
based on [209]. 
 
However, when this approach was applied to serine modified 71, no product formation was 
detected. Instead, side products with mass differences of +14 Da, +30 Da, +32 Da and  
-2 Da were observed in different fractions after HPLC purification. The most apparent 
explanation would be additional oxidation of peptide side chains. Commonly, oxidation is 
found in peptides containing methionine, cysteine or tryptophan. While oxidation of 
tryptophan proceeds slowest, it is the only amino acid on this list to be present in the 
sequence of 71. Indeed, a mass difference of +32 Da could be explained by double 
hydroxylation of the tryptophan residue.[210] Data obtained by HR-MS did not support this 
theory.  
Due to the aforementioned difficulties, a different approach for the introduction of the 
aldehyde moiety was pursued. Duflocq et al. introduced thiazolidine as an aldehyde 
precursor, which would undergo deprotection under Pd(II) or Ag(I) mediation and acidic 
conditions.[211] N-Boc-protected 2-carboxy thiazolidine was synthesized according to a 
literature known procedure.[212] Condensation of 2-aminoethane thiol (88) with glyoxylic 
acid (89) led to thiazolidine 2-carboxylic acid (90) in good yields, followed by Boc protection 
with di-tert-butyl dicarbonate in excellent yields, to give the desired SPPS applicable 
product (91, see Figure 64). 
 
 
Figure 64: Synthesis of Boc-protected aldehyde precursor 2-carboxy thiazolidine (Thz, 91). 
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Introduction of the building block to peptide 71 was successful under standard coupling 
conditions. However, formation of the aldehyde after treatment with PdCl2 was not 
observed (see Figure 65). 
 
 
Figure 65: Introduction of an aldehyde moiety by Pd(II) mediated cleavage of a thiazolidine precursor. 
 
Since a chromatogram similar to the oxidation approach was obtained, oxidation of the 
tryptophan residue seems unlikely. Instead, a different side reaction might be the root 
problem. A nucleophilic attack of the ε-amino group of a lysine residue would be the next 
explanation, due to its positioning as the second to last amino acid on the N-terminal end. 
It would furthermore explain the presence of multiple, near inseparable peaks in the HPLC 
chromatogram due to different resulting stereoisomers.  
Based on this assumption, functional groups on the E3 and K3 strand were interchanged. 
Attachment of the hydroxylamine moiety to K3 and of the thiazolidine precursor to E3 was 
successful applying standard coupling conditions. Removal of the protecting group was 
achieved by PdCl2 under acidic conditions. The resulting purified peptides were suspended 
in phosphate buffer (pH 7.0) and agitated for 7 h at 37 °C. After lyophilization and 
purification by HPLC, the ligation product was obtained under loss of water (see Figure 66). 
 
 
Figure 66: Oxime ligation between aldehyde modified 94 and hydroxylamine bearing 95. 
To obtain more insight into the reaction progress, a new set of coiled-coil peptides was 
synthesized, equipped with an additional N-terminal glycine cap, as well as an optional 
alloc-protected lysine residue at the C-terminus. Due to the additional layer of orthogonality 
introduced by the alloc protecting group, this residue can be used to introduce a fluorescent 
label for quantification of the conversion via peak integration in the UHPLC chromatogram. 
Furthermore, a reference peptide was synthesized to serve as comparison for the non-
templated reaction (see Table 5). 
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Table 5: Sequence and heptad register of the arginine containing coiled-coil strands based on [208] and 
additional sets bearing an attachment point for a fluorophore. Sequence of the reference peptide 101, based 
on [213]. Peptides were synthesized as C-terminal amides and 99 and 100 were synthesized as Fmoc-
protected species for further derivatization. 
   Sequence and heptad register  
Entry Name N-term. gabcdef gabcdef gabcdef C-term. 
1 CC-E3N2 (97) G EIAALEK ENAALEW EIAALEQ GG 
2 CC-K3N2 (98) G KIAALKY KNAALKK KIAALKQ GG 
3 *CC-E3N2 (99) G EIAALEK ENAALEW EIAALEQ GGK(alloc) 
4 *CC-K3N2 (100) G KIAALKY KNAALKK KIAALKQ GGK(alloc) 
5 101  EWAETAAAKFLAAHA  
 
With these peptides in hand, aldehyde containing peptides 102 and 105 were synthesized, 
in addition to hydroxylamine modified 100, to which fluorescein isothiocyanate (FITC) 
isomer I was attached (103). Both aldehydes were combined with the hydroxylamine under 
oxime ligation conditions (see Figure 67) and their reaction progress was monitored over 
the course of 20 and 8 h, respectively (see Figure 68a,b). Afterwards, the successfully 
ligated products were purified by analytical HPLC and 104 was subjected to CD-
spectroscopic analysis to verify its α-helical structure (see Figure 68d).  
 
 
Figure 67: (a) Coiled-coil mediated oxime ligation and (b) non-templated reference. The star represents FITC. 
Although product formation and the structural integrity of the coiled-coil were confirmed, 
reaction monitoring showed several discrepancies. First, the aliquot analyzed after 5 min 
shows a high conversion (31% for 104, 70% for 106) for both reactions. While this reaction 
behavior might be explained by the template effect, it does not fit the kinetic profile for the 
non-templated oxime ligation at pH 7.0.[32,54] Secondly, product formation for the templated 
reaction did not follow a linear pathway. While the intensity of the product peak was strong 
in the t = 5 min chromatogram, it was almost non-existent after t = 20 min. This behavior 
(a) 
(b) 
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was accompanied by an increase in the aldehyde signal intensity and almost complete 
disappearance of the hydroxylamine. Following this point in time, the product signal 
increased steadily in line with a decrease of the aldehyde signal to reach 61% conversion 
after 4 h and 71% after 6 h. Two possible explanations come to mind. First, the aldehyde 
exists in equilibrium with its diol form, being shifted towards the latter.[214] However, this 
phenomenon is not in agreement with the observed chromatograms. Second, dynamic 
covalent chemistry between the aldehyde moiety and the ε-amino groups of the K3 strand 
are plausible. Since this reaction behavior would also be accompanied by consumption of 
the aldehyde this explanation is also not plausible. In comparison to these observations, 
the non-templated ligation proceeded in a more linear fashion. Therefore, an unidentified 
interaction with the coiled-coil template seems likely, it does however not appear to 
influence formation of the desired product. Owing to these effects, a ligation with a positive 
templating effect could not be observed. Instead a faster, more steady conversion was 
observed for the non-templated approach. 
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Figure 68: UHPLC reaction monitoring (215 nm) of (a) the coiled-coil mediated oxime ligation (104) and (b) of 
the non-templated reference (106). (c) Chromatogram (215 nm) of the purified ligation product 104 and (d) CD 
spectrum of the purified ligation product 104. CD spectra were recorded at a concentration of 25 μM in 
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4.3.3 Coiled-coil templated alkylation of cysteine with chloroacetamide 
 
Having established the successful product formation via oxime ligation, a reaction with a 
similar geometry was investigated. The choice fell on the alkylation of an N-terminal 
cysteine residue with chloroacetamide. While this reaction does not conform to the 
principles of bioorthogonal chemistry, it follows a similar reaction pathway in the form of a 
nucleophilic substitution. Furthermore, there is no reversibility of the reaction equilibrium 
and possible side reactions are excluded for the presented experimental setup, since only 
one cysteine residue is present. In addition, this ligation approach was already 
demonstrated to be successful in linking coiled-coil strands, albeit with different geometries 
by placing the reactive moieties in the hydrophobic core[137] or by introduction of a peptidic 
spacer.[215] 
Nonetheless, chloroacetic acid was introduced to E3 strand 97 by standard coupling 
procedures to yield 107. Similarly, cysteine was introduced to K3 strand 100, labeled with 
FITC and acetylated at the N-terminus. Chloroacetic acid was also attached to the 
reference peptide 101 to yield 110. Both chloroacetamide bearing peptides were combined 
with the cysteine containing peptide in a reducing buffer for 6 h (see Figure 69.) 
 
 
Figure 69: (a) Coiled-coil mediated cysteine alkylation and (b) non-templated reference. The star represents 
FITC. 
 
Surprisingly, only the non-templated approach led to product formation, while the starting 
materials were retained in the templated approach. This seems to indicate the necessity of 
a linker of at least moderate length between template and reactive centers. The hypothesis 
could however not be tested, since incorporation of a PEG(3) linker between 97 and 
chloroacetic acid failed. Of note, the non-templated cysteine alkylation proceeded much 
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Figure 70: UHPLC reaction monitoring (215 nm) of the non-templated cysteine alkylation. 
 
4.3.4 Coiled-coil templated SPAAC ligation 
 
To complete the assessment of coiled-coil peptides as a reaction template, the SPAAC 
ligation was investigated. While its kinetics are inherently faster than that of oxime ligation, 
introduction of the sterically demanding cyclooctyne might offer additional insight into the 
compatibility of reaction templates and bulky functional groups.  
In line with the experiments described in the previous sections, 4-azidobutyric acid was 
introduced to FITC labeled 99. The building block (113) was synthesized according to a 
procedure by Maltzahn et al.[216] via nucleophilic substitution of ethyl 4-bromobutyrate (112) 
with sodium azide, followed by basic hydrolysis of the ethyl ester protecting group. The 
product was obtained in excellent yields (see Figure 71). Subsequent attachment to the 
peptide was performed following standard coupling protocols to yield 114. 
 
 
Figure 71: Synthesis of 4-azidobutyric acid. 
 
Commercially available DBCO-acid was attached to K3 peptide 98 and reference peptide 
101 to yield 115 and 117, respectively. Both peptides were combined with azide-modified 








Figure 72: (a) Coiled-coil mediated SPAAC ligation and (b) non-templated reference. The star represents FITC. 
 
This result seems to be indicative for high steric constraint between the peptide and the 
attached functional groups. Surprisingly, for this approach even the non-templated 
geometry seems to be unfitting. To further investigate this phenomenon, a PEG(3) linker 
was introduced as an additional spacer between the CC-K3N2 peptide and DBCO-acid to 
yield 119. However, no reaction was observed after 6 h when combined with 114 (see 
Figure 73), suggesting a crowding of the functional groups that cannot be easily overcome. 
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4.3.5 Coiled-coil mediated functional group transfer with partial scaffold 
release  
 
Of the investigated reactions, oxime ligation was the only approach to yield the covalently 
cross-linked coiled-coil dimer. Monitoring of the reaction progress did show reaction 
kinetics that do not conform to a second-order rate. The observed deviations in combination 
with no apparently observed template effect could complicate future applications in protein 
labeling. Nonetheless, a proof of concept experiment was designed to demonstrate the 
functional group transfer with subsequent removal of the donor strand. For this, 
commercially available Fmoc-D-β-Phe(2-NO2)-OH was introduced as a PCL between the 
CC-K3N2 donor strand and the hydroxylamine to give 121. It was combined with aldehyde 
modified 102 under ligation conditions, to yield the cross-linked species 122 (see Figure 
74a). Due to the long irradiation times associated with the PCL, use of a fluorophore was 
foregone, since bleaching and possible degradation were suspected, which would result in 




Figure 74: (a) Oxime ligation between aldehyde modified 102 and hydroxylamine bearing 121. (b) Removal of 
the donor strand by irradiation at 347 nm (600 W). 
 
The identity of 122 was confirmed by HR-MS after purification by HPLC and a solution of 
the pure peptide was irradiated in phosphate buffer at 347 nm and 600 W (see Figure 74b). 
The photolysis was followed by high-resolution LC-MS. The first aliquot was analyzed after 
45 min, which revealed an incomplete cleavage, but still identified the species 123 and 124 
(see Figure 75). These results are in line with the generally accepted photolysis mechanism 
of o-nitrobenzyl compounds (see Figure 45, chapter 4.2.2). Photocleavage was found to 
be complete after 2 h, owing to the poor photophysical properties of the linker. Despite the 
(a) 
(b) 
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expected slow removal of the helper strand, the proof of concept experiment was 
successful, yielding the functionalized peptide 124, as well as the removed helper fragment 
123. Photocleavage could be optimized by utilizing a linker with more beneficial properties, 









In this chapter the viability of coiled-coil peptides as templates for a variety of biocompatible 
reactions was investigated. Contrary to the previously described approach utilizing PNA, 
an architecture leading to the transfer of a functional group from a donor to an acceptor 
strand, with release of the former, was pursued. Tying in with the findings of the previous 
chapter, the Suzuki cross-coupling was first investigated. Starting from Hodges’ parallel 
heterodimeric IAAL E3/K3 peptides, templates with different flexibility, length, and linker 
region were investigated without success. Since CD spectroscopy revealed an intact 
template and binding of the catalyst to the amino acids is highly unlikely, a more reasonable 
explanation is the preorganization of the functional groups by the template into an 
unsuitable geometry or a low reactivity of the employed reagents. Therefore, a number of 
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only oxime ligation and cysteine alkylation showed product formation. Application of the 
template only led to success of the former. Surprisingly, no increase in reaction rate was 
measured compared to the non-templated approach. Instead, a non-linear reaction 
behavior was observed that could not be explained based on experimental data. 
Nonetheless, a proof of concept experiment was designed, ligating hydroxylamine 
equipped coiled-coil 121 and aldehyde modified coiled-coil 102. Irradiation of an  
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5 Summary and outlook 
 
Site-selective protein modification is an important tool to study and influence the function 
of proteins. The use of template assisted ligation allows for substrate selectivity and an 
enhanced reaction rate due to an increase of the reactant’s effective molarity. Employing 
more than one template in a series of parallel ligation events would provide selectivity, 
while the concentration of a non-templated reaction should be too low to form a significant 
amount of product, even if competing functional groups are involved. In this work, a peptide 
nucleic acid template was investigated towards this goal, utilizing NCL as the ligation 
reaction. To further broaden the scope of the template and improve its photolytic release, 
a Suzuki cross-coupling reaction with the potential for fluorescence generation upon 
ligation was studied. In addition, a different template architecture, based on a heterodimeric 
parallel coiled-coil was explored to facilitate functional group transfer via a variety of 
biocompatible ligations. Common to all approaches was the use of a photocleavable linker 
that led to (partial) scaffold release after the ligation. 
 
Based on previous work in our group by Middel et al.,[12,154] a template directed NCL 
strategy applying photocleavable PNA strands was selected to be studied in the parallel 
mediation of two ligation events. PNA associates via Watson-Crick base pairing and 
strands with a non-complementary sequence should be discriminated based on the energy 
penalty associated with a mismatched base pair. In order to identify orthogonal templates, 
an automated protocol for the synthesis of PNA strands was developed in collaboration 
with Denis Pahlke and Patrick Menzel that has recently found application in the synthesis 
of PNA-peptide conjugates as functional SNARE protein mimetics.[217] To this end, three 
PNA duplexes containing zero, two or three mismatched base pairs, as well as two 
duplexes of different length and sequence (10-mer, 12-mer) were synthesized. The stability 
of matched and mismatched pairs was studied by UV-Vis melting curve measurements. 
While positional mismatches did not show the expected difference in melting temperature, 
a difference of 11.4 °C was observed between length mismatched complexes  
PNA 1∙PNA 2 and PNA 3∙PNA 4. However, a discrepancy between length and sequence 
mismatched pairs (combinations of PNA 1 or PNA 2 with PNA 3 or PNA 4) was almost 
nonexistent. This behavior seems to differ from antiparallel PNA duplexes or PNA∙DNA or 
PNA∙RNA duplexes, although the studied sample size was small.[144,161,162] Nonetheless, 
the corresponding building blocks for a parallel ligation approach were synthesized (20-23) 
and their selective native chemical ligation studied. Neither starting material nor a (cross) 
reaction product was identified. This may have been the result of the nucleobase 





recognition not being sufficiently selective, therefore forming mixed products, effectively 
lowering the concentrations under the detection limit. While the absent selectivity of the 
PNA duplexes prevents their use in a simultaneous ligation, they could still find application 
in combination with a structurally different template.  
 
In order to expand the scope of reactions templated by photocleavable PNA strands, a 
method with fluorescence generation upon ligation was investigated. A second reaction 
type would furthermore bypass the use of competing functional groups. Suzuki cross-
coupling was selected, since a reaction of halogenated tryptophan and phenylboronic acid 
would result in a fluorophore to monitor the reaction progress and track a protein of interest 
with different microscopy techniques. Initial tests verified the established methods for 
cross-coupling of a peptide and a small organic substrate and were expanded to show 
application in the coupling of two small peptide fragments. Reaction times increased 
substantially for the more complex reaction architectures, suggesting steric inhibition.  
Implementation of the guiding PNA strands to increase the reaction rate of the cross-
coupling reaction however revealed problems. No reactivity was observed for a templated 
cross-coupling approach and screening of various catalyst systems revealed inhibition by 
PNA. UV-Vis measurements observing the change in melting temperature and absorbance 
of dsPNA at various Pd(II) concentrations suggested direct binding of the palladium ion to 
the PNA nucleobases, thereby stalling the reaction. While an increase in catalyst 
concentration might lead to a successful cross-coupling reaction, it would also most likely 
result in the unwinding of the template.  
 
Coiled-coil peptides were investigated as an alternative reaction template since the 
different dimer recognition mode would result in orthogonality to PNA templates. Their 
facile synthesis would also provide a toolbox approach for a variety of bioorthogonal 
ligations. The employed architecture provides a functional group transfer, while a PCL 
releases the donor strand. Initially, Suzuki cross-coupling was tested and while the 
template remained intact, no reaction was observed. This led to the assumption that the 
template might pre-organize the functional groups into an undesirable reaction geometry. 
In this light, biocompatible reactions with different steric demands were screened. Oxime 
ligation, cysteine alkylation and SPAAC were studied under influence and absence of a 
coiled-coil template. Of the templated reactions, only oxime ligation led to product 
formation, while cysteine alkylation additionally led to the reaction product without use of a 
template. Notably, both reactions possess simple reaction architectures and have a low 
steric demand. Absence of a reaction for the templated cysteine alkylation approach seems 
to suggest a specific distance of the functional group from the template and orientation are 
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necessary for a successful ligation. Reaction monitoring of the templated oxime ligation 
further revealed a non-linear conversion that proved to be slower than the non-templated 
approach. Nonetheless, oxime ligation was successfully applied in a proof of concept 
experiment that resulted in the transfer of the functional group from the donor to the 
acceptor strand and a successful release of the former by photolysis. The general approach 
is outlined in Figure 76. 
 
 
Figure 76: Concept of the coiled-coil mediated functional group transfer. The strategy allowed oxime ligation 
between donor (blue) and acceptor strand (red) with removal of the former by photolysis. 
 
For the future of the project, different reactions should be studied in combination with the 
coiled-coil template. An inverse electron demand Diels-Alder reaction between 
methylcyclopropene and s-tetrazine might offer a compromise between low steric demand 
and fast reaction kinetics. Furthermore, a detailed study into the geometry necessary to 
provide a positive templating effect should be conducted. The already established coiled-
coil templated NCL could be studied regarding linker length, reaction kinetics and possibly 
X-ray crystal-structures to determine suitable alignments and distances between the 
functional groups. Another possibility is the investigation of orthogonal peptide tectons to 
facilitate simultaneous reactions. Furthermore, the applied PCL lacks desirable 
photophysical properties. Within this thesis, an improved PCL based on DEACM has been 
synthesized for conjugation of the PNA template. A bifunctional variant suitable for direct 
incorporation into peptides via automated SPPS is imaginable based on the studies by 
Yamazoe et al.[187] Since the coiled-coil templated oxime ligation was successful, a 
combination with the PNA mediated NCL might be conceivable for an application where 
site-selectivity and parallel labelling would compensate slow reaction times. This 
combination of PNA and coiled-coil template might offer the best results towards facilitating 
parallel ligation events. However, for ease of synthesis and higher selectivity, the PNA 
sequence should be changed to accommodate antiparallel alignment. Different linkers 





based on an orthogonal release mechanism, such as higher wavelength, change in pH 
value or susceptibility to proteases might complement this approach. 
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6 Experimental section 
6.1 Materials and methods 
6.1.1 Reagents and solvents 
 
Fmoc-protected amino acids and PNA monomers were purchased from Carbolution 
Chemicals GmbH (St. Ingbert, Germany), Iris Biotech GmbH (Marktredwitz, Germany), GL 
Biochem Ltd. (Shanghai, China), Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) 
ChemPUR (Karlsruhe, Germany), BLD Pharmatech Ltd. (Shanghai, China), Chem-Impex 
International, Inc. (Wood Dale, IL, USA) and ASM Research Chemicals GmbH (Hannover, 
Germany). Oxyma Pure and HATU were obtained from Carl Roth GmbH & Co. KG 
(Karlsruhe, Germany), DIC was supplied by Iris Biotech GmbH and HOAt by GL Biochem 
Ltd. H-Rink amide ChemMatrix® resin was purchased from Sigma-Aldrich, Wang resins 
and NovaPEG Rink amide resins were obtained from VWR International GmbH 
(Darmstadt, Germany). DMF used for peptide synthesis was obtained from Thermo Fisher 
Scientific GmbH (Schwerte, Germany) in laboratory reagent quality. Piperidine and 
piperazine in peptide synthesis quality was acquired from Carl Roth GmbH & Co. KG and 
abcr GmbH (Karlsruhe, Germany), respectively. 2,6-Lutidine for PNA synthesis was 
purchased from Thermo Fisher Scientific GmbH. Acetonitrile and methanol used for HPLC 
were supplied by Thermo Fisher Scientific GmbH in HPLC grade quality. Water used for 
HPLC was obtained by purifying deionized water with an arium® mini lab water system from 
Sartorius (Göttingen, Germany). All other reagents were supplied by abcr GmbH, Alfa 
Aesar (Thermo Fisher GmbH, Kandel, Germany), Carl Roth GmbH & Co. KG, ChemPUR, 
Fluorochem (Hadfield, United Kingdom), J&K Scientific bvba (Lommel, Belgium), Merck 
KGaA, Sigma-Aldrich, TCI Deutschland GmbH (Eschborn, Germany), Thermo Fisher 
Scientific GmbH and Th. Geyer GmbH & Co.KG. All reagents were of synthesis grade 
quality and were used as supplied. 
 
6.1.2 Thin-layer chromatography (TLC) and column chromatography 
 
TLC analysis was performed on aluminum TLC plates with silica gel 60 F254 from Merck 
KGaA. Compounds were detected by fluorescence quenching with UV-light (λ = 254 or 
366 nm). Column chromatography was performed on Geduran® silica gel 60 (40-63 μm), 
supplied by Merck KGaA. 
  





6.1.3 High Performance Liquid Chromatography (HPLC) 
 
HPLC purification was mainly carried out on three devices from JASCO Deutschland 
GmbH (Pfungstadt, Germany). For sample purification on a preparative scale, a device 
equipped with PU-4086 pumps, a UV-4075 detector and a CO-4060 column oven was used 
at flow rates of 10 mL/min. Semi-preparative purification was performed on a system with 
PU-2080plus pumps and a MD-2010 detector at flow rates of 3 mL/min. A system with 
identical pumps and a MD-4015 detector was used for purification on an analytical scale at 
flow rates of 1 mL/min.  
Peptide samples were detected at 215, 254 and 280 nm. PNA samples were detected at 
215, 265 and 280 nm. Samples containing coumarin derived building blocks were detected 
at 215, 280 and 380 nm. Samples containing nitroveratryloxycarbonyl derived building 
blocks were detected at 215, 280 and 350 nm. Samples containing fluorescein 
isothiocyanate were detected at 215, 280 and 440 nm. For preparative HPLC, only the 
signal at 215 and 280 nm was followed. 
The solvents used for purification are listed below. Linear gradients of solvent B and C were 
used. 
 
Solvent A H2O + 0.1% TFA 
Solvent B MeCN + 0.1% TFA 
Solvent C MeOH + 0.1%TFA 
 
The employed columns were purchased from MACHEREY-NAGEL GmbH & Co. KG 
(Düren, Germany) Advanced Chromatography Technologies Ltd. (Aberdeen, Scotland) 
and KNAUER Wissenschaftliche Geräte GmbH (Berlin, Germany) and are specified below. 
 
Column 1 MN Nucleodur, 100-5 C18ec, 250 x 21 mm, 5 μm 
Column 2 MN Nucleodur, 100-5 C18ec, 250 x 10 mm, 5 μm 
Column 3 MN Nucleodur, 100-5 C18ec, 250 x 4.6 mm, 5 μm 
Column 4 MN Nucleodur Sphinx RP, 250 x 10 mm, 5 μm 
Column 5 Ace® 5 C18-100, 150 x 10 mm, 5 μm 
Column 6 Knauer Eurosil Bioselect 300-5 C18, 250 x 4.6 mm, 5 μm 
 
The gradient composition is indicated in the respective experimental procedures.  
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6.1.4 Ultra High Performance Liquid Chromatography (UHPLC)  
 
Reaction monitoring and analysis of sample quality by UHPLC was performed on an 
UltiMate 3000 system from Thermo Fisher Scientific GmbH, using an ACE® Excel® 2 C18-
100 (100 x 2.1 mm, 2 μM) column at a flow rate of 0.45 mL/min at 50 °C. Linear gradients 
of A (water + 0.1% TFA) and B (MeCN + 0.1% TFA) were applied as stated in the respective 
experimental procedures. 
 
6.1.5 Nuclear Magnetic Resonance (NMR) Spectroscopy 
 
1H-NMR spectra were recorded on Avance III HD (300 or 500 Mhz) and Avance Neo (400 
or 600 MHz) devices from Bruker BioSpin GmbH (Rheinstetten, Germany) at 25 °C. 13C-
NMR spectra were recorded on the same devices at the corresponding frequencies of 75, 
100, 125 and 150 MHz at 25 °C. The utilized deuterated solvents are indicated for each 
compound individually. The residual proton signal of the solvent served as an internal 
standard and was referenced according to Gottlieb et al. (see table below).[218] Chemical 
shifts δ are given in ppm and coupling constants J are given in Hertz (Hz). For peak 
assignment, the following abbreviations for multiplicities and descriptors were used: s = 
singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet, dd = doublet of 
doublets, dt = doublet of triplets, td = triplet of doublets and br = broad signal. 
 
 CDCl3 (CD3)2SO CD3OD D2O 
solvent residual peak (1H-NMR) 7.26 ppm 2.50 ppm 3.31 ppm 4.79 ppm 
solvent residual peak (13C-NMR) 77.16 ppm 39.52 ppm 49.00 ppm  
 
6.1.6 Mass spectrometry (MS) 
 
Peptides were characterized by high-resolution mass spectrometry (HR-MS). Electrospray 
ionization (ESI-HRMS) spectra were recorded on a maXis (ESI-QTOF-MS) or a micrOTOF 
(ESI-TOF-MS) device from Bruker Daltonik GmbH (Bremen, Germany). The detected ion 
masses are reported in m/z (mass-to-charge ratio). 
 
6.1.7 Liquid chromatography-mass spectrometry (LC-MS) 
 
Chromatographic analysis was performed on an Accela™ system from Thermo Fisher 
Scientific GmbH, using a Kinetex® C18-100 (150 x 2.1 mm, 5 μM) column from 





Phenomenex Ltd. Deutschland (Aschaffenburg, Germany) at a flow rate of 0.2 mL/min. 
Linear gradients of A (water + 0.05% FA) and B (MeOH + 0.05% FA) were applied as stated 
in the respective experimental procedures. Mass spectra were recorded on a coupled LTQ 
Orbitrap XL™ spectrometer from Thermo Fisher Scientific GmbH. 
 
6.1.8 Concentration determination 
 
Peptide concentrations were determined by UV-absorbance using a NanoDrop™2000c or 
NanoDrop™OneC spectrophotometer from Thermo Fisher Scientific GmbH. The following 
tabulated wavelengths and extinction coefficients were used for calculation according to 
the Beer-Lambert law. 
 
Compound λ [nm] ελ [M-1 cm-1]  Reference 
Trp 280 5690 [219] 
Tyr 280 1280 [219] 
PNA-A 260 13700 [220] 
PNA-C 260 6600 [220] 
PNA-G 260 11700 [220] 
PNA-T 260 8600 [220] 
Nvoc 350 5485 [221] 
DEACM-OH 385 16000 [177] 
FITC 494 77000 [215] 
 
6.1.9 UV-Vis spectroscopy 
 
UV-Vis measurements were carried out on a Jasco V-650 spectrophotometer equipped 
with a Jasco ETCS-761 temperature controller. Suitable cuvettes from Hellma GmbH & Co. 
KG (Müllheim, Germany) with a path length of 1 cm were employed. 
PNA melting curves were recorded from 5 μM duplex solutions in TBS buffer (50 mM Tris-
Cl, 150 mM NaCl, pH 7.5). The time course measurement program was chosen, and the 
wavelength set to 260 nm. Spectra were recorded in the range of 5-80 °C, where each 
measurement consisted of a heating (580 °C) and a cooling (805 °C) cycle. Three 
accumulations were measured for every duplex pair. The UV-Vis bandwidth was set to 
2.0 nm with a fast response time. The acquired data was interpreted according to the 
following equation for the hyperchromicity H: 
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with A(T) (absorbance at a given temperature) and A0 (minimum absorbance). The melting 
temperature Tm is the maximum of the first derivative of the resulting curve. 
PNA titration experiments in the presence of Pd-catalyst were carried out using a total 
strand concentration of 5 μM in phosphate buffer (50 mM, pH 8.0). Spectra measurement 
was performed in the range of 200-350 nm in intervals of 0.5 nm at 20 °C. A scanning 
speed of 100 nm/min with a fast response time and a bandwidth of 1.0 nm was selected. 
Three accumulations were recorded for every experiment. Every measurement was 
corrected for a blank containing the buffer and the titrated amount of catalyst. 
 
6.1.10 Circular dichroism (CD) spectroscopy 
 
CD spectra were recorded on a Jasco J1500 CD spectrometer equipped with a Julabo 
(Seelbach, Germany) F250 cooler. Suitable cuvettes from Hellma GmbH & Co. KG with a 
path length of 0.1 cm were employed. 
CD measurements were recorded from 80 μM coiled-coil solutions in phosphate buffer 
(50 mM, pH 7.0 or 8.0). Spectra measurement was performed in the range of 190-250 nm 
in intervals of 1.0 nm at 20 °C. A scanning speed of 100 nm/min was selected, the CD scale 
was set to 2000 mdeg/1.0 dOD and the bandwidth to 1.0 nm. Ten accumulations were 
recorded for every experiment. Alternatively, for a coiled-coil concentration of 25 μM 
intervals of 0.1 nm were chosen with a scanning speed of 50 nm/min.  
Raw data was corrected by subtracting a blank containing the buffer and then interpreted 
according to the following equation[206] for the molar ellipticity [𝛩]: 
[𝛩] (deg ∙ cm2 ∙ dmol−1) =  
𝛩obs  ∙  𝑀𝑅𝑊
10 ∙ 𝑑 ∙ 𝑐
 
where 𝛩obs is the measured ellipticity (mdeg), MRW is the mean residue molecular weight 
(g ∙ dmol-1), d is the path length (cm) and c is the concentration (g ∙ dm-3). 
 
6.1.11 Photolysis  
 
Photolytic cleavage was performed in a UV cuvette (1 cm) from Hellma GmbH & Co. KG 
using an Ark Lamp Source (66924) from Newport Spectra-Physics GmbH (Darmstadt, 
Germany), consisting of a 1000 W Arc Housing-IGN F/1.0 (66921), a 1000 W Hg-Xe lamp 
(6295NS), power supply (69920), dichroic mirror (280-400 nm, 66226) and optionally a 
347 nm longwave cut-on filter (20CGA-345, setup a). Alternatively, an Osela inc. (Lachine, 





QC, Canada) Streamline Laser (405 nm, 100 mW, 70 mA) was used as the irradiation 




ChemDraw Professional 16.0 (PerkinElmer Informatics, Waltham, MA, United States) was 
used for the drawing of chemical structures and calculation of molecular masses. Figures 
were created with the help of Affinity Designer (Serif (Europe) Ltd, Nottingham, United 
Kingdom) and data files from the RCSB protein data bank (PDB)[222] were interpreted and 
modified using UCSF Chimera. The identifier of the corresponding PDB entry is indicated 
in the respective figure. For coiled-coil peptides and generic protein structures entries 1U0I 
and 4FC1 were used for illustrative purposes. Chimera is developed by the Resource for 
Biocomputing, Visualization, and Informatics at the University of California, San Francisco, 
with support from NIH P41-GM103311.[223] NMR spectra were analyzed with MestReNova 
10.0 (Mestrelab Research, S.L., Santiago de Compostella, Spain) and graphs were 
compiled using OriginPro 8.5G (OriginLab Corporation, Northampton, MA, United States). 
 




2-Amino-4,6-dihydroxypyrimidine (25.4 mg, 0.2 mmol, 2.0 eq.), 1,1,3,3-tetramethyl- 
guanidine (23.0 mg, 0.2 mmol, 2.0 eq.) and 1-(3-(trimethylammonium)propyl)-3-
methylimidazole bromide (68.6 mg, 0.2 mmol, 2.0 eq.) were each dissolved in NaOH 
(0.1 M, 4 mL) in a 10 mL volumetric flask at 65 °C. Pd(OAc)2 (22.5 mg, 0.1 mmol, 1.0 eq.) 
was added and the solution was stirred at 65 °C for 2 h. The solution was allowed to cool 
to room temperature and diluted to 10 mL, giving a 0.01 M stock solution of the respective 
catalyst. 
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Boc-pIPhe-OH (1 μmol) and phenylboronic acid (1.2 μmol) were dissolved in 1000 μL of 
the indicated solvent. 5 mol% of the respective catalyst were added and the reaction 
mixture was agitated at 37 °C. 10 μL aliquots were taken after 0.5, 1, 2, 3 and 4 h, 
quenched by the addition of 6 mol% glutathione and diluted to 20 μL with H2O. Samples 
containing PNA strands as an additive were additionally analyzed after 20 h. Conversion 
was determined by UHPLC (gradient: 5-90% B in 15 min). 
 
6.2 Standard Operating Procedures (SOPs) 
 
SOP 1: Automated Solid Phase Peptide Synthesis (SPPS) 
Peptides were synthesized on a Liberty Blue automated microwave peptide synthesizer 
from CEM GmbH (Kamp-Lintfort, Germany). Prior to coupling, the resin was swollen in 
DMF for at least 30 min. Synthesis was performed according to standard Fmoc/tBu-
protocol using diisopropylcarbodiimide (DIC) and Oxyma as coupling reagents and a 
solution of piperidine in DMF (20% (v/v)) for Fmoc deprotection. Attachment of the amino 
acid building blocks was performed as double coupling, using a modified CarboMax 
method (5 eq. aa, 10 eq. DIC, 5 eq. Oxyma, 0.5 eq. DIPEA in DMF; 1: 75 °C, 170 W, 15 s; 
2: 90 °C, 30 W, 110 s). Milder conditions with an elongated reaction time were applied for 
the coupling of His (1: 25 °C, 0 W, 120 s; 2: 50 °C, 35 W, 480 s). Removal of the temporary 
protecting group was carried out under standard conditions (1: 75 °C, 260 W, 15 s;  
2: 90 °C, 60 W, 50 s). 
After completion of the peptide synthesis, the resin was transferred to a Discardit II™ 
syringe equipped with a filter supplied by Becton Dickinson GmbH (BD syringe, Heidelberg, 
Germany), washed with DMF (10x5 mL) and DCM (10x5 mL) and dried in vacuo.  
  





SOP 1b: Synthesis of branched peptides 
Synthesis of the linear peptide was carried out according to SOP 1. The branching point 
was marked by Fmoc-Dap(Mmt)-OH. Following automated SPPS, the resin was 
transferred to a BD syringe. Deprotection of the side chain was performed with 
DCM/TIS/TFA (94:5:1, 1 mL/10 μmol) for 2 x 5 min at room temperature. Afterwards, the 
resin was washed with DMF, DCM and DMF (each 5 x 1 mL/10 μmol). Then, Boc-
Cys(StBu)-OH (5.0 eq.) was coupled to the side chain with PyBOP (5.0 eq.) and DIPEA 
(10 min) for 2 x 30 min at room temperature. Further elongation of the main chain was 
achieved following SOP2. 
 
SOP 2: Microwave assisted manual SPPS 
Manual coupling of peptides was carried out in a BD syringe, according to Fmoc/Boc-
strategy following the subsequent procedure. Prior to coupling the dry resin was swollen in 
DMF for 30 min. 5.0 eq. of the Fmoc-protected amino acid were dissolved in DMF to give 
a 0.05 M solution. 4.9 eq. HATU, 5.0 eq. HOAt and 10.0 eq. DIPEA were added and the 
solution was added to the resin, which was transferred to the reaction cavity of a Discover® 
microwave synthesizer from CEM and coupling was performed at 75 °C (25 W) for 5 min. 
Afterwards, the resin was washed five times with DMF and the coupling step was repeated. 
If necessary, capping was carried out by treating the resin with a solution of 
DMF/Ac2O/DIPEA (17:2:1 (v/v)) for 2 x 5 min. Afterwards, the resin was washed five times 
with DMF. Deprotection of the Fmoc-protecting group was achieved by treatment of the 
resin with 20% piperidine in DMF at 40 °C (20 W) for 30 s and repeated at 75 °C (50 W) 
for 3 min. After each deprotection step, the resin was washed five times with DMF. After 
completion of the peptide synthesis, the resin was washed ten times with DMF and DCM 
and dried in vacuo.  
 
SOP 2b: Microwave assisted manual SPPS at lower temperatures 
The same procedure as for SOP2 was applied. However, deprotection was performed at 
40 °C (20 W) for 1 min and repeated at 50 °C (25 W) for 5 min. Coupling of the amino acids 
was performed at 50 °C (25 W) for 15 min and repeated once.  
 
SOP 2c: Manual SPPS at room temperature 
Alternatively, coupling at room temperature was performed applying deprotection times of 
15 min and coupling times of 1 h. 
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SOP 3: Manual solid phase PNA synthesis 
Manual coupling of the PNA strands was carried out in a BD syringe according to 
Fmoc/Bhoc-strategy on NovaPEG Rink amide resin (0.17 mmol/g) resin following the 
subsequent procedure. Prior to coupling the dry resin was swollen in DMF for 30 min. 
5.0 eq. of the Fmoc-protected building block were dissolved in DMF to give a 0.05 M 
solution. 4.9 eq. HATU, 5.0 eq. HOAt, 10.0 eq. DIPEA and 10.0 eq. 2,6-lutidine were added 
and the solution was transferred to the resin, which was agitated for 45 min. Afterwards, 
the resin was washed with DMF (5 x 2 mL/10 μmol) and the coupling step was repeated. 
Capping was carried out by treating the resin with a solution of DMF/Ac2O/2,6-lutidine 
(17:2:1 (v/v), 2 mL/10 μmol) for 2 x 5 min. The resin was washed five times each with 5% 
DIPEA in DMF (2 mL/10 μmol) and DMF (2 mL/10 μmol). Deprotection of the Fmoc-
protecting group was achieved by treatment of the resin with 20% piperidine in DMF 
(2 mL/10 μmol) for 2 x 10 min. After each deprotection step, the resin was washed with 
DMF (5 x 2 mL/10 μmol). After completion of the peptide synthesis, the resin was washed 
with DMF (10 x 2 mL/10 μmol) and DCM (10 x 2 mL/10 μmol) and dried in vacuo.  
 
SOP 4: Microwave assisted manual solid phase PNA synthesis 
Microwave assisted manual coupling of the PNA strands was carried out in a BD syringe 
according to Fmoc/Bhoc-strategy on NovaPEG Rink amide resin (0.17 mmol/g) following 
the subsequent procedure. Prior to coupling the dry resin was swollen in DMF for 30 min. 
5.0 eq. of the Fmoc-protected building block were dissolved in DMF to give a 0.05 M 
solution. 4.9 eq. HATU, 5.0 eq. HOAt, 10.0 eq. DIPEA and 10.0 eq. 2,6-lutidine were added 
and the solution was transferred to the resin, which was placed in the reaction cavity of a 
Discover® microwave synthesizer from CEM and coupling was performed at 50 °C (25 W) 
for 20 min. Afterwards, the resin was washed with DMF (5 x 2 mL/10 μmol) and the 
coupling step was repeated. Capping was carried out by treating the resin with a solution 
of DMF/Ac2O/DIPEA (17:2:1 (v/v), 2 mL/10 μmol) for 2 x 5 min. The resin was washed five 
times each with 5% DIPEA in DMF (2 mL/10 μmol) and DMF (2 mL/10 μmol). Deprotection 
of the Fmoc-protecting group was achieved by treatment of the resin with 20% piperidine 
in DMF at 40 °C (20 W) for 1 min and repeated at 50 °C (25 W) for 5 min. After each 
deprotection step, the resin was washed with DMF (5 x 2 mL/10 μmol). After completion of 
the peptide synthesis, the resin was washed with DMF (10 x 2 mL/10 μmol) and DCM 
(10 x 2 mL/10 μmol) and dried in vacuo.  
 
  





SOP 5: Automated solid phase PNA synthesis 
PNA strands were synthesized on NovaPEG Rink amide resin (0.17 mmol/g) at a 
0.01 mmol scale following Fmoc/Bhoc-strategy on a Liberty Blue automated microwave 
peptide synthesizer from CEM. Fmoc-deprotection was achieved with a solution of 2% 
piperazine in DMF. Building blocks were used as 0.08 M solutions in DMF. Activation of 
the building blocks was accomplished with DIC (0.1 M in DMF) and Oxyma (0.1 M + 0.1 eq. 
DIPEA in DMF). A solution of DMF/Ac2O/DIPEA (17:2:1 (v/v)) was used for capping via 
external positions. A 5% DIPEA solution in DMF was used as an additional wash at the end 
of the cycle. Prior to coupling, the dry resin was swollen in DMF for 30 min and afterwards 
transferred to the microwave reaction vessel. The deprotection solution (3 mL) was added 
and the Fmoc-protecting group was removed at elevated temperatures (40 °C, 20 W, 60 s). 
After washing with the main solvent (3 x 2 mL), the step was repeated for an extended time 
period (50 °C, 25 W, 300 s). After washing of the resin (5 x 2 mL), coupling of the building 
blocks (0.62 mL aa, 1.5 mL Act, 0.75 mL ActB) was performed under microwave irradiation 
(50 °C, 20 W, 1800 s) as a double coupling step. The resin was washed with DMF 
(3 x 3 mL) and capping was performed by addition of the aforementioned solution (3 mL) 
at room temperature for 300 s. The resin was washed with 5% DIPEA in DMF (3 x 2 mL) 
and DMF (4 x 2 mL). After completion of the synthesis, the resin was transferred to a BD 
syringe. The resin was washed with DMF (10 x 3 mL) and DCM (10 x 3 mL) and dried in 
vacuo.  
 
SOP 6: Cleavage from resin and work up 
Cleavage of the crude peptide from resin and global deprotection of acid labile protecting 
groups was performed in a BD syringe. The resin was suspended in the appropriate 
cleavage cocktail (1 mL/10 μmol) and agitated at room temperature for 2 h. Afterwards, the 
mixture was filtered off and concentrated under a nitrogen stream. The crude peptide was 
precipitated by addition of ice-cold diethyl ether, centrifuged and the supernatant discarded. 
This step was repeated four times, followed by drying of the crude peptide in vacuo. 
A mixture of TFA/H2O/TIS (95:2.5:2.5) was used as the standard cleavage cocktail, 
whereas a mixture of TFA/H2O/EDT/TIS (94:2.5:2.5:1) was used for peptides containing 
cysteine or FITC. 
 
SOP 7: On-resin attachment of photocleavable linker 
The caging group BK073 or BK059 (2.0 eq.) was dissolved in DMF (0.5 mL/10 μmol) and 
DIPEA (5.0 eq.) was added. The solution was transferred to the resin-bound peptide 
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(1.0 eq.) in a BD syringe and shaken for 18 h at room temperature. Afterwards, the resin 
was washed with DMF (10 x 3 mL) and DCM (10 x 3 mL) and dried in vacuo. 
 
SOP 8: On-resin alkyne modification 
Propiolic acid (1.2 eq.) was dissolved in DMF (1 mL/10 μmol) and EEDQ (1.2 eq.) was 
added. The solution was transferred to the resin-bound peptide in a BD syringe and shaken 
for 12 h at room temperature. Afterwards, the resin was washed with DMF (10 x 2 mL) and 
DCM (10 x 2 mL) and dried in vacuo. 
 
SOP 9: On-resin CuAAc reaction 
In a BD syringe, resin-bound alkyne functionalized PNA (1.0 eq.), the PCL containing 
peptide (1.25 eq.), CuI (1.4 eq.) and NaAsc (1.5 eq.) were suspended in dry DMF 
(1.5 mL/10 μmol). The mixture was shaken at room temperature for 48 h. Afterwards, the 
resin was washed with DMF (10 x 2 mL) and DCM (10 x 2 mL) and dried in vacuo. 
 
SOP 10: Template-directed NCL 
The tert-butyl protected thiol (100 nmol, 1.0 eq) was dissolved in 1.0 mL degassed buffer 
(10 mM NaH2PO4, 100 mM NaCl, 20 mM TCEP, pH 7.0) and stirred at room temperature 
for 30 minutes to remove the protecting group. Then, the thioester (100 nmol, 1.0 eq) was 
added and the reaction mixture was stirred for 24 h. Progress of the reaction was analyzed 
by UHPLC. 
 
SOP 11: On-resin Miyaura borylation 
Synthesis of the iodinated precursor was carried out following SOP 2 with pIPhe marking 
the cross-coupling site.  
In a Schlenk tube, the resin-bound iodinated peptide (1.0 eq.) was suspended in dry DMSO 
(5 mL/10 μmol). Bis(pinacolato)diboron (4.0 eq.), PdCl2(dppf) (0.18 eq.), dppf (0.09 eq.) 
and KOAc (6.0 eq.) were added and the reaction mixture was stirred slowly at 80 °C for 
24 h. Afterwards, the resin was transferred to a BD syringe, washed with DMSO, DCM, 
Et2O and DCM (10 x 5 mL each) and dried in vacuo. 
 
SOP 12: Suzuki coupling of peptides 
Stock solutions of the purified peptides were prepared in H2O/MeCN (4:1). 0.1 μmol of each 
peptide strand were combined in a 1.5 mL Eppendorf AG (Hamburg, Germany) safe-lock 
tube and diluted with phosphate buffer (50 mM, pH 8.0) to 1000 μL to give a 100 μM 





solution. 10 mol% of Na2[ADHP]2∙Pd(OAc)2 was added and the reaction mixture was 
agitated at 37 °C. 
Quenching of the reaction was performed by addition of 15 mol% L-glutathion (reduced) as 
an aqueous solution. Aliquots (20 μL) for analysis were taken at specified time points, 
diluted with H2O (10 μL) and quenched with aqueous L-glutathion solution (10 μL). 
 
SOP 13: Synthesis of peptide aldehydes by oxidation of serine 
Introduction of an N-terminal aldehyde moiety was achieved by coupling of  
Fmoc-Ser(tBu)-OH as the last amino acid according to SOP 2c. The N-terminal protecting 
group was removed, followed by global deprotection and cleavage from resin following 
SOP 6. The crude peptide was dissolved in PBS buffer (10 mM KH2PO4, 100 mM 
Na2HPO4, 0.137 M NaCl, 27 mM KCl, pH 7.0), 10.0 eq. NaIO4 were added and the reaction 
mixture was agitated at 37 °C for 15 min. The reaction was stopped by freezing the solution 
in liquid nitrogen, followed by lyophilization. The crude peptide aldehyde was purified by 
HPLC as indicated in the experimental procedures. 
 
SOP 13b: Synthesis of peptide aldehydes from thiazolidine 
Introduction of an N-terminal aldehyde moiety was achieved by coupling of Boc-Thz-OH 
(BK314) as the last amino acid according to SOP 2c. Global deprotection and cleavage 
from resin was performed following SOP 6. The crude peptide was dissolved in H2O + 0.1% 
TFA (1 mL), PdCl2 (1.0 eq) was added and the reaction mixture agitated for 6 h at 37 °C. 
The mixture was filtered, lyophilized and purified by HPLC as indicated in the experimental 
procedure. 
 
SOP 14: Oxime ligation of peptides 
Stock solutions of the purified aldehyde- and aminooxy-containing peptides were prepared 
in H2O/MeCN (7:3). Equimolar amounts were transferred into a 1.5 mL Eppendorf safe-
lock tube and diluted with phosphate buffer (50 mM, pH 7.0) to give a 100 μM solution. The 
reaction mixture was agitated at 37 °C and the progress monitored by UHPLC. 
 
SOP 15: Microwave assisted removal of the alloc protecting group 
The resin-bound peptide was swollen in DCM (2 mL) for 30 min. Alloc deprotection was 
carried out by suspending the resin in DCM and PhSiH3 (15.0 eq.), followed by addition of 
Pd(PPh3)4 (0.5 eq.) and heating to 38 °C (15 W) for 5 min. The resin was washed with DCM 
(5 x 1 mL) and the deprotection step was repeated twice, followed by washing with DCM 
(10 x 1.5 mL) and drying in vacuo. 
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SOP 16: SPAAC ligation of peptides 
Stock solutions of the purified azide- and dibenzocyclooctyne-containing peptides were 
prepared in H2O/MeCN (7:3). Equimolar amounts were transferred into a 1.5 mL Eppendorf 
safe-lock tube and diluted with PBS buffer (10 mM KH2PO4, 100 mM Na2HPO4, 0.137 M 
NaCl, 27 mM KCl, pH 7.0) to give a 100 μM solution. The reaction mixture was agitated at 
37 °C and the progress monitored by UHPLC. 
 
SOP 17: Ligation of peptides containing chloroacetic acid and cysteine 
The cysteine containing peptide (1.0 eq) was incubated in 10 x TCEP-buffer (25 mM 
HEPES, 100 mM NaCl, 10 mM TCEP, pH 7.4) at 37 °C for 30 min. Then, the chloroacetic 
acid containing peptide (1.0 eq.) was added as a stock solution in H2O/MeCN (7:3) and the 
reaction mixture was diluted with HEPES buffer (25 mM HEPES, 100 mM NaCl, pH 7.4) to 
give a TCEP concentration of 1 mM and a peptide concentration of 100 μM per strand. The 
reaction mixture was agitated at 37 °C and the progress monitored by UHPLC. 
  





6.3 Organic synthesis 
 




Bis(2-chloroethylamine) hydrochloride (5.19 g, 29.1 mmol, 1.0 eq.) and 
triphenylmethanethiol (16.1 g, 58.1 mmol, 2.0 eq.) were dissolved in DMF (85 mL) and the 
solution was cooled to 0 °C. DBU (17.9 g, 17.6 mL, 116 mmol, 4.0 eq.) was added 
dropwise and the reaction mixture was allowed to warm to room temperature and stirred 
for 12 h. The solvent was reduced under reduced pressure, the residue was dissolved in 
DCM (200 mL) and washed with an aqueous 5% KH2PO4 solution (3 x 100 mL). The 
organic layer was dried over MgSO4 and the solvent was removed under reduced pressure. 
The crude product was purified by column chromatography (Hexane/EtOAc/NEt3 8:2:0.1) 
to yield 8.79 g (14.1 mmol, 48%) of the title compound. 
1H-NMR (400 MHz, CD2Cl2): δ =7.42-7.39 (m, 12H, CHar), 7.31-7.19 (m, 18H, CHar), 2.37-
2.20 (m, 8H, CH2) ppm. 
13C-NMR (100 MHz, CD2Cl2): δ = 145.6 (Cq,ar), 130.1 (CHar), 128.4 (CHar), 127.2 (CHar), 
67.0 (Cq),48.3 (CH2), 32.9 (CH2) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 622.2597; found: 622.2590. 
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Boc-Glu-OtBu (1.87 g, 6.15 mmol, 1.0 eq.) was dissolved in DMF (22.5 mL) and added 
dropwise to a solution of bis({2-[triphenylmethyl]sulfanyl}ethyl)amine (7.50 g, 12.3 mmol, 
2.0 eq.) in DCM (45 mL). Then, PyBrOP (2.87 g, 6.15 mmol, 1.0 eq.) and DIPEA (2.38 g, 
3.21 mL, 18.5 mmol, 3.0 eq.) were added and the resulting mixture was stirred for 20 h at 
room temperature. The solvent was removed under reduced pressure and the crude 
product was purified by column chromatography (hexane/EtOAc/NEt3 8:2:0.1) to yield 
2.87 g (3.16 mmol, 51%) of the title compound. 
1H-NMR (400 MHz, CD2Cl2): δ =7.40-7.19 (m, 30H, CHar), 5.15 (d, 3JH,H = 7.5 Hz, 1H, NH), 
3.98 (m, 1H, α-CH), 2.78-2.70 (m, 4H, CH2), 2.28-2.24 (m, 2H, CH2), 2.16 (t, 3JH,H = 7.8 Hz 
2H, CH2), 1.99-1.90 (m, 3H, CH2), 1.78-1.72 (m, 1H, CH2), 1.44 (s, 9H, CH3), 1.41 (s, 9H, 
CH3)  ppm. 
13C-NMR (100 MHz, CD2Cl2): δ = 172.2 (CO), 171.9 (CO), 156.0 (COcarbamate), 145.4 (Cq,ar), 
145.1 (Cq,ar), 130.2 (CHar), 130.1 (CHar), 128.6 (CHar), 128.5 (CHar), 127.4 (CHar), 127.3 
(CHar), 82.0 (Cq,tBu), 79.8 (Cq,tBu), 67.7 (Cq,Trt), 67.3 (Cq,Trt), 60.8 (α-CH), 47.8 (CH2), 45.8 
(CH2), 30.9 (CH2), 30.0 (CH2), 29.5 (CH2) 28.7 (CH3), 28.3 (CH3), 28.0 (CH2) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 907.4173; found: 907.4168. 
 
  









Boc-Glu(SEA{Trt}2)-OtBu (2.87 g, 3.16 mmol, 1.0 eq.) was dissolved in DCM (175 mL) and 
NaHCO3 (0.80 g, 9.48 mmol 3.0 eq.) and I2 (2.41 g, 9.48 mmol, 3.0 eq.) were added. The 
solution was stirred for 1 h at room temperature and then quenched with an aqueous 3 M 
Na2S2O3 solution (100 mL). The aqueous layer was extracted with DCM (3 x 100 mL), the 
combined organic layers were dried over MgSO4 and the solvent was removed under 
reduced pressure. The crude product was purified by column chromatography 
(hexane/EtOAc/NEt3 1:1:0.1) to yield 1.03 g (2.45 mmol, 78%) of the title compound.  
1H-NMR (400 MHz, CD2Cl2): δ = 5.21 (d, 3JH,H = 7.7 Hz, 1H, NH), 4.15 (m, 1H, α-CH), 3.96-
3.77 (m, 4H, CH2), 3.07 (t, 3JH,H = 5.8 Hz, 2H, CH2), 2.91 (td, 3JH,H = 5.7 Hz, 2.0 Hz, 2H, 
CH2), 2.48-2.30 (m, 2H, CH2), 2.25-2.16 (m, 1H, CH2), 2.00-1.91 (m, 1H, CH2) 2.16 (t, 3JH,H 
= 7.8 Hz, 2H, CH2), 1.99-1.90 (m, 3H, CH2), 1.78-1.72 (m, 1H, CH2), 1.46 (s, 9H, CH3), 1.43 
(s, 9H, CH3)  ppm. 
13C-NMR (100 MHz, CD2Cl2): δ = 172.3 (CO), 171.6 (CO), 155.7 (COcarbamate), 82.2 (Cq,tBu), 
79.8 (Cq,tBu), 53.9 (α-CH), 52.5 (CH2), 50.4 (CH2), 39.6 (CH2), 35.7 (CH2), 29.3 (CH2), 28.4 
(CH3), 28.1 (CH3) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 421.1825; found: 421.1830. 
  
  6 EXPERIMENTAL SECTION 
105 
 




Boc-Glu(SEAoff)-OtBu (1.03 g, 2.46 mmol, 1.0 eq.) was dissolved in TFA/TIS/H2O 
(95:2.5:2.5, 20 mL), stirred for 2 h at room temperature and the solvent was removed under 
a N2-stream. The residue was dissolved in H2O (30 mL), washed with DCM (3 x 20 mL) 
and the aqueous phase lyophilized. The intermediate was used without further purification. 
H2N-Glu(SEAoff)-OH ∙ TFA (0.93 g, 2.46 mmol, 1.0 eq.) and NaHCO3 (0.83 g, 9.84 mmol, 
4.0 eq.) were dissolved in H2O (30 mL) and cooled to 0 °C. Fmoc-OSu (1.24 g, 3.69 mmol, 
1.5 eq.) in dioxane (50 mL) was added and the pH was adjusted to 9 with an aqueous 0.1 M 
NaHCO3 solution. The reaction mixture was allowed to warm to room temperature and was 
stirred for 20 h. The solution was washed with Et2O (2 x 75 mL), the aqueous phase was 
adjusted to pH 1 with 1 M HCl and extracted with DCM (3 x 100 mL). The combined organic 
layers were dried over NaSO4, the solvent was removed under reduced pressure and the 
crude product was purified by preparative HPLC to yield 0.44 g (0.90 mmol, 37%) of the 
title compound. 
HPLC (column 1, gradient: 40-90 %B in 30 min): tR = 24.21 min. 
UHPLC (gradient: 30-80% B in 20 min): tR = 9.30 min. 
1H-NMR (400 MHz, (CD3)2SO): δ = 12.63 (sbr, 1H, CO2H), 7.89 (d, 3JH,H = 7.8 Hz, 2H, CHar), 
7.74-7.66 (m, 2H, CHar), 7.42 (t, 3JH,H = 7.3 Hz, 2H, CHar), 7.33 (t, 3JH,H = 7.3 Hz, 2H, CHar), 
4.29-4.20 (m, 3H), 4.05-3.98 (m, 1H), 3.8-3.75 (m, 4H), 2.99-2.94 (m, 4H), 2.45-2.33 (m, 
2H), 2.08-1.76 (m, 2H) ppm. 
13C-NMR (100 MHz, (CD3)2SO): δ = 172.9 (CO), 172.2 (CO), 156.2 (COcarbamate), 143.9 
(Cq,Fmoc), 143.7 (Cq,Fmoc), 141.1 (Cq,Fmoc), 127.5 (CHar), 126.9 (CHar), 124.9 (CHar), 119.8 
(CHar), 53.3 (α-CH), 52.2 (CH2), 50.1 (CH2), 47.1 (C-9Fmoc), 39.2 (CH2), 35.3 (CH2), 29.2 
(CH2), 27.6 (CH2)  ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 487.1356, found: 487.1360. 
 
  









Synthesis was performed according to a protocol adapted from literature.[224] 
NaH (1.88 g, 46.9 mmol, 2.0 eq.) was suspended in DMSO (75 mL) and stirred for 1.5 h at 
60 °C. The solution was allowed to cool to room temperature and Me3SI (9.57 g, 
46.9 mmol, 2.0 eq.) was added in three portions at 0 °C and stirred for 1 h. 4,5-Dimethoxy-
2-nitrobenzaldehyde (5.00 g, 23.5 mmol, 1.0 eq.) in THF (75 mL) was added dropwise at 
0 °C and the reaction mixture was allowed to warm to room temperature over night. The 
reaction was quenched by the addition of a saturated aqueous NH4Cl-solution (100 mL). 
The solvent was removed under reduced pressure and the crude product was extracted 
with diethyl ether (3 x 150 mL). The combined organic layers were dried over MgSO4 and 
the solvent was removed under reduced pressure. The crude product was purified by 
column chromatography (pentane/EtOAc 8:1  4:1) to yield 2.59 g (11.5 mmol, 49%) of 
the title compound.  
1H-NMR (400 MHz, CDCl3): δ = 7.73 (s, 1H, CHar), 7.04 (s, 1H, CHar), 4.54-4.52 (dd, 3JH,H 
= 4.4 Hz, 2.6 Hz, 1H, PhCH), 3.98 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 3.31-3.28 (dd, 2JH,H 
= 5.5 Hz, 3JH,H = 4.4 Hz, 1H, CHCH2), 2.65-2.63 (dd, 2JH,H = 5.5 Hz, 3JH,H = 2.6 Hz, 1H, 
CHCH2). 
13C-NMR (100 MHz, CDCl3): δ = 154.4 (Cq,ar), 148.3 (Cq,ar), 140.3 (Cq,ar), 130.0 (Cq,ar), 108.1 
(CHar), 107.9 (CHar), 56.7 (OCH3), 56.6 (OCH3), 51.4 (Cepoxide), 50.8 (Cepoxide) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 226.0710; found: 226.0714. 
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2-(4,5-Dimethoxy-2-nitrophenyl)oxirane (2.59 g, 11.5 mmol, 1.0 eq.) and NH4Cl (1.23 g, 
23 mmol, 2.0 eq.) were dissolved in MeOH/H2O 8:1 (45 mL). Sodium azide (5.98 g, 
91.9 mmol, 8.0 eq.) was added and the solution was stirred for 6 h at 65 °C. The solvent 
was removed under reduced pressure and the residue was diluted with water and extracted 
with Et2O (3 x 75 mL). The combined organic layers were dried over MgSO4 and the solvent 
was removed in vacuo. The crude product was purified by column chromatography 
(pentane/EtOAc 5:1) to yield 1.62 g (6.02 mmol, 52%) of the title compound. 
1H-NMR (400 MHz, CDCl3): δ = 7.67 (s, 1H, CHar), 7.35 (s, 1H, CHar), 5.64-5.61 (dd, 3JH,H 
= 7.6 Hz, 2.8 Hz, 1H, PhCH), 4.00 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 3.72-3.68 (dd, 2JH,H 
= 12.6 Hz, 3JH,H = 2.8 Hz, 1H, CH2N3), 2.65-2.63 (dd, 2JH,H = 12.6 Hz, 3JH,H = 7.6 Hz, 1H, 
CH2N3) ppm. 
13C-NMR (100 MHz, CDCl3): δ = 154.0 (Cq,ar), 148.4 (Cq,ar), 139.6 (Cq,ar), 131.7 (Cq,ar), 109.5 
(CHar), 108.0 (CHar), 69.3 (PhCH), 57.3 (CH2N3), 56.7 (OCH3), 56.5 (OCH3) ppm. 
HR-MS (ESI+): calcd. for [M+Na]+: 291.0700; found: 291.0702. 
  










Synthesis was performed according to a protocol adapted from literature.[12] 
2-Azido-1-(4,5-dimethoxy-2-nitrophenyl)ethanol (1.62 g, 6.02 mmol, 1.0 eq.) and N,N’-
disuccinimidyl carbonate (2.47 g, 9.63 mmol, 1.6 eq.) were dissolved in DMF (35 mL). Et3N 
(1.83 g, 18.1 mmol, 3.0 eq.) was added and the reaction mixture was stirred for 20 h at 
room temperature. The solvent was removed under reduced pressure and the crude 
product was purified by column chromatography (pentane/EtOAc 1:1) to yield 2.02 g 
(4.95 mmol, 82%) of the title compound. 
1H-NMR (400 MHz, CDCl3): δ = 7.70 (s, 1H, CHar), 7.10 (s, 1H, CHar), 6.56-6.54 (dd, 3JH,H 
= 6.3 Hz, 2.7 Hz, 1H, PhCH), 4.09 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 3.96-3.92 (m, 1H, 
CH2N3), 2.65-2.63 (dd, 2JH,H = 13.6 Hz, 3JH,H = 6.3 Hz, 1H, CH2N3), 2.81 (s, 4H, CH2) ppm. 
13C-NMR (100 MHz, CDCl3): δ = 168.3 (COsuccinimide), 154.5 (Cq,ar), 150.7 (COcarbonate), 149.3 
(Cq,ar), 139.7 (Cq,ar), 126.0 (Cq,ar), 108.5 (CHar), 108.4 (CHar), 78.3 (PhCH), 56.9 (CH3), 56.6 
(CH3), 54.3 (CH2N3), 25.6 (CH2) ppm. 
HR-MS (ESI+): calcd. for [M+Na]+: 432.0762; found: 432.0755. 
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Synthesis was performed according to a protocol adapted from literature.[225] 
7-Diethylamino-4-methylcoumarin (4.21 g, 18.2 mmol, 1.0 eq.) and selenium dioxide 
(2.10 g, 18.9 mmol, 1.04 eq.) were dissolved in xylene (350 mL). The reaction mixture was 
refluxed for 48 h, allowed to cool to room temperature and filtered. The solvent was 
removed under reduced pressure and the crude product was purified by column 
chromatography (DCM/acetone 95:5) to yield 2.23 g (9.10 mmol, 50%) of the title 
compound. 
1H-NMR (300 MHz, CDCl3): δ = 10.00 (s, 1H, CHO), 8.27 (d, 3JHH = 9.2 Hz, 1H, H-5), 6.63-
6.59 (dd, 3JHH = 9.2 Hz, 4JHH = 2.7 Hz, 1H, H-6), 6.50 (d, 4JHH = 2.7 Hz, 1H, H-8), 6.42 (s, 
1H, H-3), 3.42 (q, 3JHH = 7.1 Hz, 4H, CH2CH3), 1.20 (t, 3JHH = 7.1 Hz, 6H, CH2CH3) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 192.4 (CHO), 161.7 (C-2), 157.3 (C-8’), 151.0 (C-4), 143.9 
(C-7), 127.0 (C-5), 117.3 (C-4’), 109.6 (C-6), 103.8 (C-3), 97.7 (C-8), 45.0 (CH2CH3), 12.6 
(CH2CH3) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 246.1125, found: 246.1123. 
  









Synthesis was performed according to a protocol adapted from literature.[152]  
Propargyl bromide (80 wt.% in toluene, 2.37 mL, 21.3 mmol, 2.5 eq.) was added to a 
mixture of zinc (3.34 g, 51.1 mmol, 6.0 eq.) in THF (25 mL) at 0 °C. The solution was stirred 
for 1 h. 7-Diethylamino-4-formylcoumarin (2.09 g, 8.52 mmol, 1.0 eq.) was dissolved in 
THF (8 mL) and added to the reaction mixture. The mixture was allowed to warm to room 
temperature, stirred for 2 h and quenched by the slow addition of an aqueous saturated 
NH4Cl solution (35 mL). The reaction mixture was filtered, treated with an aqueous 10% 
HCl solution (100 mL) and extracted with EtOAc (3 x 75 mL). The combined organic layers 
were dried over MgSO4 and the solvent was removed under reduced pressure. The crude 
product was purified by column chromatography (DCM/acetone 95:5) to yield 1.02 g 
(3.57 mmol, 42%) of the title compound. 
1H-NMR (300 MHz, CDCl3): δ = 7.38 (d, 3JHH = 9.0 Hz, 1H, H-5), 6.53-6.51 (dd, 3JHH = 
9.0 Hz, 4JHH = 2.6 Hz, 1H, H-6), 6.41 (d, 4JHH = 2.6 Hz, 1H, H-8), 6.25 (d, 5JHH = 0.9 Hz, 1H, 
H-3), 5.11-5.09 (m, 1H, CHOH), 3.65 (d, 3JHH = 4.2 Hz, 1H, OH), 3.35 (q, 3JHH = 7.1 Hz, 4H, 
CH2CH3), 2.78-2.74 (ddd, 2JHH = 17.0 Hz, 3JHH = 7.4 Hz, 4JHH = 2.6 Hz, 1H, CHCH2), 2.62-
2.57 (ddd, 2JHH = 17.0 Hz, 3JHH = 4.7 Hz, 4J HH= 2.7 Hz, 1H, CHCH2), 2.08 (t, 4JHH = 2.6 Hz, 
1H, CCH), 1.14 (t, 3JHH = 7.1 Hz, 6H, CH2CH3) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 162.2 (C-2), 156.6 (C-8’), 155.2 (C-4), 150.4 (C-7), 124.7 
(C-5), 108.8 (C-6), 106.1 (C-3), 98.3 (C-8), 79.4 (CCH), 68.2 (CHOH), 45.0 (CH2CH3), 28.0 
(CHCH2), 12.7 (CH2CH3) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 286.1438; found: 286.1440. 
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N,N′-Disuccinimidyl carbonate (0.47 g, 1.84 mmol, 1.60 eq.) and 32 (0.32 g, 1.15 mmol, 
1.00 eq.) were dissolved in 7 ml DMF. NEt3 (0.16 ml, 1.15 mmol, 1.00 eq.) was slowly 
added and the reaction was stirred for 20 h at room temperature. The solvent was removed 
under reduced pressure and the crude product was purified by column chromatography 
(DCM  DCM/acetone 19:1) to yield 0.23 g (0.54 mmol, 47%) of the title compound. 
1H-NMR (300 MHz, CDCl3): δ = 7.35 (d, 3JHH = 9.0 Hz, 1H, H-5), 6.62-6.58 (dd, 3JHH = 
9.0 Hz, 4JHH = 2.6 Hz, 1H, H-6), 6.53 (d, 4JHH = 2.6 Hz, 1H, H-8), 6.23 (d, 5JHH = 0.8 Hz, 1H, 
H-3), 6.05-6.00 (m, 1H, α-CH), 3.42 (q, 3JHH = 7.1 Hz, 4H, CH2CH3), 2.97-2.92 (m, 2H,  
β-CH2), 2.84 (s, 4H, CH2,succin.), 2.15 (t, 4JHH = 2.6 Hz, 1H, CCH), 1.21 (t, 3JHH = 7.1 Hz, 6H, 
CH2CH3) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 168.1 (COsuccin.), 161.3 (COcoum.), 156.7 (C-8'), 151.0 
(COcarbonate), 150.8 (C-7), 149.4 (C-4), 124.5 (C-5), 109.0 (C-6), 107.1 (C-3), 105.2 (C-4'), 
98.4 (C-8), 76.9 (CCH), 76.7 (α-CH), 73.3 (CCH) 45.0 (CH2CH3), 25.7 (CH2,succin.), 25.4 (β-
CH), 12.7 (CH2CH3) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 427.1500; found: 427.1487. 
  









Synthesis was carried out according to a protocol adapted from literature.[192] 
Boc-pIPhe-OH (3.00 g, 7.67 mmol, 1.0 eq.), B2pin2 (3.89 g, 15.3 mmol, 2.0 eq.), 
PdCl2(dppf) (0.56 g, 0.77 mmol, 0.1 eq.), dppf (0.43 g, 0.77 mmol, 0.1 eq.) and KOAc 
(3.01 g, 30.7 mmol, 4.0 eq.) were suspended in dry DMSO (50 mL). The reaction mixture 
was stirred overnight at 80 °C. The reaction mixture was allowed to cool to room 
temperature and then diluted with a saturated aqueous NaCl solution (250 mL). The 
aqueous phase was extracted with EtOAc (3 x 150 mL), the combined organic phases 
were dried over MgSO4 and the solvent was removed under reduced pressure. The crude 
product was purified by column chromatography (hexane/EtOAc 3:2  EtOAc + 0.1% 
HOAc) and lyophilized from dioxane/H2O to yield 1.91 g (4.89 mmol, 64%) of the title 
compound. 
1H-NMR (500 MHz, CDCl3): δ = 7.75 (d, 3JH,H = 7.9 Hz, 2H, CHar), 7.19 (d, 3JH,H = 7.9 Hz, 
2H, CHar), 4.95 (d, 3JH,H = 7.8 Hz, 1H, NH), 4.60 (m, 1H, α-CH), 3.21 (dd, 3JH,H = 14.0 Hz, 
2JH,H = 5.8 Hz, 1H, β-CH2), 3.10 (dd, 3JH,H = 14.0 Hz, 2JH,H = 5.8 Hz, 1H, β-CH2), 1.41 (s, 
9H, CH3,bpin), 1.33 (s, 12H, CH3,tBu) ppm. 
13C-NMR (125 MHz, CDCl3): δ = 175.6 (CO2H), 155.5 (COcarbamate), 139.3 (Car,bpin), 135.2 
(Car), 129.0 (Car), 84.0 (Cq,bpin), 80.4 (Cq,tBu), 54.3 (α-CH), 37.9 (β-CH2), 28.4 (CH3,tBu), 25.0 
(CH3,bpin) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 392.2243; found: 392.2225. 
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Synthesis was carried out according to a protocol adapted from literature.[192] 
51 (1.90 g, 4.86 mmol) was dissolved in dioxane (2 mL) and 4 M HCl in dioxane (6 mL) 
were added. The reaction mixture was stirred over night and purged with N2 gas for 20 min 
to remove the HCl gas. The residue was taken up in H2O (20 mL) and lyophilized to yield 
1.41 g (4.84 mmol, quant.) of the title compound. 
1H-NMR (500 MHz, CD3OD): δ = 7.75 (d, 3JH,H = 8.1 Hz, 2H, CHar), 7.32 (d, 3JH,H = 8.1 Hz, 
2H, CHar), 4.28 (dd, 3JH,H = 7.8 Hz, 5.5 Hz, 1H, α-CH), 3.34 (dd, 3JH,H = 5.5 Hz, 2JH,H = 
14.8 Hz, 1H, β-CH2), 3.19 (dd, 3JHH = 7.8 Hz, 2JHH = 14.8 Hz, 1H, β-CH2), 1.34 (s, 12H, 
CH3,bpin) ppm. 
13C-NMR (125 MHz, CD3OD): δ = 171.1 (CO2H), 138.9 (Car,bpin), 136.4 (Car), 129.9 (Car), 
85.2 (Cq,bpin), 54.9 (α-CH), 37.5 (β-C2), 25.2 (CH3,bpin) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 292.1728; found: 292.1726. 
 
  









Synthesis was carried out according to a protocol adapted from literature.[192] 
52 (0.30 g, 1.03 mmol, 1.0 eq.) was dissolved in a 10% aqueous Na2CO3 solution (25 mL) 
and cooled to 0 °C. Fmoc-Osu (0.42 g, 1.24 mmol, 1.2 eq.) was dissolved in dioxane 
(10 mL) and slowly added. The reaction mixture was allowed to warm to room temperature 
and stirred over night, after which time H2O/dioxane (1:1, 30 mL) was added and the 
reaction mixture was stirred for another 8 h. 1 M aqueous HCl (100 mL) was added and 
the aqueous phase was extracted with EtOAc (3 x 150 mL). The combined organic layers 
were washed with brine (100 mL), dried over MgSO4 and the solvent was removed under 
reduced pressure. The crude product was dissolved in MeOH (2 mL) and purified by 
preparative HPLC to yield 0.21 g (0.49 mmol, 48%) of the title compound. 
HPLC (column 1, gradient: 50-99% C in 30 min): tR =27.64 min. 
UHPLC (gradient: 50-90% C in 20 min): tR = 8.14 min. 
1H-NMR (300 MHz, (CD3)3SO): δ = 7.97 (sbr, 2H, B(OH)2), 7.88 (d, 3JH,H = 7.6 Hz, 2H, CHar), 
7.74-7.70 (m, 2H, CHar), 7.64 (t, 3JH,H = 7.6 Hz, 2H, CHar), 7.43-7.37 (m, 2H, CHar), 7.34-
7.20 (m, 4H, CHar), 4.22-4.15 (m, 4H, α-CHFmoc, β-CHFmoc, α-CH), 3.08 (dd, 2JHH = 13.5 Hz, 
3JHH = 4.2 Hz, 1H, β-CH2), 2.87 (dd, 2JHH = 13.5 Hz, 3JHH = 10.4 Hz, 1H, β-CH2) ppm. 
13C-NMR (75 MHz, (CD3)3SO): δ = 173.4 (CO2H), 156.0 (COcarbamate), 143.9 (Cq), 140.7 (Cq), 
139.9 (Cq) 134.1 (CHar), 128.2 (CHar), 127.7 (CHar), 127.1 (CHar), 125.3 (CHar), 120.1 
(CHar), 65.7 (β-CH2,Fmoc), 55.4 (α-CH), 46.6 (α-CH), 36.5 (β-CH2) ppm. 
HR-MS (ESI+): calcd. for [M+CH2-H]-: 444.1628; found: 444.1624 (corresponds to methyl 
ester of the boronic acid) 
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N-Boc-hydroxylamine (5.00 g, 37.6 mmol, 1.0 eq.) and KOH (2.11 g, 37.6 mmol, 1.0 eq.) 
were dissolved in MeOH (55 mL) and stirred at 60 °C for 30 min. Then, ethyl 4-
bromobutyrate (7.33 g, 5.28 mL, 37.6 mmol, 1.0 eq.) was added and the resulting mixture 
was stirred at 60 °C for 24 h. The solvent was removed under reduced pressure and H2O 
(100 mL) was added to the residue before extraction with EtOAc (3 x 75 mL). The 
combined organic phases were dried over Na2SO4, filtered and the solvent was removed 
under reduced pressure. The crude product was purified by column chromatography 
(hexane/ethyl acetate 9:1  4:1) to yield the intermediate as a colorless oil. The oil was 
dissolved in MeOH/H2O (1:1 v/v, 30 mL), KOH (1.30 g, 23.1 mmol, 1.5 eq.) was added and 
the solution was stirred for 3.5 h at room temperature. The reaction mixture was extracted 
with DCM (3 x 50 mL), the aqueous phase was acidified with 1 M HCl to pH 2 and extracted 
once more with DCM (3 x 50 mL). The combined organic layers were dried over Na2SO4, 
filtered and the solvent removed in vacuo to yield 3.46 g (15.8 mmol, 42%) of the title 
compound. 
1H-NMR (600 MHz, CDCl3): δ = 7.48 (sbr, 1H, NH), 3.89 (t, 3JH,H = 6.0 Hz, 2H, H-4), 2.51 (t, 
3JH,H = 7.1 Hz, 2H, H-2), 1.95 (quint, 3JH,H = 7.1 Hz, 6.0 Hz, 2H, H-3), 1.48 (s, 9H, 
CH3,tBu) ppm. 
13C-NMR (150 MHz, CDCl3): δ = 178.8 (CO2H.), 157.4 (COcarbamate), 82.1 (Cq,tBu), 75.6 (C-
4), 30.7 (C-2), 28.3 (CH3,tBu), 23.2 (C-3) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 220.1179; found: 220.1178.  
  









Glyoxylic acid (50wt. % in H2O, 6.52 g, 44.0 mmol, 1.0 eq.) was dissolved in EtOH (10 mL). 
A solution of 2-aminoethanethiol hydrochloride (5.00 g, 44.0 mmol, 1.0 eq) in 
EtOH/pyridine (5:2 (v/v), 28 mL) was added and the resulting mixture was stirred at room 
temperature for 2 h. The resulting precipitate was filtered, washed with EtOH and dried 
under reduced pressure to yield 4.48 g (33.6 mmol, 76%) of the title compound. 
1H-NMR (600 MHz, D2O): δ = 5.18 (s, 1H, H-2), 3.82-3.76 (m, 1H, CH), 3.71-3.64 (m, 1H, 
CH), 3.27-3.24 (m, 2H, CH2) ppm. 
13C-NMR (150 MHz, D2O): δ = 171.7 (CO2H.), 62.3 (C-2), 49.3 (CH2), 29.5 (CH2) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 134.0270; found: 134.0271. 
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90 (4.47 g, 33.6 mmol, 1.0 eq.) was dissolved in THF (100 mL) and the solution was cooled 
to 0 °C. Di-tert-butyl dicarbonate (18.3 g, 83.9 mmol, 2.5 eq.) was added, followed by a 
solution of NaHCO3 (16.6 g, 0.20 mol, 6.0 eq) in H2O (100 mL). The mixture was allowed 
to warm to room temperature and was stirred for 15 h. The organic solvent was removed 
under reduced pressure, H2O was added, and the aqueous phase was washed with Et2O 
(3 x 75 mL). The aqueous phase was acidified with conc. HCl to pH 2 and extracted with 
DCM (3 x 75 mL). The combined organic phases were dried over Na2SO4, filtered and the 
solvent was removed under reduced pressure to yield 7.56 g (32.4 mmol, 96%) of the title 
compound. 
1H-NMR (600 MHz, (CD3)2SO): δ = 12.99 (sbr, 1H, CO2H), 5.18 (s, 1H, H-2), 3.82-3.76 (m, 
1H, CH2), 3.71-3.64 (m, 1H, CH2), 3.27-3.24 (m, 2H, CH2) ppm. 
13C-NMR (150 MHz, (CD3)2SO): δ = 171.9 and 171.5 (CO2H.), 152.9 and 152.1 (COcarbamate), 
80.0 (Cq,tBu), 59.5 and 59.0 (CH), 49.6 and 49.3 (CH2), 30.2 and 29.1 (CH2), 27.8 
(CH3,tBu) ppm. 
HR-MS (ESI+): calcd. for [M+H]+: 234.0795; found: 234.0799. 
 
  









Ethyl 4-bromobutyrate (5.58 g, 4.29 mL, 30.0 mmol, 1.0 eq.) was dissolved in DMSO 
(25 mL) and sodium azide (2.92 g, 45.0 mmol, 1.5 eq.) was added. The resulting mixture 
was stirred at 55 °C for 20 h, before being allowed to cool to room temperature. H2O 
(150 mL) was added and the solution was extracted with Et2O (3 x 100 mL). The combined 
organic phases were washed with H2O (150 mL) and brine (150 mL), dried over Na2SO4, 
filtered and the solvent was removed under reduced pressure. The crude intermediate was 
treated with 1 M NaOH (35 mL), MeOH (5 mL) was added and the solution was stirred at 
room temperature for 3 h. The organic solvent was removed under reduced pressure, the 
solution was diluted with H2O (75 mL), acidified with conc. HCl to pH 1. The aqueous phase 
was extracted with Et2O (3 x 75 mL) and the combined organic layers were dried over 
Na2SO4, filtered and the solvent was removed in vacuo to yield 3.71 g (28.7 mmol, 96%) of 
the title compound.  
1H-NMR (600 MHz, CDCl3): δ = 10.53 (sbr, 1H, CO2H), 3.36 (t, 3JH,H = 6.7 Hz, 2H, H-2), 2.46 
(t, 3JH,H = 7.1 Hz, 2H, H-4), 1.90 (quint, 3JH,H = 7.1 Hz, 6.7 Hz, 2H, H-3) ppm. 
13C-NMR (150 MHz, CDCl3): δ = 179.3 (CO2H.),50.5 (C-2), 31.0 (C-4), 23.9 (C-3) ppm. 
HR-MS (ESI-): calcd. for [M-H]-: 128.0466; found: 128.0469. 
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N-Methylimidazole (0.82 g, 10.0 mmol, 3.3 eq.) was dissolved in MeCN (5 mL) and (3-
bromopropyl)trimethylammonium bromide (0.78 g, 3.00 mmol, 1.0 eq.) as a solution in 
MeOH (30 mL) was added. The reaction mixture was stirred at 65 °C for two days and then 
allowed to cool to room temperature. The solvent was removed under reduced pressure 
and the residue was taken up in MeOH (5 mL). Upon addition of Et2O (20 mL) a precipitate 
formed, which was filtered off and dried in vacuo to yield 0.25 g (0.72 mmol, 24%) of the 
title compound. 
1H-NMR (300 MHz, (CD3)2SO): δ = 9.30 (s, 1H, H-2imidazole), 7.87 (m, 1H, H-4imidazole), 7.77 
(m, 1H, H-5imidazole), 4.28 (t, 3JH,H = 6.9 Hz, 2H, NCH2), 3.88 (s, 3H, NCH3), 3.45-3.40 (m, 
2H, (CH3)3NCH2), 3.11 (s, 9H, N(CH3)3), 2.38-2.28 (m, 2H, CH2) ppm. 
13C-NMR (75 MHz, (CD3)2SO): δ = 136.9 (C-2imidazole), 123.7 (C-4imidazole), 122.2 (C-5imidazole), 
61.9 ((CH3)3NCH2), 52.4 (N(CH3)3), 45.9 (NCH2), 35.9 (NCH3), 23.1 (CH2) ppm. 
HR-MS (ESI+): calcd. for [M-Br+H]+: 262.0913; found: 262.0911, calcd. for [M-2Br+2H]2+: 
91.59; found: 91.59. 
  





6.4 Peptide synthesis and related reactions 
 




Coupling of the PNA sequence was performed following SOP 4 on a 25 μmol scale. 
5 μmol of the peptide were cleaved from the resin following SOP 6 and purified by semi-
preparative HPLC. 
HPLC (column 4, gradient: 5-35% B in 30 min): tR = 15.91 min. 
UHPLC (gradient: 1-40% B in 20 min): tR = 9.45 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1492.1484; found: 1492.1497, calcd. for [M+3H]3+: 
995.1014; found: 995.1027, calcd. for [M+4H]4+: 746.5779; found: 746.5792, calcd. for 
[M+5H]5+: 597.4637; found: 597.4645, calcd. for [M+6H]6+: 498.0543; found: 498.0548. 
 




Coupling of the PNA sequence was performed following SOP 4 on a 25 μmol scale. 
5 μmol of the peptide were cleaved from the resin following SOP 6 and purified by semi-
preparative HPLC. 
HPLC (column 4, gradient: 5-35% B in 30 min): tR = 15.66 min. 
UHPLC (gradient: 1-40% B in 20 min): tR = 9.62 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1080.4980; found: 1080.4986, calcd. for [M+4H]4+: 
810.6253; found: 810.6271, calcd. for [M+5H]5+: 648.7017; found: 648.7027, calcd. for 
[M+6H]6+: 540.7527; found: 540.7533, calcd. for [M+7H]7+: 463.6462; found: 463.6465. 
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Coupling of the PNA sequence was performed following SOP 4 on a 25 μmol scale. 
5 μmol of the peptide were cleaved from the resin following SOP 6 and purified by semi-
preparative HPLC. 
HPLC (column 4, gradient: 5-35% B in 30 min): tR = 16.62 min. 
UHPLC (gradient: 5-45% B in 20 min): tR = 6.25 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1492.1484; found: 1492.1494, calcd. for [M+3H]3+: 
995.1014; found: 995.1026, calcd. for [M+4H]4+: 746.5779; found: 746.5793, calcd. for 
[M+5H]5+: 597.4637; found: 597.4648, calcd. for [M+6H]6+: 498.0543; found: 498.0546. 
 




Coupling of the PNA sequence was performed following SOP 4 on a 25 μmol scale. 
5 μmol of the peptide were cleaved from the resin following SOP 6 and purified by semi-
preparative HPLC. 
HPLC (column 4, gradient: 5-35% B in 30 min): tR = 15.63 min. 
UHPLC (gradient: 5-45% B in 20 min): tR = 5.63 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1496.6542; found: 1496.6530, calcd. for [M+3H]3+: 
998.1052; found: 998.1060, calcd. for [M+4H]4+: 748.8307; found: 748.8311, calcd. for 
[M+5H]5+: 599.2660; found: 599.2653, calcd. for [M+6H]6+: 499.5563; found: 499.5550. 
  









Coupling of the PNA sequence was performed following SOP 4 on a 25 μmol scale. 
5 μmol of the peptide were cleaved from the resin following SOP 6 and purified by semi-
preparative HPLC. 
HPLC (column 4, gradient: 5-35% B in 30 min): tR = 15.88 min. 
UHPLC (gradient: 1-40% B in 20 min): tR = 9.67 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1160.1748; found: 1160.1753, calcd. for [M+4H]4+: 
870.3829; found: 870.3845, calcd. for [M+5H]5+: 696.5078; found: 696.5088, calcd. for 
[M+6H]6+: 580.5910; found: 580.5918, calcd. for [M+7H]7+: 497.7934; found: 497.7937. 
 




Coupling of the PNA sequence was performed following SOP 4 on a 25 μmol scale. 
5 μmol of the peptide were cleaved from the resin following SOP 6 and purified by semi-
preparative HPLC. 
HPLC (column 4, gradient: 5-35% B in 30 min): tR = 16.39 min. 
UHPLC (gradient: 1-40% B in 20 min): tR = 10.28 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1276.9007; found: 1276.9010, calcd. for [M+4H]4+: 
957.9273; found: 957.9285, calcd. for [M+5H]5+: 766.5433; found: 766.5442, calcd. for 
[M+6H]6+: 638.9540; found: 638.9546, calcd. for [M+7H]7+: 547.8187; found: 547.8196. 
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Alkyne functionalization of 1 (15 μmol) was performed according to SOP 8. An analytical 
sample of the peptide was cleaved from the resin following SOP 6 and analyzed by HR-
MS. 
UHPLC (gradient: 1-40% B in 20 min): tR = 8.87. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1518.1459; found: 1518.1452, calcd. for [M+3H]3+: 
1012.4330; found: 1012.4336, calcd. for [M+4H]4+: 759.5766; found: 759.5763, calcd. for 
[M+5H]5+: 607.8627; found: 607.8603. 
 




Alkyne functionalization of 4 (15 μmol) was performed according to SOP 8. An analytical 
sample of the peptide was cleaved from the resin following SOP 6 and analyzed by UHPLC 
and HR-MS. 
UHPLC (gradient: 1-40% B in 20 min): tR = 10.12. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1097.8297; found: 1097.8305, calcd. for [M+4H]4+: 
823.6241; found: 823. 6248. 
 
  









Alkyne functionalization of 5 (15 μmol) was performed according to SOP 8. An analytical 
sample of the peptide was cleaved from the resin following SOP 6 and analyzed by UHPLC 
and HR-MS. 
UHPLC (gradient: 1-40% B in 20 min): tR = 8.92. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1177.5065; found: 1177.5076, calcd. for [M+4H]4+: 
883.3817; found: 883.3826, calcd. for [M+5H]5+: 706.9068; found: 706.9066, calcd. for 
[M+6H]6+: 589.2569; found: 589.2642. 
 




Alkyne functionalization of 6 (15 μmol) was performed according to SOP 8. An analytical 
sample of the peptide was cleaved from the resin following SOP 6 and analyzed by UHPLC 
and HR-MS. 
UHPLC (gradient: 1-40% B in 20 min): tR = 10.85. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1294.2323; found: 1294.2320, calcd. for [M+4H]4+: 
970.9260; found: 970.9266, calcd. for [M+5H]5+: 776.9423; found: 776. 9413. 
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Synthesis of the peptide was performed according to SOP 1b at a 0.05 mmol scale on 
preloaded Wang resin (0.32 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 10-60% B in 20 min): tR = 11.26 min. 
HR-MS (ESI+): calcd. for [M+H]+: 1262.5908; found: 1262.5918, calcd. for [M+2H]2+: 
631.7990; found: 631.7998, calcd. for [M+3H]3+: 421.5351; found: 421.5355. 
 




Synthesis of the peptide was performed according to SOP 1b at a 0.05 mmol scale on 
preloaded Wang resin (0.32 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 10-60% B in 20 min): tR = 12.78 min. 
HR-MS (ESI+): calcd. for [M+H]+: 1319.6468; found: 1319.6483, calcd. for [M+2H]2+: 
660.3280; found: 660.3280, calcd. for [M+3H]3+: 440.5544; found: 440.5548. 
  









The photocleavable linker was attached to 128 according to SOP 7. The peptide was 
cleaved from the resin following SOP 6 and purified by preparative HPLC. 
HPLC (column 1, gradient: 20-80% B in 30 min): tR = 19.57 min. 
UHPLC (gradient: 20-70% B in 20 min): tR = 11.62 min. 
HR-MS (ESI+): calcd. for [M+H] +: 1556.6508; found: 1556.6498, calcd. for [M+2H]2+: 
778.8291; found: 778.8305. 
 




The photocleavable linker was attached to 129 according to SOP 7. The peptide was 
cleaved from the resin following SOP 6 and purified by preparative HPLC. 
HPLC (column 1, gradient: 30-80% B in 30 min): tR = 17.66 min. 
UHPLC (gradient: 20-70% B in 20 min): tR = 12.60 min. 
HR-MS (ESI+): calcd. for [M+H]+: 1613.7087; found: 1613.7078, calcd. for [M+2H]2+: 
807.3580; found: 807.3581. 
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The peptide was coupled on a preloaded Wang resin (0.31 mmol/g) at a 0.1 mmol scale. 
Attachment of the photocleavable linker was performed according to SOP 7. The peptide 
was cleaved from the resin following SOP 6 and purified by preparative HPLC. 
HPLC (column 1, gradient: 20-65% B in 30 min): tR = 20.82 min. 
UHPLC (gradient: 10-50% B in 20 min): tR = 13.63 min. 
HR-MS (ESI+): calcd. for [M+H] +: 1031.3557; found: 1031.3562, calcd. for [M+2H]2+: 
516.1815; found: 516.1808. 
 




The peptide was coupled on a preloaded Wang resin (0.31 mmol/g) at a 0.1 mmol scale. 
Attachment of the photocleavable linker was performed according to SOP 7. The peptide 
was cleaved from the resin following SOP 6 and purified by preparative HPLC. 
HPLC (column 1, gradient: 20-65% B in 30 min): tR = 21.62 min. 
UHPLC (gradient: 10-50% B in 20 min): tR = 13.30 min. 
HR-MS (ESI+): calcd. for [M+H] +: 1003.3244; found: 1003.3243, calcd. for [M+H+Na]2+: 
513.1568; found: 513.1564. 
  









Generation of the PNA/peptide hybrid was achieved by CuAAc reaction following SOP 9 
between 44 (10 μmol) and 130. The peptide was cleaved from the resin following SOP 6 
and purified by semi-preparative HPLC. 
HPLC (column 4, gradient: 5-55% B in 30 min): tR = 23.66 min. 
UHPLC (gradient: 0-60% B in 20 min): tR = 12.55. 
HR-MS (ESI+): calcd. for [M+4H]4+: 1148.7381; found: 1148.7320, calcd. for [M+5H]5+: 
919.1919; found: 919.1885, calcd. for [M+6H]6+: 766.1611; found: 766.1604.  
  
  6 EXPERIMENTAL SECTION 
129 
 




Generation of the PNA/peptide hybrid was achieved by CuAAc reaction following SOP 9 
between 18 (10 μmol) and 17. The peptide was cleaved from the resin following SOP 6 
and purified by semi-preparative HPLC. 
HPLC (column 4, gradient: 1-60% B in 30 min): tR = 20.70 min. 
UHPLC (gradient: 0-60% B in 20 min): tR = 9.76. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1441.6137; found: 1441.6124, calcd. for [M+4H]4+: 
1081.4621; found: 1081.4622, calcd. for [M+5H]5+: 865.3712; found: 865.3710, calcd. for 
[M+6H]6+: 721.3105; found: 721.3100, calcd. for [M+7H]7+: 618.4100; found: 618.4087.  
 
  









Generation of the PNA/peptide hybrid was achieved by CuAAc reaction following SOP 9 
between 133 (10 μmol) and 131. The peptide was cleaved from the resin following SOP 6 
and purified by semi-preparative HPLC. 
HPLC (column 4, gradient: 10-55% B in 30 min): tR = 21.98 min. 
UHPLC (gradient: 0-60% B in 20 min): tR = 12.56. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1715.7426; found: 1715.7397, calcd. for [M+4H]4+: 
1287.0588; found: 1287.0598, calcd. for [M+5H]5+: 1029.8485; found: 1029.8487, calcd. for 
[M+6H]6+: 858.3749; found: 858.3750, calcd. for [M+7H]7+: 735.8938; found: 735.8936, 
calcd. for [M+8H]8+: 644.0330; found: 644.0343.  
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Generation of the PNA/peptide hybrid was achieved by CuAAc reaction following SOP 9 
between 134 (10 μmol) and 132. The peptide was cleaved from the resin following SOP 6 
and purified by semi-preparative HPLC. 
HPLC (column 4, gradient: 5-55% B in 30 min): tR = 20.54 min. 
UHPLC (gradient: 0-60% B in 20 min): tR = 9.94. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1628.3375; found: 1628.3385, calcd. for [M+4H]4+: 
1221.5050; found: 1221.5071, calcd. for [M+5H]5+: 977.4054; found: 977.4069, calcd. for 
[M+6H]6+: 814.6724; found: 814.6731, calcd. for [M+7H]7+: 698.4345; found: 698.4339.  
 
  









19 was dissolved in degassed buffer (1 mL; 10 mM NaH2PO4, 100 mM NaCl, 20 mM TCEP, 
5% MPAA (v/v)). The pH was adjusted to 3 and the solution was stirred at 37 °C for 48 h. 
The reaction mixture was lyophilized and the crude product was purified by semi-
preparative HPLC. 
HPLC (column 4, gradient: 10-55% B in 30 min): tR = 12.76 min. 
UHPLC (gradient: 0-60% B in 20 min): tR = 8.96. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1431.9442; found: 1431.9424, calcd. for [M+4H]4+: 
1074.2099; found: 1074.2100, calcd. for [M+5H]5+: 859.5694; found: 859.5694, calcd. for 
[M+6H]6+: 716.4757; found: 716.4753, calcd. for [M+7H]7+: 614.2659; found: 614.2650. 
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135 was dissolved in degassed buffer (1 mL; 10 mM NaH2PO4, 100 mM NaCl, 20 mM 
TCEP, 5% MPAA (v/v)). The pH was adjusted to 3 and the solution was stirred at 37 °C for 
48 h. The reaction mixture was lyophilized and the crude product was purified by analytical 
HPLC. 
HPLC (column 3, gradient: 10-55% B in 30 min): tR = 12.88 min. 
UHPLC (gradient: 0-60% B in 20 min): tR = 9.20. 
HR-MS (ESI+): calcd. for [M+4H]4+: 1214.2528; found: 1214.2547, calcd. for [M+5H]5+: 
971.6037; found: 971.6052, calcd. for [M+6H]6+: 809.8376; found: 809.8382, calcd. for 
[M+7H]7+: 694.2904; found: 694.2914. 
  









The peptide was synthesized according to SOP 2 at a 0.1 mmol scale on preloaded Wang 
resin (0.71 mmol/g). The peptide was cleaved from resin following SOP 6 and purified by 
preparative HPLC. 
HPLC (column 1, gradient: 15-60% B in 30 min): tR =16.55 min. 
UHPLC (gradient: 5-90% B in 20 min): tR = 7.45 min. 
HR-MS (ESI+): calcd. for [M+H] +: 590.1470; found: 590.1471. 
 




26 (10 mg, 17 μmol, 1.0 eq.), phenylboronic acid (5.17 mg, 42.4 μmol, 2.5 eq.) and K2CO3 
(16.42 mg, 0.12 mmol, 7.0 eq.) were dissolved in 1 mL deionized H2O. 
Na2[ADHP]2∙Pd(OAc)2 (5 mol%) was added and the reaction mixture was agitated at 37 °C. 
Aliquots of 10 μL were taken after 0, 12, 24 and 36 h and diluted with 40 μL deionized H2O 
for analysis by UPLC. The reaction was stopped by freezing the sample in liquid nitrogen, 
followed by lyophilization. The crude reaction mixture was purified by semi-preparative 
HPLC. 
HPLC (column 2, gradient: 20-60% B in 30 min): tR =22.19 min. 
UHPLC (gradient: 15-60% B in 20 min): tR = 10.23 min. 
HR-MS (ESI+): calcd. for [M+H] +: 540.2817; found: 540.2818. 
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The peptide was synthesized following SOP 11 at a 0.15 mmol scale on preloaded Wang 
resin (0.71 mmol/g). The peptide was cleaved from resin following SOP 6 and purified by 
preparative HPLC. 
HPLC (column 1, gradient: 10-45% B in 30 min): tR =11.51 min. 
UHPLC (gradient: 5-90% B in 20 min): tR = 5.99 min. 
HR-MS (ESI+): calcd. for [M+H] +: 508.2577; found: 508.2562. 
 




26 (10 mg, 17 μmol, 1.0 eq.), 28 (8.62 mg, 17 μmol, 1.0 eq.) and K2CO3 (16.42 mg, 
0.12 mmol, 7.0 eq.) were dissolved in 1 mL deionized H2O. Na2[ADHP]2∙Pd(OAc)2 
(5 mol%) was added and the reaction mixture was agitated at 37 °C. Aliquots of 10 μL were 
taken after 0, 12, 24, 36, 46, 60 and 84 h and diluted with 40 μL deionized H2O for analysis 
by UPLC. The reaction was stopped by freezing the sample in liquid nitrogen, followed by 
lyophilization. The crude reaction mixture was purified by semi-preparative HPLC. 
HPLC (column 2, gradient: 10-60% B in 30 min): tR =16.47 min. 
UHPLC (gradient: 5-90% B in 20 min): tR = 7.91 min. 
HR-MS (ESI+): calcd. for [M+H] +: 925.4778; found: 925.4775. 
  









Synthesis of the peptide was performed according to SOP 2 at a 0.05 mmol scale on 
preloaded Wang resin (0.31 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 5-90% B in 20 min): tR = 11.60 min. 
HR-MS (ESI+): calcd. for [M+H] +: 422.2398; found: 422.2398. 
 




The photocleavable linker was attached to resin-bound 34 (25 μmol) according to SOP 7. 
An analytical sample of the peptide was cleaved from the resin following SOP 6 and 
analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 10-60% B in 20 min): tR = 13.65 min. 
HR-MS (ESI+): calcd. for [M+H] +: 716.2998; found: 716.2992. 
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Generation of the peptide/cargo hybrid was achieved by CuAAc reaction following SOP 9 
between resin-bound 35 (25 μmol) and 5-hexynoic acid. The peptide was cleaved from the 
resin following SOP 6 and purified by preparative HPLC. 
HPLC (column 1, gradient: 10-60% B in 30 min): tR = 20.96 min. 
UHPLC (gradient: 10-60% B in 20 min): tR = 11.14. 
HR-MS (ESI+): calcd. for [M+H] +: 828.3523; found: 828.3514. 
  









36 was dissolved in water (1 mL) to give a final concentration of 50 μM. The solution was 
irradiated at 347 nm (1000 W, lamp setup a) for 10 min. Samples were taken every 60 s 
and analyzed by UHPLC. Afterwards, the solution was frozen in liquid nitrogen, lyophilized 
and analyzed by HR-MS. 
UHPLC (gradient: 5-90% B in 20 min): tR = 4.75 min. 
HR-MS (ESI+): calcd. for [M+H] +: 422.2398; found: 422.2393. 
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The photocleavable linker was attached to resin-bound 34 (25 μmol) according to SOP 7. 
An analytical sample of the peptide was cleaved from the resin following SOP 6 and 
analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 10-60% B in 20 min): tR = 15.35 min. 
HR-MS (ESI+): calcd. for [M+H] +: 733.3556; found: 733.3541. 
 




Generation of the peptide/cargo hybrid was achieved by CuAAc reaction following SOP 9 
between resin-bound 37 (25 μmol) and 4-azidobutyric acid. The peptide was cleaved from 
the resin following SOP 6 and purified by preparative HPLC. 
HPLC (column 1, gradient: 10-60% B in 30 min): tR = 26.11 min. 
UHPLC (gradient: 5-90% B in 20 min): tR = 11.23. 
HR-MS (ESI+): calcd. for [M+H] +: 862.4094; found: 862.4093. 
  









38 was dissolved in water (1 mL) to give a final concentration of 50 μM. The solution was 
irradiated at 405 nm (100 mW, lamp setup b) for 5 min. Samples were taken every 30 s 
and analyzed by UHPLC. Afterwards, the solution was frozen in liquid nitrogen, lyophilized 
and analyzed by HR-MS. 
UHPLC (gradient: 5-90% B in 20 min): tR = 4.76 min. 
HR-MS (ESI+): calcd. for [M+H] +: 422.2398; found: 422.2393. 
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The peptide was synthesized on preloaded Wang resin (0.33 mmol/g) at a 0.1 mmol scale 
according to SOP 2. The photocleavable linker was attached according to SOP 7. The 
peptide was cleaved from the resin following SOP 6 and purified by semi-preparative 
HPLC. 
HPLC (column 2, gradient: 45-80% B in 30 min): tR = 16.20. 
UHPLC (gradient 5-90% B in 20 min): tR = 14.18 min. 
HR-MS (ESI+): calcd. for [M+H] +: 1028.2758; found: 1028.2751. 
 




The peptide was synthesized following SOP 11 at a 25 μmol scale on preloaded Wang 
resin (0.33 mmol/g), with the last amino acid being Trt-Gly-OH. After Miyaura borylation, 
the N-terminal protecting group was removed by treatment with DCM/H2O/TFA (98.8:1:0.2 
(v/v), 0.5 mL/10 μmol) for 3 x 10 min, followed by washing five times each with DMF, 5% 
DIPEA in DCM, DCM and DMF (1 mL/10 μmol). The photocleavable linker was attached 
to BK051 according to SOP 7, the peptide was cleaved from resin following SOP 6 and 
purified by preparative HPLC. 
HPLC (column 1, gradient: 45-75% B in 30 min): tR =9.13 min. 
UHPLC (gradient: 5-90% B in 20 min): tR = 12.16 min. 
HR-MS (ESI+): calcd. for [M+H] +: 946.3868; found: 946.3854. 
 
  









The PNA was synthesized following SOP 5. The dried resin (5 μmol) was suspended in 
DMF and chain elongation proceeded following SOP 2b. An analytical sample of the 
peptide was cleaved from the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 5-60% B in 20 min): tR = 10.28 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1249.8302; found: 1249.8315, calcd. for [M+4H]4+: 
937.3735; found: 937.3748, calcd. for [M+5H]5+: 750.3010; found: 750.3025. 
 




The PNA was synthesized following SOP 5. The dried resin (5 μmol) was suspended in 
DMF and chain elongation proceeded following SOP 2b. The peptide was cleaved from 
resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 4, gradient 5-60% B in 30 min): tR = 13.71 min. 
UHPLC (gradient: 5-60% B in 20 min): tR = 7.94 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1222.1995; found: 1222.1988, calcd. for [M+4H]4+: 
916.9014; found: 916.9007, calcd. for [M+5H]5+: 733.7226; found: 733.7210, calcd. for 
[M+CH2+3H]3+: 1226.8741; found: 1226.8713, calcd. for [M+CH2+4H]4+: 920.4035; found: 
920.4050, calcd. for [M+CH2+5H]5+: 736.5257; found: 736.5249, calcd. for [M+CH2+6H]6+: 
613.9393; found: 613.9381. 
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The PNA was synthesized following SOP 5. The dried resin (5 μmol) was suspended in 
DMF and chain elongation proceeded following SOP 2b. The peptide was cleaved from 
resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 4, gradient 5-60% B in 30 min): tR = 19.21 min. 
UHPLC (gradient: 5-60% B in 20 min): tR = 10.13 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1335.2269; found: 1335.2253, calcd. for [M+4H]4+: 
1001.6720; found: 1001.6714, calcd. for [M+5H]5+: 801.5390; found: 801.5384, calcd. for 
[M+6H]6+: 668.1171; found: 668.1163, calcd. for [M+7H]7+: 572.8157; found: 572.8144. 
 




The PNA was synthesized following SOP 4, cleaved from resin following SOP 6 and 
purified by semi-preparative HPLC. 
HPLC (column 4, gradient 5-60% B in 30 min): tR = 12.95 min. 
UHPLC (gradient: 1-40% B in 20 min): tR = 9.15 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1094.5016; found: 1094.5056, calcd. for [M+4H]4+: 
821.1280; found: 821.1308, calcd. for [M+5H]5+: 657.1038; found: 657.1059, calcd. for 
[M+6H]6+: 547.7544; found: 547.7561. 
  









The peptide was synthesized following SOP 1 at a 0.1 mmol scale on H-Rink amide 
ChemMatrix® resin (0.41 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 20-80% B in 15 min): tR = 8.67 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1199.1587; found: 1199.1574, calcd. for [M+3H]3+: 
799.7749; found: 799.7747. 
 




The peptide was synthesized following SOP 1 at a 0.1 mmol scale on H-Rink amide 
ChemMatrix® resin (0.41 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 20-80% B in 15 min): tR = 5.53 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 798.5114; found: 798.5107, calcd. for [M+4H]4+: 
599.1353; found: 599.1362, calcd. for [M+5H]5+: 479.5097; found: 479.5090. 
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10 μmol of resin-bound 56 were elongated following SOP 2c. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 20-80% B in 30 min): tR = 21.40 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 10.47 min. 
HR-MS (ESI+): calcd. for [M+H+Na]2+: 1291.1746; found: 1291.1728, calcd. for 
[M+2H+Na]3+: 861.1188; found: 861.1192. 
 




10 μmol of resin-bound 57 were elongated following SOP 2c. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 20-80% B in 30 min): tR = 14.66 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 7.54 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 903.5032; found: 903.5029, calcd. for [M+4H]4+: 
677.8793; found: 677.8805, calcd. for [M+5H]5+: 542.5049; found; 542.5042. 
  









10 μmol of resin-bound 56 were elongated following SOP 2c. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 20-80% B in 30 min): tR = 20.78 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 10.53 min. 
HR-MS (ESI+): calcd. for [M+CH2+2H]2+: 1308.6944; found: 1308.6933, calcd. for 
[M+CH2+2H+Na]3+: 880.1260; found: 880.1258. 
 




10 μmol of resin-bound 57 were elongated following SOP 2c. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 20-80% B in 30 min): tR = 14.89 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 7.37 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1340.7356; found: 1340.7339, calcd. for [M+3H]3+: 
894.1595; found: 894.1596, calcd. for [M+4H]4+: 670.8714; found: 670.8728, calcd. for 
[M+5H]5+: 536.8986; found; 539.8988. 
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10 μmol of resin-bound 57 were elongated following SOP 2c. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 20-80% B in 30 min): tR = 15.04 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 7.53 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1369.2463; found: 1369.2454, calcd. for [M+3H]3+: 
913.1666; found: 913.1665, calcd. for [M+4H]4+: 685.1268; found: 685.1282, calcd. for 
[M+5H]5+: 548.3029; found; 548.3028. 
 




10 μmol of resin-bound 57 were elongated following SOP 2c. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 20-80% B in 30 min): tR = 15.07 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 7.62 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1376.2541; found: 1376.2527, calcd. for [M+3H]3+: 
917.8385; found: 917.8391, calcd. for [M+4H]4+: 688.6307; found: 688.6321, calcd. for 
[M+5H]5+: 551.1060; found; 551.1063, calcd. for [M+6H]6+: 459.4229; found: 459.4223. 
 
  









10 μmol of resin-bound 57 were elongated following SOP 2c. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 20-80% B in 30 min): tR = 13.96 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 7.43 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1383.2620; found: 1383.2605, calcd. for [M+3H]3+: 
922.5104; found: 922.5107, calcd. for [M+4H]4+: 692.1346; found: 692.1354, calcd. for 
[M+5H]5+: 553.9091; found; 553.9086. 
 




The peptide was synthesized following SOP 1 at a 0.1 mmol scale on H-Rink amide 
ChemMatrix® resin (0.41 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 20-60% B in 15 min): tR = 6.31 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1228.1306; found: 1228.1300, calcd. for [M+3H]3+: 
819.0895; found: 819.0879. 
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The peptide was synthesized following SOP 1 at a 0.1 mmol scale on H-Rink amide 
ChemMatrix® resin (0.41 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 10-50% B in 15 min): tR = 7.73 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1225.2877; found: 1225.2861, calcd. for [M+3H]3+: 
817.1942; found: 817.1947, calcd. for [M+4H]4+: 613.1475; found: 613.1488, calcd. for 
[M+5H]5+: 490.7195; found: 490.7192. 
 




15 μmol of resin-bound 70 were elongated following SOP 2c. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 10-70% B in 30 min): tR = 21.27 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 7.47 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1302.1477; found: 1302.1478, calcd. for [M+3H]3+: 
868.4343; found: 868.4330. 
 
  









5 μmol of resin-bound 71 were elongated following SOP 2c. The peptide was cleaved from 
resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 20-80% B in 30 min): tR = 12.05 min. 
UHPLC (gradient: 10-50% B in 15 min): tR = 10.36 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 922.1861; found: 922.1855, calcd. for [M+4H]4+: 
691.8914; found: 691.8922, calcd. for [M+5H]5+: 533.7146; found: 533.7158, calcd. for 
[M+6H]6+: 461.5967; found: 461.5961. 
 




3.3 μmol of resin-bound 71 were elongated following SOP 2c. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 20-80% B in 30 min): tR = 11.32 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 5.27 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1446.8048; found: 1446.8038, calcd. for [M+3H]3+: 
964.8723; found: 964.8721, calcd. for [M+4H]4+: 723.9061; found: 723.9069, calcd. for 
[M+5H]5+: 579.3263; found: 579.3281, calcd. for [M+6H]6+: 482.9398, found: 482.9409. 
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3.3 μmol of resin-bound 71 were elongated following SOP 2c. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 20-60% B in 30 min): tR = 10.54 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 4.93 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1007.5706; found: 1007.5698, calcd. for [M+4H]4+: 
755.9298; found: 755.9299, calcd. for [M+5H]5+: 604.9453; found: 604.9462, calcd. for 
[M+6H]6+: 504.2890; found: 540.2902, calcd. for [M+7H]7+: 432.3916; found: 432.3919. 
 




3.3 μmol of resin-bound 71 were elongated following SOP 2c. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient 20-80% B in 30 min): tR = 11.64 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 5.50 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1045.2653; found: 1045.2646, calcd. for [M+4H]4+: 
784.2008; found: 784.2012, calcd. for [M+5H]5+: 627.5621; found: 627.5630, calcd. for 
[M+6H]6+: 523.1363; found: 523.1373, calcd. for [M+7H]7+: 448.5464; found: 448.5470. 
 
  









5 μmol of resin-bound 70 were elongated with 86 following SOP 2c. The peptide was 
cleaved from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, 5-65% B in 30 min): tR = 21.13 min. 
UHPLC (gradient: 5-65% B in 15 min): tR = 10.45 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1278.6545; found: 1278.6558, calcd. for [M+3H]3+: 
852.7721; found: 852.7722. 
 




5 μmol of resin-bound 71 were elongated with 91 following SOP 2c. The peptide was 
cleaved from resin following SOP 6 and an analytical sample was analyzed by UHPLC and 
HR-MS. 
UHPLC (gradient: 5-65% B in 15 min): tR = 7.63 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1282.7923; found: 1282.7919, calcd. for [M+3H]3+: 
855.5306; found: 855.5304, calcd. for [M+4H]4+: 641.8998; found: 641.9005, calcd. for 
[M+5H]5+: 513.7213; found: 513.7216, calcd. for [M+6H]6+: 428.2690; found: 428.2691. 
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Introduction of the peptide aldehyde was performed according to SOP 13b on 5 μmol of 
resin-bound 70. The crude peptide was purified by semi-preparative HPLC. 
HPLC (column 5, 10-70% B in 30 min): tR = 21.73 min. 
UHPLC (gradient: 5-65% B in 15 min): tR = 11.13 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1256.8116; found: 1256.1220, calcd. for [M+3H]3+: 
837.7528; found: 837.7505. 
 




5 μmol of resin-bound 71 were elongated with 86 following SOP 2c. The peptide was 
cleaved from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, 5-65% B in 30 min): tR = 14.39 min. 
UHPLC (gradient: 5-65% B in 15 min): tR = 7.46 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1275.8116; found: 1275.8107, calcd. for [M+3H]3+: 
850.8768; found: 850.8761, calcd. for [M+4H]4+: 638.4094; found: 638.4096, calcd. for 
[M+5H]5+: 510.9290; found: 510.9294, calcd. for [M+6H]6+: 425.9420; found: 452.9414. 
 
  









94 and 95 were ligated following SOP 14 with a strand concentration of 100 μM and a total 
volume of 400 μL. After 7 h, the reaction solution was frozen in liquid nitrogen and 
lyophilized.  
UHPLC (gradient: 1-90% B in 15 min): tR = 8.69 min. 
HR-MS (ESI+): calcd. for [M-H2O+5H]5+: 1005.7721; found: 1005.7732, calcd. for  
[M-H2O+6H]6+: 838.3113; found: 838.3120. 
 




The peptide was synthesized following SOP 1 at a 0.1 mmol scale on H-Rink amide 
ChemMatrix® resin (0.41 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 10-50% B in 15 min): tR = 11.64 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1256.6414; found: 1256.6422, calcd. for [M+3H]3+: 
838.0967; found: 838.0970. 
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The peptide was synthesized following SOP 1 at a 0.1 mmol scale on H-Rink amide 
ChemMatrix® resin (0.41 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 10-50% B in 15 min): tR = 6.84 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1242.2905; found: 1242.2883, calcd. for [M+3H]3+: 
828.5294; found: 828.5290, calcd. for [M+4H]4+: 621.6489; found: 621.6490, calcd. for 
[M+5H]5+: 497.5205; found: 497.5205. 
 




The peptide was synthesized following SOP 1 at a 0.1 mmol scale on H-Rink amide 
ChemMatrix® resin (0.41 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 20-80% B in 15 min): tR = 9.85 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1473.7335; found: 1473.7343, calcd. for [M+3H]3+: 
982.8247; found: 982.8260. 
 
  









The peptide was synthesized following SOP 1 at a 0.1 mmol scale on H-Rink amide 
ChemMatrix® resin (0.41 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 20-80% B in 15 min): tR = 5.90 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1459.3826; found: 1459.3797, calcd. for [M+3H]3+: 
973.2575; found: 973.2564, calcd. for [M+4H]4+: 730.1949; found: 730.1952, calcd. for 
[M+5H]5+: 584.3574; found: 584.3577, calcd. for [M+6H]6+: 487.1324; calcd: 487.1315. 
 




The peptide was synthesized following SOP 1 at a 0.1 mmol scale on H-Rink amide 
ChemMatrix® resin (0.41 mmol/g). An analytical sample of the peptide was cleaved from 
the resin following SOP 6 and analyzed by UHPLC and HR-MS. 
UHPLC (gradient: 5-65% B in 15 min): tR = 8.81 min. 
HR-MS (ESI+): calcd. for [M+H]+: 1585.8122; found: 1585.8092, calcd. for [M+2H]2+: 
793.4097; found: 793.4093, calcd. for [M+3H]3+ 529.2756; found: 529.2758. 
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The peptide aldehyde was introduced to 5 μmol of 97 following SOP 13 and purified by 
semi-preparative HPLC. 
HPLC (column 5, gradient: 10-70% B in 30 min): tR = 18.89 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 7.00 min. 
HR-MS (ESI+): calcd. for [M+H2O+2H]2+: 1293.6416; found: 1293.6409, calcd. for 
[M+H2O+3H]3+ 862.7635; found: 862.7632. 
 




10 μmol of resin-bound 100 were elongated with 86 following SOP 2c. The alloc protecting 
group of the C-terminal lysine was removed following SOP 15 and FITC was introduced 
following SOP 2c using only DIPEA as an additive. The peptide was cleaved from resin 
following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient: 5-65% B in 30 min): tR = 18.58 min. 
UHPLC (gradient: 5-65% B in 15 min): tR = 8.26 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1034.5889; found: 1034.5880, calcd. for [M+4H]4+: 
776.1935; found: 776.1937, calcd. for [M+5H]5+ 621.1562; found: 621.1564, calcd. for 
[M+6H]6+: 517.7981; found: 517.7979. 
  









102 and 103 were ligated following SOP 14 with a strand concentration of 100 μM and a 
total volume of 1000 μL. Aliquots of the reaction mixture were taken after 5, 20, 45 and 
60 min, and after 2, 4, 6, 10 and 20 h and analyzed by UHPLC. After 20 h, the reaction 
solution was frozen in liquid nitrogen, lyophilized and subsequently purified by analytical 
HPLC. 
HPLC (column 6, gradient: 20-80% B in 30 min): tR = 14.55 min. 
UHPLC (gradient: 5-95% B in 15 min): tR = 7.93 min. 
HR-MS (ESI+): calcd. for [M+4H]4+: 1413.7563; found: 1413.7578, calcd. for [M+5H]5+: 
1131.2065; found: 1131.2078, calcd. for [M+6H]6+ 942.8400; found: 942.8416, calcd. for 
[M+7H]7+: 808.2925; found: 808.2936, calcd. for [M+8H]8+: 707.3818; found: 707.3827. 
 




The peptide aldehyde was introduced to 5 μmol of 101 following SOP 13 and purified by 
semi-preparative HPLC. 
HPLC (column 5, gradient: 5-65% B in 30 min): tR = 21.44 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 5.88 min. 
HR-MS (ESI+): calcd. for [M+H] +: 1641.8020; found: 1641.7999, calcd. for [M+2H]2+: 
821.4046; found: 821.4033, calcd. for [M+3H]3+ 547.9388; found: 547.9380. 
calcd. for [M+H2O+H]+: 1659.88125; found: 1659.8103, calcd. for [M+H2O+2H]2+: 
830.4099; found: 830.4105, calcd. for [M+3H]3+ 553.9424; found: 553.9416. 
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103 and 105 were ligated following SOP 14 with a strand concentration of 100 μM and a 
total volume of 1000 μL. Aliquots of the reaction mixture were taken after 5, 20, 45 and 
60 min, and after 2, 4 and 8 h and analyzed by UHPLC. After 8 h, the reaction solution was 
frozen in liquid nitrogen, lyophilized and subsequently purified by analytical HPLC. 
HPLC (column 6, gradient: 20-80% B in 30 min): tR = 15.44 min. 
UHPLC (gradient: 5-95% B in 15 min): tR = 7.60 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1575.8512; found: 1575.8518, calcd. for [M+4H]4+: 
1182.1402; found: 1182.1412, calcd. for [M+5H]5+: 945.9136; found: 945.9143, calcd. for 
[M+6H]6+ 788.4292; found: 788.4297, calcd. for [M+7H]7+: 675.9404; found: 675.9409, 
calcd. for [M+8H]8+: 591.5737; found: 591.5741, calcd. for [M+9H]9+: 525.9552; found: 
525.9551. 
  









5 μmol of resin-bound 97 were elongated with chloroacetic acid following SOP 2c. The 
peptide was cleaved from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, 10-70% B in 30 min): tR = 21.90 min. 
UHPLC (gradient: 5-65% B in 15 min): tR = 11.40 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1294.6272; found: 1294.6266, calcd. for [M+3H]3+: 
863.4205; found: 863.4203, calcd. for [M+3H+Na]4+: 653.3127; found: 653.3114. 
 




5 μmol of resin-bound 100 were elongated with Fmoc-Cys(Trt)-OH following SOP 2c. After 
removal of the temporary protecting group and subsequent acetylation of the  
N-terminus, the alloc protecting group of the C-terminal lysine was removed following 
SOP 15 and FITC was introduced following SOP 2c using only DIPEA as an additive. The 
peptide was cleaved from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient: 5-65% B in 30 min): tR = 20.70 min. 
UHPLC (gradient: 10-70% B in 15 min): tR = 7.35 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1049.2462; found: 1049.2460, calcd. for [M+4H]4+: 
787.1865; found: 787.1882, calcd. for [M+5H]5+: 629.9507; found: 629.9494, calcd. for 
[M+6H]6+: 525.1268; found: 525.1279. 
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5 μmol of resin-bound 101 were elongated with chloroacetic acid following SOP 2c. The 
peptide was cleaved from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, 20-80% B in 30 min): tR = 17.29 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 6.98 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 831.3955; found: 831.3953, calcd. for [M+3H]3+: 
554.5994; found: 554.5993. 
 




Ligation was performed between 108 and 110 according to SOP with a strand 
concentration of 100 μM and a total volume of 1000 μL. Aliquots of the reaction mixture 
were taken after 5, 40 and 75 min, and after 3.25, 4, 6 and 8 h and analyzed by UHPLC. 
After 8 h, the reaction solution was frozen in liquid nitrogen, lyophilized and subsequently 
purified by analytical HPLC. 
HPLC (column 6, gradient: 10-70% B in 30 min): tR = 20.31 min. 
UHPLC (gradient: 5-95% B in 15 min): tR = 7.21 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1591.1804; found: 1591.1790, calcd. for [M+4H]4+: 
1193.6371; found: 1193.6362, calcd. for [M+5H]5+: 955.1111; found: 955.1103, calcd. for 
[M+6H]6+: 796.0938; found: 796.0931, calcd. for [M+7H]7+: 682.5100; found: 682.5094, 
calcd. for [M+8H]8+: 597.3222; found: 597.3217. 
 
  









5 μmol of resin-bound 99 were elongated with 113 following SOP 2c. The alloc protecting 
group of the C-terminal lysine was removed following SOP 15 and FITC was introduced 
following SOP 2c using only DIPEA as an additive. The peptide was cleaved from resin 
following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient: 20-80% B in 30 min): tR = 19.08 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 8.43 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1570.7284; found: 1570.7285, calcd. for [M+3H]3+: 
1047.4880; found: 1047.4889, calcd. for [M+4H]4+: 785.8678; found: 785.8676. 
 




5 μmol of resin-bound 98 were elongated with DBCO acid following SOP 2c. Deviating from 
the SOP, 3.0 eq. of the building block were used in the coupling step and activation was 
performed with 3.0 eq. HOAt, 2.9 eq. HATU and 6.0 eq. DIPEA. The peptide was cleaved 
from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient: 10-70% B in 30 min): tR = 18.74 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 6.00 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1399.8535; found: 1399.8524, calcd. for [M+3H]3+: 
933.5714; found: 933.5702, calcd. for [M+4H]4+: 700.4304; found: 700.4307, calcd. for 
[M+5H]5+ 560.5457; found: 560.5466, calcd. for [M+6H]6+: 467.2893; found: 467.2897. 
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5 μmol of resin-bound 98 were elongated with Fmoc-NH-PEG(3)-OH and DBCO acid 
following SOP 2c. Coupling of the latter was performed deviating from the SOP, 3.0 eq. of 
the building block were used in the coupling step and activation was performed with 3.0 eq. 
HOAt, 2.9 eq. HATU and 6.0 eq. DIPEA. The peptide was cleaved from resin following SOP 
6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient: 10-70% B in 30 min): tR = 21.19 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 5.98 min. 
HR-MS (ESI+): calcd. for [M+3H]3+: 1001.2767; found: 1001.2788, calcd. for [M+4H]4+: 
751.2093; found: 751.2077, calcd. for [M+5H]5+ 601.1689; found: 601.1686, calcd. for 
[M+6H]6+: 501.1420; found: 501.1426. 
 




5 μmol of resin-bound 101 were elongated with DBCO acid following SOP 2c. Deviating 
from the SOP, 3.0 eq. of the building block were used in the coupling step and activation 
was performed with 3.0 eq. HOAt, 2.9 eq. HATU and 6.0 eq. DIPEA. The peptide was 
cleaved from resin following SOP 6 and purified by semi-preparative HPLC. 
HPLC (column 5, gradient: 20-80% B in 30 min): tR = 24.52 min. 
UHPLC (gradient: 20-80% B in 15 min): tR = 10.24 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 951.4742; found: 951.4740, calcd. for [M+3H]3+: 
634.6519; found: 634.6516. 
 
  









5 μmol of resin-bound 98 were elongated with Fmoc-D-β-Phe(2-NO2)-OH and 86 following 
SOP 2c. The peptide was cleaved from resin following SOP 6 and purified by semi-
preparative HPLC. 
HPLC (column 5, gradient: 5-65% B in 30 min): tR = 17.37 min. 
UHPLC (gradient: 5-65% B in 15 min): tR = 7.69 min. 
HR-MS (ESI+): calcd. for [M+2H]2+: 1388.8410; found: 1388.8374, calcd. for [M+3H]3+: 
926.2298; found: 926.2275, calcd. for [M+4H]4+: 694.9242; found: 694.9238, calcd. for 
[M+5H]5+: 556.1408; found: 556.1417, calcd. for [M+6H]6+: 463.6185; found: 463.6184. 
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102 and 121 were ligated following SOP 14 with a strand concentration of 100 μM and a 
total volume of 1000 μL. Aliquots of the reaction mixture were taken after 0, 4 and 17.5 h 
and analyzed by UHPLC. After 18 h, the reaction solution was frozen in liquid nitrogen, 
lyophilized and subsequently purified by analytical HPLC. 
HPLC (column 6, gradient: 10-70% B in 30 min): tR = 19.31 min. 
UHPLC (gradient: 5-95% B in 15 min): tR = 7.86 min. 
HR-MS (ESI+): calcd. for [M+4H]4+: 1332.4870; found: 1332.4850, calcd. for [M+5H]5+: 
1066.1911; found: 1066.1896, calcd. for [M+6H]6+ 888.6604; found: 888.6589, calcd. for 
[M+7H]7+: 761.8528; found: 761.8518. 
  









122 was dissolved in phosphate buffer (250 μL, 50 mM, pH 7.0) to give a concentration of 
25 μM. The solution was irradiated at 600 W (lamp setup a) for 40 min without using the 
cut-on filter. The reaction solution was analyzed by LC-MS. 
LC-MS (gradient: 10-100% B in 15 min): tR (123) = 5.05 – 5.35 min, tR (124) = 12.02 – 
12.25 min. 
HR-MS (ESI+): calcd. for [123+3H]3+: 886.8719; found: 886.8717, calcd. for [123+4H]4+: 
665.4057; found: 665.4054, calcd. for [123+5H]5+: 532.5260; found: 532.5257. 
HR-MS (ESI+): calcd. for [124+2H]2+: 1334.6683; found: 1334.6681, calcd. for [124+3H]3+: 
890.1147; found: 890.1146. 
 






Figure A 1: 1H-NMR spectrum of Fmoc-Glu(SEAoff)-OH (11). 
 
 







Figure A 3: 1H-NMR spectrum of 1-(7-diethylamino-coumarinyl)-3-butynyl N-succinimidyl carbonate (33). 
 
 
Figure A 4: 1H-NMR spectrum of Fmoc-Bpa (53). 
 
 




Figure A 5: 1H-NMR spectrum of 1-(3-(trimethylammonium)propyl)-3-methylimidazole bromide (127). 
 
 









Figure A 7: 1H-NMR spectrum of N-Boc-thiazolidine-2-carboxylic acid (91). 
 
 
Figure A 8: 1H-NMR spectrum of 4-azidobutyric acid (113). 
 




Figure A 9: Deconvoluted ESI (+) mass spectrum of 20. 
 
 
Figure A 10: Deconvoluted ESI (+) mass spectrum of 21. 
 
 








Figure A 12: Deconvoluted ESI (+) mass spectrum of 23. 
 
 
Figure A 13: High-resolution ESI (+) mass spectrum of 29. 
 
 
Figure A 14: High-resolution ESI (+) mass spectrum of 36. 





Figure A 15: High-resolution ESI (+) mass spectrum of 38. 
 
 
Figure A 16: Deconvoluted ESI (+) mass spectrum of 48. 
 








Figure A 18: Deconvoluted ESI (+) mass spectrum of 75. 
 
 
Figure A 19: Deconvoluted ESI (+) mass spectrum of 76. 
 
 
Figure A 20: Deconvoluted ESI (+) mass spectrum of 96 (-H2O). 





Figure A 21: Deconvoluted ESI (+) mass spectrum of 104. 
 
 
Figure A 22: Deconvoluted ESI (+) mass spectrum of 106. 
 








Figure A 24: Deconvoluted ESI (+) mass spectrum of 114. 
 
 
Figure A 25: Deconvoluted ESI (+) mass spectrum of 115. 
 
 
Figure A 26: Deconvoluted ESI (+) mass spectrum of 122. 
 




Figure A 27: HPLC Chromatogram of the photolysis of 122. 
 
 
Figure A 28: High-resolution ESI (+) mass spectrum of 123. 
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8 List of abbreviations 
 
Standard α-amino acids were abbreviated using one- or three-letter code. Single 
nucleobases were abbreviated using capital letters (A, C, G, T), while PNA sequences were 
written in lower case. 
 
A absorbance 
AA amino acid 
abs absorption 
Ac acetylated 
Ac2O acetic anhydride 
ADC antibody-drug conjugate 
ADHP 2-amino-4,6-dihydroxy-pyrimidine 
aeg N-2-(aminoethyl)-glycine 







BD syringe syringe supplied by Becton Dickinson 
Bhoc benzhydryloxycarbonyl 
Boc tert-butyloxycarbonyl 
Boc2O di-tert-butyl dicarbonate 
BODIPY dipyrrometheneboron difluoride 
bp base pair 
Bpa 4-borono-L-phenylalanine 
br broad 
BSA bovine serum albumin 
BSL Bacillus lentus 
BTTES 3-(4-((bis((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)amino) 
methyl)-1H-1,2,3-triazol-1-yl)propane-1-sulfonic acid 
bZip basic leucine zipper 
C. elegans Caenorhabditis elegans 
calcd. calculated 






CD circular dichroism 
CHO chinese hamster ovary 
ClAc chloroacetic acid 
CM cross-metathesis 
CM coumarin 
CPMV cowpea mosaic virus 
cPNA complementary peptide nucleic acid 
CuAAC Cu(I)-catalyzed azide-alkyne cycloaddition 
Cy cyanine (dye) 
Da Dalton 














DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DOTA 1,4,7,10-tetracyclododecane-1,4,7,10-tetraacetic acid 
dppf 1,1'-bis(diphenylphosphino)ferrocene 
ds double stranded 
DSC N,N'-disuccinimidyl carbonate 
DTPS DNA-templated protein conjugation 
DTS DNA-templated organic synthesis 
E. coli Escherichia coli 
EEDQ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline 
EGFR epidermal growth factor 





ESI electrospray ionization 
Et2O diethyl ether 
Et3N triethylamine 
EtOAc ethyl acetate 
EtOH ethanol 
ex excitation 
Fab fragment antigen binding 
FBS fetal bovine serum 
FG functional group 
FITC fluorescein isothiocyanate 
FLAG protein tag with sequence DYKDDDDK 
Fmoc fluorenylmethoxycarbonyl 
FRET Förster resonance energy transfer 
FA formic acid 
GABA γ-aminobutyric acid 
GFP green fluorescent protein 
GLP glucagon-like peptide 
GPCR G protein-coupled receptor 
GST glutathione S-transferase 
GYG glycosyltransferase enzyme 
H hyperchromicity 
HAT H-atom transfer 
HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] 
pyridinium 3-oxide hexafluorophosphate 
HBSS Hanks' balanced salt solution 
hDR human dopamine receptor 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Her human epirdermal growth factor receptor 
HFIP 1,1,1,3,3,3-hexafluoro-propan-2-ol 
HIV human immunodeficiency virus 
hNPFFR human neuropeptide FF receptor 
HOAc acetic acid 
HOAt 1-hydroxy-7-azabenzotriazole 
HOBt hydroxybenzotriazole  





hpf hours post fertilization 
HPG homopropargylglycine 
HPLC high-performance liquid chromatography 
HR-MS high-resolution mass spectrometry 
hyd hydration 
hYR human neuropeptide Y receptor 
IEDDA inverse electron demand Diels-Alder 
IgG immunoglobulin G 
iPrOH propan-2-ol 
J coupling constant 
k rate constant 
Ka acid dissociation constant 
KAHA ketoacid-hydroxylamine 
KAT potassium acyltrifluoroborate 
KD dissociation constant 
LC-MS liquid chromatography-mass spectrometry 
m/z mass-to-charge ratio 
mAb monoclonal antibody 
MBP maltose binding protein 
mCPBA meta-chloroperoxybenzoic acid 





mol% mole percentage 
MPA 3-mercaptopropanoic acid 
MPAA 4-mercaptophenylacetic acid 
MRW mean residue molecular weight 
MS mass spectrometry 
NaAsc sodium ascorbate 
NB nitrobenzyl 
NCL native chemical ligation 
NHC N-heterocyclic carbene 
NHS N-hydroxysuccinimide 
NIR near-infrared 




NMR nuclear magnetic resonance 
OAc acetate 
OMe methoxy 
OmpC outer membrane porin protein C 
ON oligonucleotide 
OSu O-succinimide 
Oxyma ethyl cyanohydroxyiminoacetate 
PBS phosphate buffered saline 
PCL photocleavable linker 
PEG polyethylene glycol 
Ph phenyl 
PIC p-iodobenzyl cysteine 
pIPhe p-iodophenylalanine 
PNA peptide nucleic acid 
pNPY porcine neuropeptide Y 
POI protein of interest 
PPG photocleavable protecting group 
PPh3 triphenylphosphine 
PS polystyrene 
PTM post-translational modification 
PyBOP benzotriazol-1-yloxytripyrrolidinophosphonium 
hexafluorophosphate 
PyBrOP bromo-tris-pyrrolidino-phosphonium hexafluorophosphate 
q quaternary 
QTOF quadrupole time-of-flight 
Ras rat sarcoma 
RNA ribonucleic acid 
rt room temperature 
SCO strained cyclooctyne 
SEA bis(2-sulfanylethyl)amido 
SN nucleophilic substitution 
SNARE soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor 
SOP standard operating procedure 
SPAAC strain-promoted azide-alkyne cycloaddition 





SPECT single photon emission computed tomography 




tBuOH tert-butyl alcohol 
TCEP tris(2-carboxyethyl)phosphine 
TCO trans-cyclooctene 
TEV tobacco etch virus 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
THPTA tris(3-hydroxypropyltriazoylmethyl)amine 
Thz 2-carboxy thiazolidine 
TIS triisopropylsilane 
TLC thin-layer chromatography 
Tm melting temperature 
TMG 1,1,3,3-tetramethylguanidine  
TMP-tag trimethoprim-based tag 
TOF time-of-flight 
TPPTS trisodium 3,3',3-phosphinetriyltribenzenesulfonate 





UAA unnatural amino acid 
Ub ubiquitin 
UHPLC ultra high performance liquid chromatography 
UV ultraviolet 
v/v volume-to-volume ratio 
vis visible 
WT wild type 
wt.% percentage by weight 
YFP yellow fluorescent protein 
δ chemical shift 
ε extinction coefficient 
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𝛩 molar elipticity 
λ wavelength 













[1] G. L. Rosano, E. A. Ceccarelli, Front. Microbiol. 2014, 5, 172. 
[2] C. T. Walsh, S. Garneau-Tsodikova, G. J. Gatto, Angew. Chem. Int. Ed. 2005, 
44, 7342–7372. 
[3] C. J. Noren, S. J. Anthony-Cahill, M. C. Griffith, P. G. Schultz, Science 1989, 
244, 182–188. 
[4] L. Wang, A. Brock, B. Herberich, P. G. Schultz, Science 2001, 292, 498–500. 
[5] T. S. Young, P. G. Schultz, J. Biol. Chem. 2010, 285, 11039–11044. 
[6] C. P. Toseland, J. Chem. Biol. 2013, 6, 85–95. 
[7] M. Chalfie, Y. Tu, G. Euskirchen, W. W. Ward, D. C. Prasher, Science 1994, 
263, 802–805. 
[8] C. Freidel, S. Kaloyanova, K. Peneva, Amino acids 2016, 48, 1357–1372. 
[9] C. D. Spicer, B. G. Davis, Nat. Commun. 2014, 5, 4740. 
[10] N. Krall, F. P. Da Cruz, O. Boutureira, G. J. L. Bernardes, Nat. Chem. 2016, 8, 
103–113. 
[11] J. A. Shadish, C. A. DeForest, Matter 2020, 2, 50–77. 
[12] S. Middel, C. H. Panse, S. Nawratil, U. Diederichsen, ChemBioChem 2017, 18, 
2328–2332. 
[13] H. P. Hemantha, S. N. Bavikar, Y. Herman-Bachinsky, N. Haj-Yahya, S. 
Bondalapati, A. Ciechanover, A. Brik, J. Am. Chem. Soc. 2014, 136, 2665–
2673. 
[14] S. Massa, C. Xavier, J. de Vos, V. Caveliers, T. Lahoutte, S. Muyldermans, N. 
Devoogdt, Bioconjugate Chem. 2014, 25, 979–988. 
[15] J. Morales-Sanfrutos, J. Lopez-Jaramillo, M. Ortega-Muñoz, A. Megia-
Fernandez, F. Perez-Balderas, F. Hernandez-Mateo, F. Santoyo-Gonzalez, 
Org. Biomol. Chem. 2010, 8, 667–675. 
[16] X. Chen, K. Muthoosamy, A. Pfisterer, B. Neumann, T. Weil, Bioconjugate 
Chem. 2012, 23, 500–508. 
[17] P. Rosa-Neto, B. Wängler, L. Iovkova, G. Boening, A. Reader, K. Jurkschat, E. 
Schirrmacher, ChemBioChem 2009, 10, 1321–1324. 
[18] A. Moosmann, J. Blath, R. Lindner, E. Müller, H. Böttinger, Bioconjugate Chem. 






[19] P. E. Dawson, T. W. Muir, I. Clark-Lewis, S. B. Kent, Science 1994, 266, 776–
779. 
[20] P. E. Dawson, S. B. Kent, Annu. Rev. Biochem. 2000, 69, 923–960. 
[21] V. Y. Torbeev, S. B. H. Kent, Angew. Chem. Int. Ed. 2007, 46, 1667–1670. 
[22] M. N. Fodje, S. Al-Karadaghi, Protein Eng., Des. Sel. 2002, 15, 353–358. 
[23] L. Z. Yan, P. E. Dawson, J. Am. Chem. Soc. 2001, 123, 526–533. 
[24] P. E. Dawson, Isr. J. Chem. 2011, 51, 862–867. 
[25] L. R. Malins, R. J. Payne, Aust. J. Chem. 2015, 68, 521. 
[26] D. S. Y. Yeo, R. Srinivasan, M. Uttamchandani, G. Y. J. Chen, Q. Zhu, S. Q. 
Yao, Chem. Commun. 2003, 2870–2871. 
[27] J. A. Prescher, C. R. Bertozzi, Nat. Chem. Biol. 2005, 1, 13–21. 
[28] V. Mäde, S. Els-Heindl, A. G. Beck-Sickinger, Beilstein J. Org. Chem. 2014, 10, 
1197–1212. 
[29] H. C. Hang, C. Yu, D. L. Kato, C. R. Bertozzi, Proc. Natl. Acad. Sci. USA 2003, 
100, 14846–14851. 
[30] E. M. Sletten, C. R. Bertozzi, Acc. Chem. Res. 2011, 44, 666–676. 
[31] L. Wang, Z. Zhang, A. Brock, P. G. Schultz, Proc. Natl. Acad. Sci. USA 2003, 
100, 56–61. 
[32] A. Dirksen, T. M. Hackeng, P. E. Dawson, Angew. Chem. Int. Ed. 2006, 45, 
7581–7584. 
[33] J. Y. Axup, K. M. Bajjuri, M. Ritland, B. M. Hutchins, C. H. Kim, S. A. Kazane, 
R. Halder, J. S. Forsyth, A. F. Santidrian, K. Stafin et al., Proc. Natl. Acad. Sci. 
USA 2012, 109, 16101–16106. 
[34] A. Dirksen, P. E. Dawson, Bioconjugate Chem. 2008, 19, 2543–2548. 
[35] Y. Zeng, T. N. C. Ramya, A. Dirksen, P. E. Dawson, J. C. Paulson, Nat. Methods 
2009, 6, 207–209. 
[36] Q. A. E. Guthrie, C. Proulx, Org. Lett. 2018, 20, 2564–2567. 
[37] Q. A. E. Guthrie, H. A. Young, C. Proulx, Chem. Sci. 2019, 10, 9506–9512. 
[38] Y. Xu, L. Xu, Y. Xia, C.-J. Guan, Q.-X. Guo, Y. Fu, C. Wang, Y.-M. Li, Chem. 
Commun. 2015, 51, 13189–13192. 
[39] Y. Xu, Y. Wang, P. Liu, G.-C. Chu, H. Xu, Y.-M. Li, J. Wang, J. Shi, Org. Biomol. 
Chem. 2018, 16, 7036–7040. 
[40] J. W. Bode, R. M. Fox, K. D. Baucom, Angew. Chem. Int. Ed. 2006, 45, 1248–
1252. 
  9 BIBLIOGRAPHY 
189 
 
[41] I. Pusterla, J. W. Bode, Angew. Chem. Int. Ed. 2012, 51, 513–516. 
[42] T. G. Wucherpfennig, F. Rohrbacher, V. R. Pattabiraman, J. W. Bode, Angew. 
Chem. Int. Ed. 2014, 53, 12244–12247. 
[43] L. Ju, J. W. Bode, Org. Biomol. Chem. 2009, 7, 2259–2264. 
[44] V. R. Pattabiraman, A. O. Ogunkoya, J. W. Bode, Angew. Chem. Int. Ed. 2012, 
51, 5114–5118. 
[45] A. O. Ogunkoya, V. R. Pattabiraman, J. W. Bode, Angew. Chem. Int. Ed. 2012, 
51, 9693–9697. 
[46] S. Baldauf, A. O. Ogunkoya, G. N. Boross, J. W. Bode, J. Org. Chem. 2020, 85, 
1352–1364. 
[47] S. Baldauf, D. Schauenburg, J. W. Bode, Angew. Chem. Int. Ed. 2019, 58, 
12599–12603. 
[48] I. Pusterla, J. W. Bode, Nat. Chem. 2015, 7, 668–672. 
[49] F. Rohrbacher, G. Deniau, A. Luther, J. W. Bode, Chem. Sci. 2015, 6, 4889–
4896. 
[50] F. Rohrbacher, A. Zwicky, J. W. Bode, Chem. Sci. 2017, 8, 4051–4055. 
[51] C. He, S. S. Kulkarni, F. Thuaud, J. W. Bode, Angew. Chem. Int. Ed. 2015, 54, 
12996–13001. 
[52] A. M. Dumas, G. A. Molander, J. W. Bode, Angew. Chem. Int. Ed. 2012, 51, 
5683–5686. 
[53] H. Noda, G. Erős, J. W. Bode, J. Am. Chem. Soc. 2014, 136, 5611–5614. 
[54] F. Saito, H. Noda, J. W. Bode, ACS Chem. Biol. 2015, 10, 1026–1033. 
[55] S. M. Liu, D. Mazunin, V. R. Pattabiraman, J. W. Bode, Org. Lett. 2016, 18, 
5336–5339. 
[56] D. Mazunin, J. W. Bode, Helv. Chim. Acta 2017, 100, e1600311. 
[57] H. Staudinger, J. Meyer, Helv. Chim. Acta 1919, 2, 635–646. 
[58] E. Saxon, C. R. Bertozzi, Science 2000, 287, 2007–2010. 
[59] P. V. Chang, J. A. Prescher, M. J. Hangauer, C. R. Bertozzi, J. Am. Chem. Soc. 
2007, 129, 8400–8401. 
[60] M. J. Hangauer, C. R. Bertozzi, Angew. Chem. Int. Ed. 2008, 47, 2394–2397. 
[61] A. S. Cohen, E. A. Dubikovskaya, J. S. Rush, C. R. Bertozzi, J. Am. Chem. Soc. 
2010, 132, 8563–8565. 
[62] B. L. Nilsson, L. L. Kiessling, R. T. Raines, Org. Lett. 2000, 2, 1939–1941. 






[64] B. L. Nilsson, R. J. Hondal, M. B. Soellner, R. T. Raines, J. Am. Chem. Soc. 
2003, 125, 5268–5269. 
[65] N. J. Agard, J. M. Baskin, J. A. Prescher, A. Lo, C. R. Bertozzi, ACS Chem. 
Biol. 2006, 1, 644–648. 
[66] R. Serwa, I. Wilkening, G. Del Signore, M. Mühlberg, I. Claussnitzer, C. Weise, 
M. Gerrits, C. P. R. Hackenberger, Angew. Chem. Int. Ed. 2009, 48, 8234–
8239. 
[67] V. Böhrsch, R. Serwa, P. Majkut, E. Krause, C. P. R. Hackenberger, Chem. 
Commun. 2010, 46, 3176–3178. 
[68] R. Serwa, P. Majkut, B. Horstmann, J.-M. Swiecicki, M. Gerrits, E. Krause, C. 
P. R. Hackenberger, Chem. Sci. 2010, 1, 596. 
[69] R. Huisgen, Angew. Chem. Int. Ed. 1963, 2, 565–598. 
[70] V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, Angew. Chem. Int. 
Ed. 2002, 41, 2596–2599. 
[71] C. W. Tornøe, C. Christensen, M. Meldal, J. Org. Chem. 2002, 67, 3057–3064. 
[72] H. C. Kolb, M. G. Finn, K. B. Sharpless, Angew. Chem. Int. Ed. 2001, 40, 2004–
2021. 
[73] V. O. Rodionov, S. I. Presolski, D. D. Díaz, V. V. Fokin, M. G. Finn, J. Am. 
Chem. Soc. 2007, 129, 12705–12712. 
[74] T. R. Chan, R. Hilgraf, K. B. Sharpless, V. V. Fokin, Org. Lett. 2004, 6, 2853–
2855. 
[75] D. Soriano Del Amo, W. Wang, H. Jiang, C. Besanceney, A. C. Yan, M. Levy, 
Y. Liu, F. L. Marlow, P. Wu, J. Am. Chem. Soc. 2010, 132, 16893–16899. 
[76] Q. Wang, T. R. Chan, R. Hilgraf, V. V. Fokin, K. B. Sharpless, M. G. Finn, J. 
Am. Chem. Soc. 2003, 125, 3192–3193. 
[77] P. V. Chang, X. Chen, C. Smyrniotis, A. Xenakis, T. Hu, C. R. Bertozzi, P. Wu, 
Angew. Chem. Int. Ed. 2009, 48, 4030–4033. 
[78] C. Uttamapinant, A. Tangpeerachaikul, S. Grecian, S. Clarke, U. Singh, P. 
Slade, K. R. Gee, A. Y. Ting, Angew. Chem. Int. Ed. 2012, 51, 5852–5856. 
[79] C. Kofoed, S. Riesenberg, J. Šmolíková, M. Meldal, S. Schoffelen, Bioconjugate 
Chem. 2019, 30, 1169–1174. 
[80] N. J. Agard, J. A. Prescher, C. R. Bertozzi, J. Am. Chem. Soc. 2004, 126, 
15046–15047. 
  9 BIBLIOGRAPHY 
191 
 
[81] J. M. Baskin, J. A. Prescher, S. T. Laughlin, N. J. Agard, P. V. Chang, I. A. 
Miller, A. Lo, J. A. Codelli, C. R. Bertozzi, Proc. Natl. Acad. Sci. USA 2007, 104, 
16793–16797. 
[82] X. Ning, J. Guo, M. A. Wolfert, G.-J. Boons, Angew. Chem. Int. Ed. 2008, 47, 
2253–2255. 
[83] J. C. Jewett, E. M. Sletten, C. R. Bertozzi, J. Am. Chem. Soc. 2010, 132, 3688–
3690. 
[84] S. T. Laughlin, J. M. Baskin, S. L. Amacher, C. R. Bertozzi, Science 2008, 320, 
664–667. 
[85] S. T. Laughlin, C. R. Bertozzi, ACS Chem. Biol. 2009, 4, 1068–1072. 
[86] J. M. Baskin, K. W. Dehnert, S. T. Laughlin, S. L. Amacher, C. R. Bertozzi, Proc. 
Natl. Acad. Sci. USA 2010, 107, 10360–10365. 
[87] P. V. Chang, J. A. Prescher, E. M. Sletten, J. M. Baskin, I. A. Miller, N. J. Agard, 
A. Lo, C. R. Bertozzi, Proc. Natl. Acad. Sci. USA 2010, 107, 1821–1826. 
[88] F. Thalhammer, U. Wallfahrer, J. Sauer, Tetrahedron Lett. 1990, 31, 6851–
6854. 
[89] M. L. Blackman, M. Royzen, J. M. Fox, J. Am. Chem. Soc. 2008, 130, 13518–
13519. 
[90] N. K. Devaraj, R. Weissleder, S. A. Hilderbrand, Bioconjugate Chem. 2008, 19, 
2297–2299. 
[91] D. Hunter, D. G. Neilson, T. J. R. Weakley, J. Chem. Soc., Perkin Trans. 1 1985, 
2709. 
[92] R. Rossin, P. R. Verkerk, S. M. van den Bosch, R. C. M. Vulders, I. Verel, J. 
Lub, M. S. Robillard, Angew. Chem. Int. Ed. 2010, 49, 3375–3378. 
[93] J. Yang, J. Šečkutė, C. M. Cole, N. K. Devaraj, Angew. Chem. Int. Ed. 2012, 
51, 7476–7479. 
[94] D. M. Patterson, L. A. Nazarova, B. Xie, D. N. Kamber, J. A. Prescher, J. Am. 
Chem. Soc. 2012, 134, 18638–18643. 
[95] I. Nikić, T. Plass, O. Schraidt, J. Szymański, J. A. G. Briggs, C. Schultz, E. A. 
Lemke, Angew. Chem. Int. Ed. 2014, 53, 2245–2249. 
[96] P. G. Isenegger, B. G. Davis, J. Am. Chem. Soc. 2019, 141, 8005–8013. 
[97] K. Kodama, S. Fukuzawa, H. Nakayama, T. Kigawa, K. Sakamoto, T. Yabuki, 







[98] J. M. Chalker, C. S. C. Wood, B. G. Davis, J. Am. Chem. Soc. 2009, 131, 
16346–16347. 
[99] C. D. Spicer, T. Triemer, B. G. Davis, J. Am. Chem. Soc. 2012, 134, 800–803. 
[100] C. D. Spicer, B. G. Davis, Chem. Commun. 2013, 49, 2747–2749. 
[101] M. K. Bilyard, H. J. Bailey, L. Raich, M. A. Gafitescu, T. Machida, J. Iglésias-
Fernández, S. S. Lee, C. D. Spicer, C. Rovira, W. W. Yue et al., Nature 2018, 
563, 235–240. 
[102] N. Li, R. K. V. Lim, S. Edwardraja, Q. Lin, J. Am. Chem. Soc. 2011, 133, 15316–
15319. 
[103] A. Dumas, C. D. Spicer, Z. Gao, T. Takehana, Y. A. Lin, T. Yasukohchi, B. G. 
Davis, Angew. Chem. Int. Ed. 2013, 52, 3916–3921. 
[104] J. Li, S. Lin, J. Wang, S. Jia, M. Yang, Z. Hao, X. Zhang, P. R. Chen, J. Am. 
Chem. Soc. 2013, 135, 7330–7338. 
[105] X. Ma, H. Wang, W. Chen, J. Org. Chem. 2014, 79, 8652–8658. 
[106] B. Bhushan, Y. A. Lin, M. Bak, A. Phanumartwiwath, N. Yang, M. K. Bilyard, T. 
Tanaka, K. L. Hudson, L. Lercher, M. Stegmann et al., J. Am. Chem. Soc. 2018, 
140, 14599–14603. 
[107] J. L. Seitchik, J. C. Peeler, M. T. Taylor, M. L. Blackman, T. W. Rhoads, R. B. 
Cooley, C. Refakis, J. M. Fox, R. A. Mehl, J. Am. Chem. Soc. 2012, 134, 2898–
2901. 
[108] X. Chen, Y.-W. Wu, Org. Biomol. Chem. 2016, 14, 5417–5439. 
[109] X. Li, D. R. Liu, Angew. Chem. Int. Ed. 2004, 43, 4848–4870. 
[110] A. A. Brakhage, Microbiol. Mol. Biol. Rev. 1998, 62, 547–585. 
[111] A. Keppler, S. Gendreizig, T. Gronemeyer, H. Pick, H. Vogel, K. Johnsson, Nat. 
Biotechnol. 2003, 21, 86–89. 
[112] A. Gautier, A. Juillerat, C. Heinis, I. R. Corrêa, M. Kindermann, F. Beaufils, K. 
Johnsson, Cell Chem. Biol. 2008, 15, 128–136. 
[113] G. V. Los, L. P. Encell, M. G. McDougall, D. D. Hartzell, N. Karassina, C. 
Zimprich, M. G. Wood, R. Learish, R. F. Ohana, M. Urh et al., ACS Chem. Biol. 
2008, 3, 373–382. 
[114] C. Jing, V. W. Cornish, ACS Chem. Biol. 2013, 8, 1704–1712. 
[115] M. W. Popp, J. M. Antos, G. M. Grotenbreg, E. Spooner, H. L. Ploegh, Nat. 
Chem. Biol. 2007, 3, 707–708. 
[116] I. Chen, M. Howarth, W. Lin, A. Y. Ting, Nat. Methods 2005, 2, 99–104. 
  9 BIBLIOGRAPHY 
193 
 
[117] C.-W. Lin, A. Y. Ting, J. Am. Chem. Soc. 2006, 128, 4542–4543. 
[118] Z. J. Gartner, D. R. Liu, J. Am. Chem. Soc. 2001, 123, 6961–6963. 
[119] Z. J. Gartner, M. W. Kanan, D. R. Liu, Angew. Chem. Int. Ed. 2002, 41, 1796–
1800. 
[120] Z. J. Gartner, R. Grubina, C. T. Calderone, D. R. Liu, Angew. Chem. Int. Ed. 
2003, 42, 1370–1375. 
[121] C. T. Calderone, J. W. Puckett, Z. J. Gartner, D. R. Liu, Angew. Chem. Int. Ed. 
2002, 41, 4104–4108. 
[122] S. Ficht, A. Mattes, O. Seitz, J. Am. Chem. Soc. 2004, 126, 9970–9981. 
[123] S. Ficht, C. Dose, O. Seitz, ChemBioChem 2005, 6, 2098–2103. 
[124] G. Hayashi, M. Yanase, Y. Nakatsuka, A. Okamoto, Biomacromolecules 2019, 
20, 1246–1253. 
[125] C. B. Rosen, A. L. B. Kodal, J. S. Nielsen, D. H. Schaffert, C. Scavenius, A. H. 
Okholm, N. V. Voigt, J. J. Enghild, J. Kjems, T. Tørring et al., Nat. Chem. 2014, 
6, 804–809. 
[126] A. L. B. Kodal, C. B. Rosen, M. R. Mortensen, T. Tørring, K. V. Gothelf, 
ChemBioChem 2016, 17, 1338–1342. 
[127] T. Liu, P. Song, A. Märcher, J. Kjems, C. Yang, K. V. Gothelf, ChemBioChem 
2019, 20, 1014–1018. 
[128] T. B. Nielsen, R. P. Thomsen, M. R. Mortensen, J. Kjems, P. F. Nielsen, T. E. 
Nielsen, A. L. B. Kodal, E. Cló, K. V. Gothelf, Angew. Chem. Int. Ed. 2019, 58, 
9068–9072. 
[129] D. H. Lee, J. R. Granja, J. A. Martinez, K. Severin, M. R. Ghadiri, Nature 1996, 
382, 525–528. 
[130] A. J. Kennan, V. Haridas, K. Severin, D. H. Lee, M. R. Ghadiri, J. Am. Chem. 
Soc. 2001, 123, 1797–1803. 
[131] W. Nomura, T. Mino, T. Narumi, N. Ohashi, A. Masuda, C. Hashimoto, H. 
Tsutsumi, H. Tamamura, Pept. Sci. 2010, 94, 843–852. 
[132] D. N. Woolfson in Subcellular Biochemistry, Vol. 82 (Eds.: D. A. D. Parry, J. M. 
Squire), Springer International Publishing, Basel, 2017, 35–61. 
[133] J. R. Litowski, R. S. Hodges, J. Biol. Chem. 2002, 277, 37272–37279. 
[134] U. Reinhardt, J. Lotze, S. Zernia, K. Mörl, A. G. Beck-Sickinger, O. Seitz, 






[135] U. Reinhardt, J. Lotze, K. Mörl, A. G. Beck-Sickinger, O. Seitz, Bioconjugate 
Chem. 2015, 26, 2106–2117. 
[136] J. Lotze, P. Wolf, U. Reinhardt, O. Seitz, K. Mörl, A. G. Beck-Sickinger, ACS 
Chem. Biol. 2018, 13, 618–627. 
[137] J. Wang, Y. Yu, J. Xia, Bioconjugate Chem. 2014, 25, 178–187. 
[138] Y. Yano, N. Furukawa, S. Ono, Y. Takeda, K. Matsuzaki, Pept. Sci. 2016, 106, 
484–490. 
[139] B. V. Popp, Z. T. Ball, J. Am. Chem. Soc. 2010, 132, 6660–6662. 
[140] B. V. Popp, Z. T. Ball, Chem. Sci. 2011, 2, 690. 
[141] Z. Chen, B. V. Popp, C. L. Bovet, Z. T. Ball, ACS Chem. Biol. 2011, 6, 920–925. 
[142] Z. Chen, F. Vohidov, J. M. Coughlin, L. J. Stagg, S. T. Arold, J. E. Ladbury, Z. 
T. Ball, J. Am. Chem. Soc. 2012, 134, 10138–10145. 
[143] P. Wittung, P. E. Nielsen, O. Buchardt, M. Egholm, B. Nordén, Nature 1994, 
368, 561–563. 
[144] T. Ratilainen, A. Holmén, E. Tuite, P. E. Nielsen, B. Nordén, Biochemistry 2000, 
39, 7781–7791. 
[145] D. R. M. Smith, T. Willemse, D. S. Gkotsi, W. Schepens, B. U. W. Maes, S. 
Ballet, R. J. M. Goss, Org. Lett. 2014, 16, 2622–2625. 
[146] A. D. Roy, R. J. M. Goss, G. K. Wagner, M. Winn, Chem. Commun. 2008, 4831–
4833. 
[147] P. Klán, T. Šolomek, C. G. Bochet, A. Blanc, R. Givens, M. Rubina, V. Popik, 
A. Kostikov, J. Wirz, Chem. Rev. 2013, 113, 119–191. 
[148] V. Hagen, S. Frings, B. Wiesner, S. Helm, U. B. Kaupp, J. Bendig, 
ChemBioChem 2003, 4, 434–442. 
[149] V. R. Shembekar, Y. Chen, B. K. Carpenter, G. P. Hess, Biochemistry 2007, 
46, 5479–5484. 
[150] L. J. G. W. van Wilderen, C. Neumann, A. Rodrigues-Correia, D. Kern-Michler, 
N. Mielke, M. Reinfelds, A. Heckel, J. Bredenbeck, Phys. Chem. Chem. Phys. 
2017, 19, 6487–6496. 
[151] L.-M. Herzig, I. Elamri, H. Schwalbe, J. Wachtveitl, Phys. Chem. Chem. Phys. 
2017, 19, 14835–14844. 
[152] P. Seyfried, L. Eiden, N. Grebenovsky, G. Mayer, A. Heckel, Angew. Chem. Int. 
Ed. 2017, 56, 359–363. 
[153] W. M. Rink, F. Thomas, Chem. Eur. J. 2019, 25, 1665–1677. 
  9 BIBLIOGRAPHY 
195 
 
[154] S. Middel, PhD thesis, Georg-August-Universität Göttingen, Germany, 2016. 
[155] E. Boll, J. Dheur, H. Drobecq, O. Melnyk, Org. Lett. 2012, 14, 2222–2225. 
[156] P. E. Nielsen, M. Egholm, O. Buchardt, Bioconjugate Chem. 1994, 5, 3–7. 
[157] M. Eriksson, P. E. Nielsen, Nat. Struct. Biol. 1996, 3, 410–413. 
[158] S. C. Brown, S. A. Thomson, J. M. Veal, D. G. Davis, Science 1994, 265, 777–
780. 
[159] M. Egholm, O. Buchardt, L. Christensen, C. Behrens, S. M. Freier, D. A. Driver, 
R. H. Berg, S. K. Kim, B. Norden, P. E. Nielsen, Nature 1993, 365, 566–568. 
[160] H. Rasmussen, J. S. Kastrup, J. N. Nielsen, J. M. Nielsen, P. E. Nielsen, Nat. 
Struct. Biol. 1997, 4, 98–101. 
[161] K. K. Jensen, H. Orum, P. E. Nielsen, B. Nordén, Biochemistry 1997, 36, 5072–
5077. 
[162] G. L. Igloi, Proceedings of the National Academy of Sciences of the United 
States of America 1998, 95, 8562–8567. 
[163] I. Sacui, W.-C. Hsieh, A. Manna, B. Sahu, D. H. Ly, J. Am. Chem. Soc. 2015, 
137, 8603–8610. 
[164] G. Höger, PhD thesis, Georg-August-Universität Göttingen, Germany, 2019. 
[165] CEM Bioscience Division, Liberty Demonstration PNA 10-mer, 
https://cem.com/media/contenttype/media/literature/PNA-10mer-
Synthesis_Report.pdf, 2016, last accessed: 17.12.2020. 
[166] CEM Corporation, Liberty Blue User Guide, 
http://cem.com/media/contenttype/media/literature/525_User_Guide_LibBlue_
600329.pdf, 2016, last accessed: 17.12.2020. 
[167] J. Weiler, H. Gausepohl, N. Hauser, O. N. Jensen, J. D. Hoheisel, Nucleic acids 
research 1997, 25, 2792–2799. 
[168] N. Ollivier, J. Dheur, R. Mhidia, A. Blanpain, O. Melnyk, Org. Lett. 2010, 12, 
5238–5241. 
[169] S. Nawratil, PhD thesis, Georg-August-Universität Göttingen, Germany, 2017. 
[170] C. D. Spicer, B. G. Davis in Encyclopedia of Metalloproteins (Eds.: R. H. 
Kretsinger, V. N. Uversky, E. A. Permyakov), Springer, New York, NY, 2013. 
[171] A. Afonso, C. Rosés, M. Planas, L. Feliu, Eur. J. Org. Chem. 2010, 2010, 1461–
1468. 







[173] I. Gavrilova, Bachelor thesis, Georg-August-Universität Göttingen, Germany, 
2018. 
[174] A. Patchornik, B. Amit, R. B. Woodward, J. Am. Chem. Soc. 1970, 92, 6333–
6335. 
[175] T. Furuta, S. S. Wang, J. L. Dantzker, T. M. Dore, W. J. Bybee, E. M. Callaway, 
W. Denk, R. Y. Tsien, Proc. Natl. Acad. Sci. USA 1999, 96, 1193–1200. 
[176] T. Solomek, S. Mercier, T. Bally, C. G. Bochet, Photochem. Photobiol. Sci. 
2012, 11, 548–555. 
[177] A. V. Pinheiro, P. Baptista, J. C. Lima, Nucleic Acids Res. 2008, 36, e90. 
[178] R. O. Schönleber, J. Bendig, V. Hagen, B. Giese, Bioorg. Med. Chem. 2002, 
10, 97–101. 
[179] V. R. Shembekar, Y. Chen, B. K. Carpenter, G. P. Hess, Biochemistry 2005, 
44, 7107–7114. 
[180] S. Sakamoto, M. Terauchi, Y. Araki, T. Wada, Biopolymers 2013, 100, 773–
779. 
[181] T. Watanabe, T. Hoshida, J. Sakyo, M. Kishi, S. Tanabe, J. Matsuura, S. 
Akiyama, M. Nakata, Y. Tanabe, A. Z. Suzuki et al., Org. Biomol. Chem. 2014, 
12, 5089–5093. 
[182] A. Taniguchi, M. Skwarczynski, Y. Sohma, T. Okada, K. Ikeda, H. Prakash, H. 
Mukai, Y. Hayashi, T. Kimura, S. Hirota et al., ChemBioChem 2008, 9, 3055–
3065. 
[183] M. Skwarczynski, M. Noguchi, S. Hirota, Y. Sohma, T. Kimura, Y. Hayashi, Y. 
Kiso, Bioorg. Med. Chem. Lett. 2006, 16, 4492–4496. 
[184] A. Z. Suzuki, T. Watanabe, M. Kawamoto, K. Nishiyama, H. Yamashita, M. Ishii, 
M. Iwamura, T. Furuta, Org. Lett. 2003, 5, 4867–4870. 
[185] M. M. Mahmoodi, S. A. Fisher, R. Y. Tam, P. C. Goff, R. B. Anderson, J. E. 
Wissinger, D. A. Blank, M. S. Shoichet, M. D. Distefano, Org. Biomol. Chem. 
2016, 14, 8289–8300. 
[186] J. Liu, J. Hemphill, S. Samanta, M. Tsang, A. Deiters, J. Am. Chem. Soc. 2017, 
139, 9100–9103. 
[187] S. Yamazoe, Q. Liu, L. E. McQuade, A. Deiters, J. K. Chen, Angew. Chem. Int. 
Ed. 2014, 53, 10114–10118. 
[188] J. Luo, R. Uprety, Y. Naro, C. Chou, D. P. Nguyen, J. W. Chin, A. Deiters, J. 
Am. Chem. Soc. 2014, 136, 15551–15558. 
  9 BIBLIOGRAPHY 
197 
 
[189] B. Schade, V. Hagen, R. Schmidt, R. Herbrich, E. Krause, T. Eckardt, J. Bendig, 
J. Org. Chem. 1999, 64, 9109–9117. 
[190] R. Schmidt, D. Geissler, V. Hagen, J. Bendig, J. Phys. Chem. A 2007, 111, 
5768–5774. 
[191] C. Malan, C. Morin, J. Org. Chem. 1998, 63, 8019–8020. 
[192] R. T. Raines, G. Ellis, M. Palte, WO 2013/110005 Al, 2013. 
[193] T. Willemse, K. Van Imp, R. J. M. Goss, H. W. T. Van Vlijmen, W. Schepens, 
B. U. W. Maes, S. Ballet, ChemCatChem 2015, 7, 2055–2070. 
[194] Z. Gao, V. Gouverneur, B. G. Davis, J. Am. Chem. Soc. 2013, 135, 13612–
13615. 
[195] B. Lippert, Coord. Chem. Rev. 2000, 200-202, 487–516. 
[196] G. L. Eichhorn, Y. A. Shin, J. Am. Chem. Soc. 1968, 90, 7323–7328. 
[197] A. M. Pyle, J. P. Rehmann, R. Meshoyrer, C. V. Kumar, N. J. Turro, J. K. Barton, 
J. Am. Chem. Soc. 1989, 111, 3051–3058. 
[198] D. N. Woolfson in Advances in Protein Chemistry, Vol. 70 (Eds.: D. A. D. Parry, 
J. M. Squire), Academic Press, Cambridge, MA, 2005. 
[199] A. N. Lupas, J. Bassler, S. Dunin-Horkawicz in Subcellular Biochemistry, Vol. 
82 (Eds.: D. A. D. Parry, J. M. Squire), Springer International Publishing, Basel, 
2017, 35–61. 
[200] E. H. C. Bromley, R. B. Sessions, A. R. Thomson, D. N. Woolfson, J. Am. Chem. 
Soc. 2009, 131, 928–930. 
[201] H. Gradišar, R. Jerala, J. Pept. Sci. 2011, 100–106. 
[202] T. Lebar, D. Lainšček, E. Merljak, J. Aupič, R. Jerala, Nat. Chem. Biol. 2020, 
513–519. 
[203] S. M. Kelly, T. J. Jess, N. C. Price, Biochim. Biophys. Acta 2005, 1751, 119–
139. 
[204] N. J. Greenfield, Nat. Protoc. 2006, 1, 2876–2890. 
[205] P. López-García, M. Goktas, A. E. Bergues-Pupo, B. Koksch, D. Varón Silva, 
K. G. Blank, Phys. Chem. Chem. Phys. 2019, 21, 9145–9149. 
[206] B. Apostolovic, H.-A. Klok, Biomacromolecules 2008, 9, 3173–3180. 
[207] J. Yang, C. Xu, C. Wang, J. Kopecek, Biomacromolecules 2006, 7, 1187–1195. 
[208] F. Thomas, A. L. Boyle, A. J. Burton, D. N. Woolfson, J. Am. Chem. Soc. 2013, 
135, 5161–5166. 






[210] J. Huang, H. Qin, Z. Sun, G. Huang, J. Mao, K. Cheng, Z. Zhang, H. Wan, Y. 
Yao, J. Dong et al., Sci. Rep. 2015, 5, 10164. 
[211] S. Duflocq, J. Zhou, F. Huguenot, M. Vidal, W.-Q. Liu, RSC Adv. 2020, 10, 
17681–17685. 
[212] R. L. Brabham, R. J. Spears, J. Walton, S. Tyagi, E. A. Lemke, M. A. Fascione, 
Chem. Commun. 2018, 54, 1501–1504. 
[213] C. E. Schafmeister, J. Po, G. L. Verdine, J. Am. Chem. Soc. 2000, 122, 5891–
5892. 
[214] D. Chelius, T. A. Shaler, Bioconjugate Chem. 2003, 14, 205–211. 
[215] C. Mueller, T. N. Grossmann, Angew. Chem. Int. Ed. 2018, 57, 17079–17083. 
[216] G. von Maltzahn, Y. Ren, J.-H. Park, D.-H. Min, V. R. Kotamraju, J. Jayakumar, 
V. Fogal, M. J. Sailor, E. Ruoslahti, S. N. Bhatia, Bioconjugate Chem. 2008, 19, 
1570–1578. 
[217] B. E. Hubrich, P. M. Menzel, B. Kugler, U. Diederichsen in Methods in Molecular 
Biology, Vol. 2105 (Ed.: P. E. Nielsen), Springer US, New York, NY, 2020. 
[218] H. E. Gottlieb, V. Kotlyar, A. Nudelman, J. Org. Chem. 1997, 62, 7512–7515. 
[219] S. C. Gill, P. H. von Hippel, Anal. Biochem. 1989, 182, 319–326. 
[220] L. Goltermann, P. E. Nielsen in Methods in Molecular Biology, Vol. 2105 (Ed.: 
P. E. Nielsen), Springer US, New York, NY, 2020. 
[221] T. J. Measey, F. Gai, Langmuir 2012, 28, 12588–12592. 
[222] H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. 
Shindyalov, P. E. Bourne, Nucleic Acids Res. 2000, 28, 235–242. 
[223] E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. 
C. Meng, T. E. Ferrin, J. Comput. Chem. 2004, 25, 1605–1612. 
[224] M. A. Avery, M. S. Verlander, M. Goodman, J. Org. Chem. 1980, 45, 2750–
2753. 
[225] X. Zhang, W. Xi, C. Wang, M. Podgórski, C. N. Bowman, ACS Macro Lett. 2016, 
5, 229–233. 
 





First of all, I would like to thank Prof. Dr. Ulf Diederichsen for the opportunity to work on 
this project, his support and the scientific freedom granted to pursue my own ideals. 
I am thankful to Prof. Dr. Manuel Alcarazo for assuming the position of my second 
supervisor, for the helpful discussions and for providing a different viewpoint on my 
experiments. 
Moreover, I would like to express my thanks to Prof. Dr. Marina Bennati, Prof. Dr. Kai 
Tittmann, Dr. Holm Frauendorf and Dr. Michael John for their willingness to be members 
of my examination board. 
I would like to thank the MS and NMR departments headed by Dr. Holm Frauendorf and 
Dr. Michael John for the measurement of countless samples. 
In addition, a big thank you goes to Angela Heinemann for her assistance regarding all 
organizational concerns. 
I would further like to extend my gratitude to Prof. Dr. Harald Kolmar and Bastian Becker 
for the fruitful cooperation as part of the priority program 1623. 
I am deeply grateful to Jun.-Prof. Dr. Franziska Thomas for the training I have received in 
her lab during my master thesis, the ongoing support, guidance, and discussions, 
especially when sharing her expertise on coiled-coil peptides. 
Thank you to Ulrike Rost, Anastasiya Schirmacher and especially Mathis Rink for sharing 
their expertise, providing counsel, and discussing my work with me.  
For their experimental contributions to my work I would like to extend my gratitude to “my” 
students Ivana Gavrilova and Valentina Kallina. 
To my proofreaders Mike Groth, Viktoria Mrđen Debono, Anastasiya Schirmacher and 
Tobias Schmidt: Thank you for the helpful suggestions, for putting the finishing touches on 
this work and in the case of Tobias for suffering through yet another experimental section.  
I would also like to express my appreciation to the past and present members of Lab 109, 
Geralin Höger, Anastasiya Schirmacher, Tobias Schmidt, Pirajeev Selvachandran, Clara 
Bosbach and Luisa Bachmann for the joyful, cooperative working atmosphere and fun 
extracurricular activities. A special thank you to Geralin and Anastasiya for welcoming me 
into “their” lab, helping me get started in the field of peptide chemistry and including me in 
their activities in and around the lab. I will always fondly remember the coffee breaks and 
evenings spent together. Anastasiya, thank you in addition for your continuous support, 
your willingness to listen and your providing of different perspectives on and off work. I’m 
grateful for your encouragement to broaden my horizon and improving my work-life balance 






Thank you to the members of the Diederichsen and Thomas group for the enjoyable 
working atmosphere, fun group trips, celebrations and distractions on the foosball table. 
Thank you as well to my friends for supporting me throughout my studies and providing 
relief on particularly stressful days, especially to Chris and Laura for the considerate, 
enjoyable, and necessary distractions. 
Last but not least, I would like to thank my family for their well-meant advice and continuous 
emotional and financial support during my time at university. A special thank you to my 
brother Felix for always listening to and supporting me. 
